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The present invention relates to isolated nucleic acid mol 
ecules encoding a type III—secreted bacterial protein 
capable of modifying a cell death pathway in a plant cell. 
One aspect of the present invention involves an isolated 
nucleic acid molecule having a nucleotide sequence that 
encodes the HopPtol)2 protein of Pseudomonas syringae pv. 
syringae DC 3000. Expression vectors, host cells, and 
transgenic plants which include the DNA molecules of the 
present invention are also disclosed. The nucleic acid mol 
ecules of the present invention can be used to impart disease 
resistance to a plant and to make a plant hypersusceptible to 
colonization by nonpathogenic bacteria. 
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1. 
NUCLEIC ACIDS ENCODING 
PSEUDOMONAS HOP PROTEINS AND USE 
THEREOF 
This application claims benefit of U.S. Provisional Patent 
Application Ser. Nos. 60/280,918, filed Apr. 2, 2001, and 
60/356,408, filed Feb. 12, 2002, each of which is hereby 
incorporated by reference in its entirety. 
This work was supported by National Science Foundation 
Grant Nos. DBI-0077622 and MCB-9982646 and National 
Research Initiative Competitive Grants Program, U.S. 
Department of Agriculture, Grant Nos. 97-35303-4488 and 
01-35319-10019. The U.S. Government may have certain 
rights in this invention. 
FIELD OF THE INVENTION 
The present invention relates to isolated DNA molecules 
corresponding to the open reading frames of Pseudomonas 
syringae pv. tomato DC3000, the isolated avirulence effector 
proteins and hrp-dependent outer proteins encoded thereby, 
as well as their various uses. 
BACKGROUND OF THE INVENTION 
The plant pathogenic bacterium Pseudomonas syringae is 
noted for its diverse and host-specific interactions with 
plants. A specific strain may be assigned to one of at least 40 
pathovars based on its host range among different plant 
species and then further assigned to a race based on differ 
ential interactions among cultivars of the host. In host plants 
the bacteria typically grow to high population levels in leaf 
intercellular spaces and then produce necrotic lesions. In 
nonhost plants or in host plants with race-specific resistance, 
the bacteria elicit the hypersensitive response (HR), a rapid, 
defense-associated programmed death of plant cells in con 
tact with the pathogen (Alfano & Collmer, J. Bacteriol. 
179:5655-5662 (1997)). The ability to produce either of 
these reactions in plants appears to be directed by hrp (HR 
and pathogenicity) and hirc (HR and conserved) genes that 
encode a type III protein secretion pathway and by avr (avirulence) and hop (Hrp-dependent outer protein) genes 
that encode effector proteins injected into plant cells by the 
pathway (Alfano & Collmer, J. Bacteriol. 179:5655-5662 
(1997)). These effectors may also betray the parasite to the 
HR-triggering R-gene surveillance system of potential hosts 
(hence the avr designation), and plant breeding for resistance 
based on such gene-for-gene (avr-R) interactions may pro 
duce complex combinations of races and differential culti 
vars (Keen, Annu. Rev. Genet. 24:447. 463 (1990)). hrp/hrc 
genes are probably universal among necrosis-causing gram 
negative plant pathogens, and they have been sequenced in 
P. syringae pv. Syringae (Psy) 61, Erwinia amylovora 
Ea321, Xanthomonas campestris pv. vesicatoria (XCV) 
85-10, and Ralstonia solanacearum GMI1000 (Alfano & 
Collmer, J. Bacteriol. 179:5655–5662 (1997)). Based on 
their distinct gene arrangements and regulatory components, 
the hrp/hrc gene clusters of these four bacteria can be 
divided into two groups: I (Pseudomonas and Erwinia) and 
II (Xanthomonas and Ralstonia). The discrepancy between 
the distribution of these groups and the phylogeny of the 
bacteria provides some evidence that hrp/hrc gene clusters 
have been horizontally acquired and, therefore, may repre 
sent pathogenicity islands (Pais) (Alfano & Collmer, J. 
Bacteriol. 179:5655-5662 (1997)). 
Virulence effector proteins delivered to or into host cells 
by type III secretion systems are key factors in the patho 
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genicity of many bacteria, including animal pathogens in the 
genera Salmonella, Yersinia, Shigella, and Escherichia, and 
plant pathogens in the genera Pseudomonas, Erwinia, Xan 
thomonas, Ralstonia, and Pantoea (Galán & Collmer, Sci 
ence 284:1322–1328 (1999)). In plant pathogens, the type 
III secretion machinery is referred to as the hypersensitive 
response and pathogenicity (Hrp) system because secretion 
mutants typically lose their ability to elicit the defense 
associated hypersensitive response in nonhost plants and to 
grow parasitically or be pathogenic in host plants (Alfano & 
Collmer, J. Bacteriol. 179:5655–5662 (1997)). These phe 
notypes demonstrate the importance of the Hrp system in 
bacterium-plant interactions, and global identification of 
effectors will be important for understanding the pathogen 
esis of bacteria that use type III secretion systems. Unfor 
tunately, several factors have hindered searches for type III 
effector genes. These factors include: (i) effectors are often 
redundant with mutants having only subtle phenotypes; (ii) 
with few exceptions (see e.g., Miao & Miller, Proc. Natl. 
Acad. Sci. USA 97:7539–7544 (2000)) motifs that can 
identify proteins as substrates for type III secretion have not 
been recognized (Lloyd et al., Mol. Microbiol. 39:520–532) 
(2001); (iii) many effectors show no similarity to known 
proteins; and (iv) some pathogens have multiple type III 
secretion systems which deliver different sets of effectors 
(Cornelis & Van Gijsegem, Annu. Rev. Microbiol. 
54:735-774 (2000)). Thus, a complete inventory of type III 
effector genes is lacking for any pathogen, although it seems 
that pathogens such as Salmonella may have many such 
genes (Worley et al., Mol. Microbiol. 36:749-761 (2000)). 
Plant pathogen type III effector proteins are mostly des 
ignated Avr or Hop, depending on whether their primary 
phenotype involves plant reaction or secretion behavior. 
Many effectors were initially discovered through their abil 
ity to betray the pathogen to the host R (resistance) gene 
surveillance system, thereby rendering the pathogen aviru 
lent on a test plant (Keen, Annu. Rev. Genet. 24:447-463 
(1990)). Over 25 effector genes have been identified by Avr 
or Hop phenotypes in various P. syringae pathovars and 
races (Vivian & Arnold, J. Plant Pathol. 82:163–178 (2000); 
Alfano et al., Proc. Natl. Acad. Sci. USA 97:4856–4861 
(2000)). The encoded effectors seem to determine both basic 
pathogenicity and host range, but the number of Such 
proteins produced by any single strain has not been system 
atically investigated. P. s. tomato DC3000 is known to carry 
at least three avr genes, avrPto (Ronald et al., J. Bacteriol. 
174:1604-1611 (1992)), avrPtoB, and avrE (Lorang & 
Keen, Mol. Plant-Microbe Interact. 8:49–57 (1995)), with 
the latter being in the Hrp pathogenicity island along with 
five other candidate effector genes (Alfano et al., Proc. Natl. 
Acad. Sci. USA 97:4856–486 (2000); Lorang & Keen, Mol. 
Plant-Microbe Interact. 8:49–57 (1995)). 
The present invention is a further advance in the effort to 
identify, clone, and sequence AVr and Hop proteins or 
polypeptides from plant pathogens. 
SUMMARY OF THE INVENTION 
One aspect of the present invention relates to isolated 
nucleic acid molecules having a nucleotide sequence which 
(i) encodes a protein or polypeptide including SEQ ID No: 
2, SEQID No. 4, SEQID No. 6, SEQID No: 8, SEQID No: 
10, SEQID No. 12, SEQID No: 14, SEQID No: 16, SEQ 
ID No: 18, SEQID No. 20, SEQID No. 22, or SEQID No: 
24; or (ii) hybridizes, under stringency conditions including 
a hybridization medium which includes 0.9xSSC at a tem 
perature of 42° C., to a DNA molecule complementary to 
US 7,138,569 B2 
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SEQID No. 1, SEQID No. 3, SEQ ID No. 5, SEQ ID No: 
7, SEQID No. 9, SEQ ID No: 11, SEQID No: 13, SEQID 
No: 15, SEQ ID No: 17, SEQ ID No: 19, SEQ ID No. 21, 
or SEQ ID No: 23; or (iii) includes a nucleotide sequence 
which is complementary to the nucleic acid molecules of (i) 
and (ii). Expression vectors, host cells, and transgenic plants 
which include the DNA molecules of the present invention 
are also disclosed. Methods of making such host cells and 
transgenic plant are disclosed. 
A further aspect of the present invention relates to isolated 
effector proteins or polypeptides encoded by the nucleic acid 
molecules of the present invention. Compositions which 
contain the proteins or polypeptides are also disclosed. 
Yet another aspect of the present invention relates to 
methods of imparting disease resistance to a plant. Accord 
ing to one approach, this method is carried out by trans 
forming a plant cell with a heterologous DNA molecule of 
the present invention and regenerating a transgenic plant 
from the transformed plant cell, wherein the transgenic plant 
expresses the heterologous DNA molecule under conditions 
effective to impart disease resistance. According to one 
approach, this method is carried out by treating a plant with 
a protein or polypeptide of the present invention under 
conditions effective to impart disease resistance to the 
treated plant. 
A further aspect of the present invention relates to a 
method of causing eukaryotic cell death which includes: 
introducing into a eukaryotic cell a cytotoxic Pseudomonas 
protein of the present invention, said introducing being 
performed under conditions effective to cause cell death. 
A still further aspect of the present invention relates to a 
method of treating a cancerous condition which includes 
introducing a cytotoxic Pseudomonas protein of the present 
invention into cancer cells of a patient under conditions 
effective to cause death of cancer cells, thereby treating the 
cancerous condition. 
Yet another aspect of the present invention relates to a 
method of modifying a metabolic pathway in a cell which 
includes: introducing into a cell a protein or polypeptide of 
the present invention which interacts with a native cellular 
protein involved in a metabolic pathway, wherein the protein 
or polypeptide modifies the metabolic pathway through its 
interaction with the native cellular protein. 
It is believed that bacteria have evolved effector proteins 
to make exquisite alterations in host metabolism. While 
plant resistance and cancer cell toxicity are important uses, 
as mentioned above, it is believed that these effector proteins 
can be used to modify or effect metabolic targets in eukary 
otes, including both yeasts and higher order species, such as 
plants and animals. It is noteworthy that several of the 
effector proteins being claimed in this application have 
homologs in other phytopathogenic bacteria. Thus, these 
proteins appear to represent a set of effectors that are 
atgaaaatac 
ggaaaggcgg 
ccaccagaaa 
gtacaaacac 
totttgccc.g 
accaaaagtic 
ggalagaggca 
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conserved among Pseudomonas, Erwinia, Xanthomonas, 
and Ralstonia spp. By disrupting the function of these 
effectors through, for example, transgenic expression 
thereof in a host plant, it is believed that use of these 
effectors may lead to widely applicable means for control 
ling diseases of plants. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is an RNA blot analysis of HrpL-dependent 
expression of representative virulence-implicated genes. 
Each well was loaded with 25ug of total RNA isolated from 
CUCPB5114 cultures carrying either vector control 
pCPP5031 or P-hrpL plasmid pCPP5032 (lanes 2 and 3, 
respectively). PCR-amplified internal fragments were used 
as probes; lane 1 in each case contains PCR product of the 
corresponding probe. AVrPpiB1 and AVrPpiB2 are 
100% identical, therefore their signals cannot be distin 
guished. 
FIGS. 2A–B illustrate assays for Hrp system-dependent 
secretion in culture or translocation in plants of various AVr 
and Hop proteins. In FIG. 2A, DC3000 or a DC3000 hrcC 
mutant (Yuan & He, J. Bacteriol. 178:6399–6402 (1996), 
which is hereby incorporated by reference in its entirety) 
carrying test ORFs (i.e., candidate effectors) fused to either 
the FLAG (F) or hemagglutinin (HA) epitopes were grown 
in Hrp-inducing media, and cultures were separated into cell 
(lanes 1–3) and Supernatant (lanes 4-5) fractions and ana 
lyzed by SDS-PAGE and immunobloting. Lanes: 1 and 4. 
wild type DC3000; 2 and 5, wild type DC3000(pTestORF): 
3 and 6, DC3000 hrcC mutant(pTestORF). As an additional 
control against leakage, pCPP2318 (which encodes the 
mature form of B-lactamase, B-lac) was included in all 
strains. The presence of an epitope-tagged protein in the 
supernatant fraction of the wild type (lane 5), but absence in 
the hrcC secretion mutant (lane 6), indicated that the test 
ORF encoded a secreted product. In FIG. 2B, AvrRpt2 
translocation assays were performed with a DC3000 Avr 
Rps4 homolog (now designated HopPtoK). Constructs that 
contained ORFs fused to AvrRpt2 lacking translocation 
signals were electroporated into P. S. phaseolicola 3121. Test 
strains were infiltrated into A. thaliana Col-0 (RPS2). Plant 
responses were scored 18 hr after inoculation for hypersen 
sitive collapse (HR) or no visible response (N). 
DETAILED DESCRIPTION OF THE 
INVENTION 
One aspect of the present invention relates to Pseudomo 
nas Syringae pv. Syringae DC 3000 nucleic acid molecules 
which encode Avr or Hop effector proteins. 
A first nucleic acid molecule is a homolog of avrPphE of 
Pseudomonas Syringae pv. phaseolicola and has a nucle 
otide sequence according to SEQ ID No. 1 as follows: 
cctaaccoca cctttgc.cgg gcatttcgaa toggaaacgtt 60 
aataacticaa cc.gcagagcc agcaaggctic titatggcttg 120 
togccct gat cgaactatoc at attcatca 180 
cgttgcgtot gctgggaaac cqct gcctda tacaccatct 240 
gttgc galagg citggaccatc gocctdtgga to aggaaggt 300 
agacaaggct gtggctgaag cqc.gc.cgtgc attgcc ctitt 360 
ggatgcgcaa ctitt.ccaatc toggaaagtgg agc.ccgcacc 420 
cittgcagdaa 
aatgagcc.ga 
aactgtgg.cg 
ggacgatctg 
gctgaaac cq 
ggttcago.ca 
acggatacgt. 
gaga aggCtt 
caagttctogc 
tttgtcc.gca 
gatattgaag 
cgacaag.ccc 
agacgagatg 
The encoded protein, designated AVrPphE has an amino 
ggtgcttgag 
tgaactggca 
aac atgctcg 
aatatgaaaa 
acgaatcc.ca 
tatttgcgga 
ttaatcttitc 
tgacgcaggit 
ccatcaaaag 
gagtgagcga. 
Cggtoggagt 
gacctttggit 
totga 
- continued 
aaaagatgcc 
tgttcttgtt 
tatago gagc 
catctacttg 
gtotggcacc 
gga Cagtagg 
aac cqcagoc 
cacaa.ccc.ga 
tggtogctat 
caagttgacc 
cgcaatgtcg 
tgagcttgca 
gaggcc.gc.cg 
gc gatgtcag 
titc.gc.ctatg 
gctgcatcga 
tdaac gattg 
tittgc gaaaa 
gaag.cgggca 
ttgcagaaac 
c gaccagaaa 
toccctgatt 
citcgg cacca 
gtgaaggtog 
US 7,138,569 B2 
gtoatgagcc 
gcc aggtgtt 
gagctittggc 
Ctgaggalaga 
to atggatcc 
atcgaaatgc 
aaattacgc.g 
gCCt9.gcgga 
aatcggtact 
tgcgg.cgtgc 
aggg.cgt.cala 
cct citcc to a 
25 
acid sequence according to SEQ ID No. 2 as follows: 
Met Lys Ile 
Asn Gly Asn 
Ser Glin Glin 
35 
Pro Asp Arg 
5 O 
Leu Pro Pro 
65 
Ser Lieu Pro 
Asp Glin Glu 
Glu Ala Arg 
115 
Ala Glin Leu 
130 
Cys Lieu Arg 
145 
Asn Glu Pro 
Phe Gly Ala 
195 
Tyr Lieu Ala 
210 
Glu Ser Glin 
225 
His Asn Ala Gly Lieu 
Wall Gly Lys Ala Ala 
Gly Ser Tyr Gly Lieu 
40 
Ala Arg Ala Asn Tyr 
55 
Val Ala Ser Ala Gly 
70 
Gly Tyr Lieu Lleu Lieu 
85 
Gly Thr Lys Ser Lieu 
100 
Arg Ala Lieu Pro Phe 
120 
Ser Asn Lieu Glu Ser 
135 
Lys Asp Ala Glu Ala 
15 O 
Met Asn Trp His Val 
1.65 
Gly Asn. Cys Gly Glu 
18O 
Leu Ala Glin Glu Asn 
200 
Ala Ser Thr Glu Glu 
215 
Ser Gly Thr Ser Thr 
230 
Thr Pro Pro 
10 
Glin Ser Ser 
25 
Pro Pro Glu 
Pro Tyr Ser 
Lys Pro Leu 
75 
Arg Arg Lieu 
90 
Ile Pro Ala 
105 
Gly Arg Gly 
Gly Ala Arg 
Ala Gly His 
155 
Leu Wall Ala 
170 
His Ala Arg 
185 
Gly Arg Ser 
Asp His Val 
Ile Wal Met 
235 
Leu Pro Gly 
Ile Thr Glin 
3O 
Ser Ser Glu 
45 
Ser Wall Glin 
60 
Pro Asp Thr 
Asp His Arg 
Asp Lys Ala 
110 
Asn. Ile Asp 
125 
Thir Leu Ala 
1 4 0 
Glu Pro Met 
Met Ser Gly 
Ile Ala Ser 
19 O 
Glu Tyr Glu 
2O5 
Trp Ala Glu 
220 
Asp Pro Trp 
tatgcct gcg 
Cgg.cgcgggc 
ccaggaaaac 
to atgtgtgg 
gtggtoaaat 
tgtagagcgt. 
tgaga cago c 
tdag Caggag 
tgatgatgca 
actacaggta 
ggacgctact 
aggCttggCg 
Ile Ser 
15 
Pro Glin 
Thr Arg 
Thr Arg 
Pro Ser 
Pro Wall 
95 
Wall Ala 
Val Asp 
Ala Arg 
Pro Ala 
160 
Glin Wall 
175 
Phe Ala 
Asn. Ile 
Thr Asp 
Ser Asn 
240 
480 
540 
600 
660 
720 
840 
9 OO 
96.O 
1020 
1080 
1140 
1155 
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- continued 
Glu Asp Ser Arg 
250 
Ala Ile Phe 
245 
Gly Ser Ala Phe Ala 
Ala Wall Glu Thr Thr Phe Asn Leu Ser Thr Ala 
265 
Arg 
260 
Asp 
Ile 
275 
Thr Glu Thir Ala 
280 
Glu Ala Thr 
285 
Gly Teu 
Thr Glin Ala Glin Glu Teu Glin 
295 
Arg Lieu 
29 O 
Arp Asp 
Ile 
305 
Glu Ser Wall Leu 
315 
Ser Gly Tyr Pro 
310 
Arg 
Phe Wall Wall 
325 
Thr 
330 
Arg Ser Asp Telu Ser Pro Asp 
Ala Glin Wall 
340 
Ile Glu Ala Wall 
345 
Telu Asp Gly Val Ala Met 
Thr Wall Ala Thr 
360 
Gly Glin Ala 
355 
Pro 
365 
Lys Asp Arg Arg 
Ala 
370 
Wall Wall Ala Glin Ala Ser Pro Teu 
375 
Teu Lys Gly Arg 
Asn 
Ala 
27 O 
Glin 
Wall 
Asp 
Telu 
Ser 
35 O 
Telu 
Arg Asn 
255 
Glu Ala 
Wall Thr 
Pro Ser 
Ala 
320 
Asp 
Arg 
335 
Arg 
Leu Gly 
Wall Glu 
Asp Wall 
AvrPphE has been shown to be expressed by DC3000. It phaseolicola which is physically linked to hrpY, new hrp 
has been demonstrated that AvrPphE of Pseudomonas syrin 
gae pv. phaseolicola is recognized within plant cells and that 
this protein alone is required for hypersensitive response 
induction (Stevens et al., “Sequence variations in alleles of 
the avirulence gene avrPphE: R2 from Pseudomonas syrin 
gae pv. phaseolicola lead to loss of recognition of the 
AvrPphE protein within bean cells and a gain in cultivar 
specific virulence.” Mol. Microbiol. 29(1):165-177 (1998); 
Mansfield et al., “Characterization of avrPphE, a gene for 
cultivar-specific avirulence from Pseudomonas syringae pv. 
atgaatcgca 
gaa.gc.gcaaa 
totato.gc.cc 
cagogacto c 
gctaaag citt 
ccacacttga 
citagaaatcc 
ggctdatcgt. 
aggg.cgcttg 
agagg cago a 
atcaacticta 
gtgtgtgcaa 
ggitat.cggct 
gctittgcaaa 
ggcagotatg 
gc gcgcttgc 
aatgttctg.c 
30 
tttcaaccag 
accgctt.cgc 
aag.cgtcgga 
gccaattgat 
ttgatgcto a 
acgct citcaia 
cagttacatc 
cacgc gagct 
agcggctgca 
acgtgttggc 
alagacggctg 
gaggcatgga 
Caccagagga 
toaaatactic 
acgacgagca 
atgitatc.cga. 
tgatgcctda 
gene identified in the halo-blight bacterium. Mol. Plant 
Microbe Interact. 7(6):726–739 (1994), each of which is 
hereby incorporated by reference in its entirety). AvrPphE 
has been shown to be secreted by a type III secretion system 
and translocated into plants. AvrPphE matches the R2 resis 
tance gene of Phaseolus. 
A second nucleic acid molecule is a homolog of avrRps4 
of Pseudomonas Syringae pv. pisi and has a nucleotide 
sequence according to SEQ ID No. 3 as follows: 
citcagtaaat to cagottca attacacggc cccitacggag 60 
cticago.gc.cc gacaatticcic citctagttgt caccacaaca 120 
agggctacaa caacgctaag catgcaggcc 180 agg.ccggggg 
ggggagc.ccg. tctgagcagt cacaatgtta 240 gcc.ggaggga 
acgcc-taaac attalacactic aag caggctic titccaa.cago 300 
cacgctccala caacgacact tcaaacct gc 360 ggctggtggg 
caacticcitta ttggg.cggtg go aggcaagt citatcaaatt 420 
aagccaccga ccggtocaatig atcagg accg cqc.gc.cct to 480 
cgc.cgagttg tittagaggtg gg.ccgattga gtttgttgcct 540 
citcaaacgtg agggatgtcg acatggacga gttc gatgtc. 600 
ccaaggcatt gg caccact g goctoggacc citgcattgca 660 
tagagaaggg ctitc.cggtgc toggtgtcta to accacagt 720 
taccatggct actottgatc aag.cgatgcg cqataaaggt 780 
cc togtaggc gg catgatca toccitaaaga 840 ggalagaggct 
aagctttittg go attgaaag go agittatto: aatcgaaggg 900 
aggcgaagag gacgtgcata coggc gagga caa.cagtgtc. 960 
cc.gc.gttctg tacggtogcg acacgctota citgctga 1017 
US 7,138,569 B2 
9 
The encoded protein, originally designated AVrRps and 
now renamed HopPtoK, has an amino acid sequence accord 
ing to SEQ ID No. 4 as follows: 
Met Asn Arg Ile Her Thr Ser Ser Val Asn Ser Ser Phe Asn Tyr Thr 
Ala Pro Thr Glu Glu Ala Glin Asn Arg Phe Ala Ser Ala Pro Asp Asn 
2O 25 3O 
Ser Pro Leu Val Val Thir Thr Thr Ser Ile Ala Glin Ala Ser Glu Gly 
35 40 45 
Leu Glin Arg Pro Gly Ala Thr Lieu Ser Met Glin Ala Glin Arg Lieu Arg 
5 O 55 60 
Glin Leu Met Gly Ser Pro Ser Glu Gln Cys Arg Arg Asp Thr Met Lieu 
65 70 75 8O 
Ala Lys Ala Phe Asp Ala Glin Arg Lieu. Asn. Ile Asn Thr Glin Ala Gly 
85 90 95 
Ser Ser Asn. Ser Pro His Lieu. Asn Ala Lieu. Asn. Thir Lieu Glin Glin Arg 
100 105 110 
His Phe Lys Pro Ala Ala Gly Gly Leu Glu Ile Pro Val Thr Ser Asn 
115 120 125 
Ser Leu Leu Gly Gly Gly Arg Glin Val Tyr Glin Ile Gly Ser Per Ser 
130 135 1 4 0 
Arg Glu Leu Ser His Arg Pro Val Asn Asp Gln Asp Arg Ala Pro Phe 
145 15 O 155 160 
Arg Ala Leu Glu Arg Lieu. His Ala Glu Lieu Phe Arg Gly Gly Pro Ile 
1.65 170 175 
Glu Phe Val Pro Arg Gly Ser Asn. Wall Leu Ala Ser Asn Val Arg Asp 
18O 185 19 O 
Val Asp Met Asp Glu Phe Asp Wal Ile Asn. Ser Lys Asp Gly Cys Glin 
195 200 2O5 
Gly Ile Gly Thir Thr Gly Lieu Gly Pro Cys Ile Ala Val Cys Ala Arg 
210 215 220 
Gly Met Asp Arg Glu Gly Leu Pro Val Leu Gly Val Tyr His His Ser 
225 230 235 240 
Gly Ile Gly Ser Pro Glu Asp Thr Met Ala Thr Leu Asp Glin Ala Met 
245 250 255 
Arg Asp Lys Gly Ala Lieu Glin Ile Lys Tyr Ser Lieu Val Gly Gly Met 
260 265 27 O 
Ile Met Pro Lys Glu Glu Glu Ala Gly Per Tyr Asp Asp Glu Glin Ser 
275 280 285 
Phe Leu Ala Lieu Lys Gly Ser Tyr Ser Ile Glu Gly Ala Arg Lieu. His 
29 O 295 3OO 
Val Ser Glu Gly Glu Glu Asp Wal His Thr Gly Glu Asp Asn. Ser Val 
305 310 315 320 
Asn Val Lieu Lleu Met Pro Asp Arg Val Lieu. Tyr Gly Arp Asp Thr Lieu 
325 330 335 
US 7,138,569 B2 
11 12 
HopPtoK has been shown to be a secreted protein that is resistance locus, RPS4, and cloning of the corresponding 
expressed by DC3000. The Pseudomonas Syringae pv. pisi avirulence gene, avrRps4, from Pseudomonas Syringae pv. 
AvrRps4 effector matches the disease locus RPS4. It has pisi," Mol. Plant Microbe Interact. 9(1):55–61 (1996), 
previously been demonstrated that Pseudomonas syringae which is hereby incorporated by reference in its entirety). 
strains carrying avrRpS4 induces a hypersensitive response 5 A third nucleic acid molecule is a homolog of avrPphF 
on specific accessions of both Arabidopsis and Soybean orf1 of Pseudomonas syringae pv. phaseolicola and has a 
(Hinsch et al., “Identification of a new Arabidopsis disease nucleotide sequence according to SEQID No. 5 as follows: 
atgaaaaacg catttgacct gcttgttggaa gggctggcta aggactacaa catgcc.gc.cc 60 
ttgcctgaca agaaacatat cqatigaagtic tattgctttg agtttcaaag togtatgaac 120 
gtaaaagtat accalagacga attitcgctgg gtatatttca cogctgacgt toggacattt 180 
caagatagoa gtattgacac attaaactac gogcto cagc togaacaactt tagc cittaga 240 
aaaccttitcc to accitt.cgg aatgacgaag gagaaaaatg gtgtattgca tacacgcacc 300 
ccottgattig aggtag acaa cqtgcaaatg cqcaggatat ttgaggagct tatagg.cgtg 360 
gcaggtogaaa to agaaaaac actaaaactic aaatag 396 
The encoded protein has an amino acid sequence according 
to SEQ ID No. 6 as follows: 
Met Lys Asn Ala Phe Asp Leu Lieu Val Glu Gly Lieu Ala Lys Asp Tyr 
Asn Met Pro Pro Leu Pro Asp Llys Lys His Ile Asp Glu Val Tyr Cys 
2O 25 30 
Phe Glu Phe Glin Ser Gly Met Asin Val Lys Val Tyr Glin Asp Glu Phe 
35 40 45 
Arp Trp Val Tyr Phe Thr Ala Asp Val Gly Thr Phe Glin Asp Ser Ser 
5 O 55 60 
Ile Asp Thr Lieu. Asn Tyr Ala Leu Glin Lieu. Asn. Asn. Phe Per Lieu Arg 
65 70 75 8O 
Lys Pro Phe Leu Thr Phe Gly Met Thr Lys Glu Lys Asn Gly Val Leu 
85 90 95 
His Thr Arg Thr Pro Leu Ile Glu Val Asp Asn Val Gln Met Arg Arp 
1 OO 105 110 
Ile Phe Glu Glu Lieu. Ile Gly Val Ala Gly Glu Ile Arg Lys Thr Lieu 
115 120 125 
Lys Lieu Lys 
130 
This protein is believed to be a chaperone protein for the 
50 protein of SEQ ID NO: 8 described below. 
A fourth nucleic acid molecule is also homolog of avrP 
phF orf2 of Pseudomonas Syringae pv. phaseolicola and has 
a nucleotide sequence according to SEQ ID No. 7 as 
follows: 
gtgtatagoc catcc catac acaacgaata acttcagotc cctotacatc. cacticatgtt 60 
ggtggagata cactdacatc cattcatcag ctitt.cgcata gtcagagaga goagtttctg. 120 
aacatgcatg atccaatgag agtaatggga cittgac catg at accgagct tttcagaacg 180 
acggatagtic gottatataaa aaacgataaa citc.gcgggca atccacaatc catggc gagt 240 
atcct tatgc atgaagaact gcgc.cccaat cqttittgcca gccatacagg tocc calacca 300 
cac galagcaa goggcgtacgt to cqaaaaga ataaaag.cca cogatctagg agttccatca 360 
citgaacgtaa tactggcto 
gataatcagg totctgtcaa 
tatgcc.gacg citt.cgtctgt 
ttgcc.caaag gacagaaagt 
13 
-continued 
gcc.ggtogala agggtctga 
US 7,138,569 B2 
10 
The encoded protein, designated AVrPphF has an amino 
acid sequence according to SEQ ID No: 8 as follows: 
Wall 
Ser 
His 
Met 
Tyr 
65 
Ile 
Gly 
Ala 
Ala 
Ser 
145 
Teu 
Thr 
Ser 
Gly 
5 O 
Ile 
Telu 
Ala 
Thr 
Arg 
130 
Wall 
Ala 
Ile 
Ser 
His 
Glin 
35 
Telu 
Lys 
Met 
Glin 
Asp 
115 
Asp 
Lys 
Asp 
Wall 
Pro 
Wall 
Arg 
Asp 
Asn 
His 
Pro 
100 
Leu 
Gly 
Met 
Ala 
Thr 
18O 
Ser 
Gly 
Glu 
His 
Asp 
Glu 
85 
His 
Gly 
Ile 
Arg 
Ser 
1.65 
Teu 
His 
Gly 
Glin 
Asp 
Lys 
70 
Glu 
Glu 
Wall 
Arg 
Teu 
15 O 
Ser 
Pro 
Thr 
Asp 
Phe 
Thr 
55 
Teu 
Teu 
Ala 
Pro 
Ala 
135 
Gly 
Wall 
Glin 
Thr 
Telu 
40 
Glu 
Ala 
Arg 
Arg 
Ser 
120 
Asp 
Ala 
Gly 
Arg 
Lou 
25 
Asn 
Telu 
Gly 
Pro 
Ala 
105 
Leu 
Asp 
Phe 
Asp 
Glin 
185 
Ile 
10 
Thr 
Met 
Phe 
Asn 
Asn 
90 
Asn 
His 
Telu 
Asp 
170 
Thr 
Ser 
His 
Arg 
Pro 
75 
Arg 
Wall 
Wall 
Met 
Glu 
155 
Gly 
Wall 
Ser Ala Pro 
Ile His Glin 
3O 
Asp Pro Met 
45 
Thir Thr Asp 
60 
Glin Ser Met 
Phe Ala Ser 
Pro Lys Arg 
110 
Met Thr Gly 
125 
Ser Asp Asn 
1 4 0 
Arg Gly Gly 
Glu Thir Ser 
Pro Wall Glu 
19 O 
AvrPphF has been shown to be expressed by DC3000. 45 
Fusion of both the homolog of AvrPphForfl and AvrPph 
F, with the AVrRpt2 reporter (AVrRpt2A40) caused a 
hypersensitive response in Arabidopsis Col-0, Suggesting 
that AVrPphF, is secreted. Neither Orfl-AvrRpt2A40 (AVr 
PphF) nor Orf2-AVrRpt2A40 alone causes the hypersen- 50 
sitive response in Arabidopsis Col-0, although mutants of 
the homolog of AvrPphForfl have shown reduced disease 
symptoms on tomato. The Pseudomonas Syringae pv. 
phaseolicola AVrPphF effector protein has been shown to 
atgaatcctc tacgatctat 
cc attagacg cqgtggg.ccc 
caattgagcc aaag.cgcto a 
cgc.cittgcat cactggtacg 
aac cacacgc aagta accta 
aga accg acc acttgattaa. 
14 
gctagogcga gacggaatta gag cittatga toacatgagt 420 
aatgc gacitg g gagattittc. tcgaaagggg togcaagg to 480 
agctgacgat ggggaaa.cat cacaagctct gattgtcaca 540 
579 
Ser Thr 
15 
Teu Ser 
Arg Val 
Ser Arg 
Ala Ser 
8O 
His Thr 
95 
Ile Lys 
Ser Lieu. 
Glin Wall 
160 
Glin Ala 
175 
Arg Val 
play a role in both development of the hypersensitive 
response and virulence in several plants (Tsiamis et al., 
“Cultivar-specific avirulence and virulence functions 
assigned to avrPphF in Pseudomonas syringae pv. phaseoli 
cola, the cause of bean halo-blight disease.” EMBO J. 
19(13):3204-3214 (2000), which is hereby incorporated by 
reference in its entirety). 
A fifth nucleic acid molecule is a homolog of avrPphl) of 
Pseudomonas Syringae pv. phaseolicola and has a nucle 
otide sequence according to SEQ ID No. 9 as follows: 
to aacacaac attgcaactic coccaatcag togcggtoag 60 
to aggcc.cag caatcccatc ctaaaaggat ttcaccittct 120 
cc aggcticta gaacgcc titt cagotaatgc cqaacaccala 180 
caacgctctg caggatggca catttcaatt to aatccagt 240 
taaag.cgtoa atctgtctgc cagotgacac cqat accgtg 300 
taacgagct g acggttcagg cocq attaaa toatcaatcg 360 

Teu 
65 
Asn 
Thr 
Glin 
Teu 
Pro 
145 
Gly 
Glu 
Pro 
Wall 
Asp 
225 
Glu 
Gly 
Ser 
Teu 
Ser 
305 
Teu 
Teu 
Ser 
Ser 
385 
Glin 
Ile 
Ala 
Tyr 
465 
Thr 
Wall 
His 
Asp 
Ala 
His 
130 
Ala 
Met 
Thr 
Ser 
210 
Glin 
Met 
Ala 
Glu 
Telu 
29 O 
Ile 
Ile 
His 
Ile 
370 
Glu 
Glu 
Gly 
Gly 
450 
Ala 
Thr 
Arg 
Thr 
Thr 
Arg 
115 
Gly 
His 
Ser 
Pro 
Pro 
195 
Asp 
Ala 
Arg 
Phe 
Arg 
275 
Gly 
Thr 
Gly 
Wall 
355 
Gly 
Telu 
Ala 
Ser 
Glu 
435 
Ala 
Gly 
Glu 
Asn 
Glin 
Wall 
100 
Telu 
Ser 
Gly 
Arg 
Telu 
18O 
Wall 
Asn 
Phe 
Pro 
Thr 
260 
Wall 
Ala 
Glin 
Ser 
Asp 
340 
Ala 
Wall 
Telu 
Telu 
Met 
420 
Glu 
Ile 
Phe 
Ala 
Ala 
Wall 
85 
Arg 
Asn 
Ser 
Ser 
Wall 
1.65 
Teu 
His 
Pro 
Pro 
Arg 
245 
Wall 
Asp 
Ile 
Asn 
Asn 
325 
Asp 
Thr 
Ser 
Lys 
Glin 
405 
Asp 
Trp 
Ser 
Lys 
Ala 
485 
Teu 
70 
Thr 
Thr 
Asp 
Ala 
15 O 
Teu 
Ser 
Ile 
Wall 
Pro 
230 
Arg 
Wall 
Glu 
Glu 
Ser 
310 
Asp 
Asp 
Ser 
Asn 
390 
Teu 
Thr 
Ser 
Ser 
Ser 
470 
Ile 
17 
- continued 
Glin Asp Gly Thr 
Tyr Lys Ala Ser 
90 
Asp His Lieu. Ile 
105 
Gln Ser Glu Tyr 
120 
Ala Ile Ser Phe 
135 
Ser Ser Wall Leu 
Ser Glin Asp Ala 
170 
Ser Pro Asp His 
185 
Gly Ser Val Arg 
200 
Wall Glin Ala Leu 
215 
Glin Ala Ala Ser 
Asp Ile Glu Lys 
250 
Lys Ala Gln Leu 
265 
Asp Wall Asn Ala 
280 
Arg Gly Ala Ala 
295 
Ala Lys Ala Phe 
Asp Wall Leu Ser 
330 
Leu Glin Val Arg 
345 
Lys Glu Phe Glin 
360 
Ile Leu Gly Ser 
375 
Ala Ile Phe Gly 
Ala Gly Ile Asp 
410 
Met Cys Val Leu 
425 
Met Ser Asp Lieu 
4 40 
Wal Wal Ser Phe 
455 
Arg Val Gly Asp 
Phe Gly Ala Ala 
490 
Phe 
75 
Ile 
Asn 
Asp 
Asp 
Ser 
155 
Wall 
Ser 
Arg 
Teu 
Ile 
235 
Ala 
Met 
Asp 
Ala 
Teu 
315 
Glu 
Teu 
Teu 
Ala 
Lys 
395 
Ser 
Ala 
Teu 
Pro 
Teu 
475 
Ser 
US 7,138,569 B2 
Glin 
Asn 
Ile 
Wall 
1 4 0 
Glu 
Asp 
Arg 
Asp 
Ser 
220 
Ala 
Teu 
Ser 
Ile 
Phe 
Ala 
Phe 
Gly 
Gly 
Trp 
Asn 
Wall 
Ile 
Pro 
Asn 
460 
Ala 
Gly 
Phe 
Teu 
Glu 
Wall 
125 
Pro 
Arg 
Ser 
Pro 
Ser 
Phe 
Gly 
Glu 
Gly 
His 
285 
Gly 
Ser 
Ile 
Ala 
Gly 
365 
Glu 
Phe 
Pro 
Ile 
Lys 
4 45 
Asn 
Ala 
Ile 
Glin 
Pro 
Telu 
110 
Ser 
Ser 
Thr 
Ser 
Pro 
19 O 
Gly 
Ala 
Wall 
Glu 
Ala 
27 O 
Ile 
Pro 
Asn 
Glin 
35 O 
Telu 
Telu 
Ser 
Pro 
Lys 
43 O 
Ala 
Wall 
Asn 
Pro 
Ser 
Ala 
95 
Thr 
Ala 
Pro 
His 
Ser 
175 
Ser 
Ser 
Glin 
Glin 
Phe 
255 
Asn 
Pro 
Asn 
Ala 
Glin 
335 
Glu 
Ala 
Gly 
Pro 
Telu 
415 
Gly 
Telu 
Telu 
Ser 
Pro 
495 
Ser 
Asp 
Wall 
His 
Pro 
Telu 
160 
Telu 
Glin 
Telu 
Ala 
Telu 
240 
Ser 
Telu 
Ala 
Pro 
320 
Telu 
Gly 
Ala 
Ser 
400 
Ile 
Met 
Glin 
Wall 
480 
Glu 
18 
Wall Lys G 
Thir Ile G 
530 
Ser Thr A 
545 
Pro Lieu. I 
Leu Arg I 
Teu Asn. A 
Asp Ser As 
610 
Arg Ala Se 
625 
Glu Lieu. Hi 
Gly Ser Al 
Ala Leu Wa 
67 
Ile Pro Ty 
69 O. 
Pro 
705 
19 
- continued 
u Ser Glu Glu Lieu Met 
5 OO 
Wal Met Ala His Ser 
u Arg Met Thr Arg His 
535 
a Val Lys Ser Met Gly 
550 
e Ala Ser Asn Lys Ala 
565 
e Phe Arg Ser Ala Val 
a Lieu Ala Leu Gly Gly 
600 
p Asn Ala Lys His Ala 
r Glin His Met Glu Ala 
630 
s Glin Met Leu Ala Pro 
645 
a Ile Val Asn Gly Met 
660 
l Arg Lys Lieu Gly Tyr 
5 680 
r Glin Asp Leu Ala Val 
Arg Ala Gly 
505 
Gly Glu Gly 
Ala Lieu. Asp 
Leu Ala Ser 
555 
Thr Gly Leu 
570 
Phe Asin Pro 
585 
Arg Val Asn 
Arg Val Val 
Gly Asp Arg 
635 
Arg Ser Glu 
650 
Asn Ala Ser 
665 
Gly Glu Ala 
Pro Asp Thr 
US 7,138,569 B2 
Leu Phe Glin 
51O. 
Val Asp Thr 
525 
Ile Ala Pro 
540 
Ile Val Gly 
Leu Ser Glu 
Ile Glu Ala 
59 O 
Val Pro Gly 
605 
Glin Thir Ile 
62O 
Asp Ile Ser 
Phe Leu Arg 
Phe Glu Ala 
67 O 
Pro Leu Ala 
685 
Ser Arg Glin 
7 OO 
HopPtold 1 has been shown to be a secreted protein that is 
expressed by DC3000. 
A sixth nucleic acid molecule is another homolog of 40 
avrPphD of Pseudomonas Syringae pv. phaseolicola and has 
a nucleotide sequence according to SEQ ID No: 11 as 
follows: 
atgaatcc cc 
caattagagg 
ctitt.cccaat 
accgatcacc 
cittcaatc.ca 
gcc.gacacca 
aatgat caac 
to catc gatg 
cgitacgcacc 
galagaccaat 
ttctitcc.gta 
to cq acct ga 
cgc.gcagogC 
tgcaaccitat 
CggagggctC 
tgagccaaag 
aacgc.gttgc 
gtaacgacac 
tggggg.ccgc 
ttgagtacga 
catccagtcc 
tagg tatgaa 
gtgttatggit 
ccactaatga 
aattggctgg 
ttggaggcgg 
totago acago 
to aggcc.cac 
cgctcaccita 
atc actogta 
gcaagtaacc 
ccact taatt 
catcgtoagc 
toccitcggcc 
togtgtc.citc 
gatcgacaaa 
cittgagcaaa 
ttgttgaacgt. 
gcc.gcto acc 
attacalaatt 
aatticcitatt 
gctictagatc 
cgcaacgctg 
tataaaactt 
aataacgagc 
gctcatttgt 
aac gatctag 
ttacgctacg 
atgcc.ccccc 
citgcc tittgg 
atttctitcc.g 
gtact agate 
cc caaatgag 
cccatcctga 
acctittcaac 
tgcaggacgg 
cagtctgtcc 
tgacggttca 
atgg.ccctitc 
cgtc.citctgg 
cggtgcc.ccc 
ccaaacacgg 
gaatggagac 
to gag caggt 
tgcgc galaga 
Ser Met 
Gly Glu 
Met Ile 
560 
Glin Wall 
575 
Ile Ala 
Leu Phe 
Leu Ala 
Ala Glu 
640 
His Wall 
655 
Ile Pro 
Glu Arg 
Pro Ala 
tggtggtcag 
caggattitcg 
tdag cctaat 
taagttccala 
gcc agctaac 
ggc.ccgatta 
ggaagccata 
cittgagc gala 
togggaalacc 
caaaatgtct 
ggg.cgggttg 
gaagagtatic 
atcto atgcg 
60 
120 
18O 
240 
360 
420 
480 
540 
600 
660 
720 
20 
attgttcaacg 
toccaggttg 
totttaacgt 
gaactgaaaa 
tatcgcc.gc.g 
gtag acatca 
ggtogggg CC 
cattcc.gcag 
gatctaggca 
caggccttitc 
tggcgc.gcaa. 
gtttgccitat 
acggagcggC 
tgg to gatgc 
atttgaatgt 
tggcc attac 
tgcgcc actd 
gtactaccac 
aaa.cccitcait 
gcatttctg.c 
acgacitat gc 
aaatagogtt 
21 
- continued 
caccittacgt 
acgtgaaagt 
caattatgta 
CCggagcgag 
c gaccataac 
cctgcaggca 
ggctatoata 
cacgc.gtatg 
acticaag.cgg 
cc.gcaacaac 
agaatga 
ggCCC gatgg 
gcc atgatta 
aaaggtaaaa 
C gagaagtcg 
aggcc tag to 
aatgagtc.gc 
atggtogaca 
gccaa.gctaa 
ccattcc tag 
ccaag.cggat 
US 7,138,569 B2 
attgggccala 
cagaactgaa 
aaagtaatcc 
ttacagaggc 
Cggaag.cgac 
tagttgttgca 
tgcttaagaa 
gctatoacta 
aggacagact 
tat citcttaa. 
The encoded protein, originally designated AVrPphD2 
and now renamed HopPtol)2, has an amino acid sequence 
according to SEQ ID No. 12 as follows: 
Met Asn. Pro 
Ser Gly Gly 
Tyr Her His 
35 
His Leu Ala 
5 O 
Arg Val Ala 
65 
Leu Glin Ser 
Pro Pro Ala 
Glu Lieu. Thr 
115 
Wal Ser Ala 
130 
Ser Ser Pro 
145 
Arg Thr His 
Pro Arg Glu 
Pro Pro Lys 
195 
Ser Lys Lieu 
210 
Leu Ala Gly 
225 
Arg Ala Ala 
Leu Glin P 
Glin Glin L. 
2O 
ro Ile Glin 
eu Glu Ala 
Pro Asp Arg Ile Ser 
Lieu. Asp H 
Ser Leu W 
40 
is Lieu. Her 
55 
al Arg Asn 
70 
Ser Asn Asp Thr Glin 
85 
Asn Ala Asp Thr Met 
100 
Val Glin Ala Arg Lieu 
120 
His Leu Tyr Gly Pro 
135 
Pro Ser Ala Asn Asp 
1 
Leu Gly M 
1.65 
50 
et Asn Arg 
Thr Glu Asp Glin Cys 
18O 
His Gly Lys Met Ser 
Pro Leu G 
200 
ly Met Glu 
215 
Cys Glu Arg Ile Ser 
2 
Leu Gly G 
245 
30 
ly Gly Pro 
His Ser Ile 
10 
Glu Gly Ser 
25 
Leu Ser Glin 
Thr Glin Pro 
Ala Wall Glin 
75 
Val Thr Tyr 
90 
Gly Ala Ala 
105 
Asn Asp Glin 
Ser Glu Ala 
Leu Ala Ser 
155 
Wall Leu Lieu 
170 
Wal Met Wall 
185 
Phe Phe Arg 
Thr Gly Gly 
Ser Wall Glu 
235 
Leu. Thr Wall 
250 
Thir Asn. Ser 
Glin Ala His 
3O 
Leu Ser Glin 
45 
Asn Thr Asp 
60 
Asp Gly Lys 
Lys Thr Ser 
His Lieu. Ile 
110 
Leu Glu Tyr 
125 
Ile Ser Ile 
1 4 0 
Ser Gly Len 
Arg Tyr Ala 
Ile Asp Lys 
19 O 
Thir Thr Asn 
2O5 
Leu Ser Asp 
220 
Glin Wall Lys 
Leu Asp Lieu 
cgc.cggccta 
gc gcactaag 
toaaacgaca 
Cgg.cgcgacC 
cgacgagcta 
citgtaacggc 
cgctogtaac 
caa.catgacg 
aaaatttctg 
ttggacacag 
Gln Met 
15 
Asn. Ser 
Ser Ala 
His Glin 
Phe Glin 
8O 
Val Cys 
95 
Asn. Asn 
Asp Ile 
Asp Ala 
Ser Glu 
160 
Wall Pro 
175 
Met Pro 
Asp Lieu 
Lieu Lys 
Ser Ile 
240 
Arg Glu 
255 
840 
9 OO 
96.O 
O20 
14 O 
200 
260 
320 
22 
Glu Ser His 
Met Asp Trp 
275 
Glu Ser Ala 
29 O 
Val Asp Ala 
305 
Glu Lieu Lys 
Ala Gly Ala 
Ser Pro Glu 
355 
Glin Ala Asn 
370 
Th Thir Thr 
385 
His Ser Ala 
Tyr Asn Met 
Leu Glu Asp 
435 
Asn. Asn. Pro 
450 
Ile Ala Leu 
465 
260 
23 
- continued 
Ala Ile Val Asn Gly 
Ala Asn Ala Gly Lieu 
280 
Met Ile Thr Glu Lieu 
295 
Asn Tyr Val Lys Gly 
310 
Asn Lieu. Asn Val Arg 
325 
Thr Tyr Arg Arg Val 
340 
Ala Thr Asp Glu Lieu 
360 
Glu Ser Leu Wal Wall 
375 
Ala Met Ile Met Wall 
390 
Glu Thir Lieu. Ile Thr 
405 
Thr Asp Leu Gly Ser 
420 
Arg Lieu Lys Phe Lieu 
4 40 
Ser Gly Leu Ser Leu 
Glu 
455 
Leu Pro Ile 
265 
Ser Glin Wall 
Lys Arg Thr 
Lys Lys Ser 
315 
Ser Glu Arg 
330 
Ala Ile Thr 
345 
Val Asp Ile 
His Cys Asn 
Asp Met Lieu 
395 
Arg Met Ala 
410 
Ile Ser Ala 
425 
Glin Ala Phe 
Asin Trp Thr 
US 7,138,569 B2 
Thr Lieu Arg 
27 O 
Asp Gly Ala 
285 
Lys Ser Lieu 
3OO 
Asn Pro Glin 
Glu Wal Wall 
Asp His Asn 
35 O 
Met Arg His 
365 
Gly Gly Arg 
38O 
Lys Asn Ala 
Lys Lieu Ser 
Leu Lys Arg 
43 O 
His Asp Tyr 
4 45 
Gln Trp Arg 
460 
HopPtol 2 has been shown to be a secreted protein that is 
expressed by DC3000. 
A seventh nucleic acid molecule is a homolog of avrP 
piC2 of Pseudomonas syringae pv. pisi and has a nucleotide 
sequence according to SEQ ID No: 13 as follows: 
atgacaatcg 
tottcggctt 
aaaaagct to 
acqaataatc 
aacatgatto 
tittctgggitt 
gag cacaaat 
gctggCacag 
citagaggaca 
Caggtgagca 
agaggggtaa 
toagatggca 
aaag.cgttgg 
gttcaagtat 
tgtctggaca 
Cggtogagaa 
cg accoaatt 
atggcatcag 
atgc.cgggaa 
cctittgaagg 
ttctgatgga 
aaagtttatt 
agtcgaactc 
cagatgaagc 
tggtgatata 
aaagagcgac 
citgatactat 
togcttcaaa 
catcggaaaa 
tdaaatgcct 
gtogtoaatt 
tdagogtgca 
agatcatgtt 
ggtggtgcat 
gcaa.gctt.cc 
gcaa.gctgct 
aggccitaccc 
tgcgctaagc 
cagocaagaa 
cittatttgat 
cgaaaacata 
aatacactga 
cacccaa.gc.c 
gatcc tocac 
acattgg.cga 
atgtgctittg 
acgcc ctato 
gctcqtactg 
gcaaaccocg 
gagttgaagg 
titcctaattg 
toctitatgttg 
attgcc.cacg 
cccaatctog 
to atcgg cag 
taaccactgt 
agttcagtga 
gattc gatca 
gcctittcatt 
catcggcaga 
titcatalactit 
gagtatcaag 
ggittaaagct 
cgtgtaagca 
atgcaattgt 
citttgggctt 
gag agtttca 
atgggct gcc 
Gly Pro 
Ala Arg 
Thir Leu 
Th Thr 
320 
Thr Glu 
335 
Arg Pro 
Cys Lieu 
Gly Arg 
Arg Asn 
400 
Tyr Asp 
415 
Pro Phe 
Ala Arg 
Ala Lys 
toaa.gctggg 
tggacggtgg 
ggatatttgc 
gagctggatt 
aagaatgagg 
citatcgg act 
tgg.cgcgatg 
tdaacctgtt 
gtoaggg.cgg 
agaaaataag 
ttctgitatca 
tacacactcg 
tittaatcggc 
60 
120 
18O 
240 
360 
420 
480 
540 
600 
660 
720 
810 
24 
US 7,138,569 B2 
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The encoded protein, originally designated AVrPpiC2, and 
now renamed HopPtoC, has an amino acid sequence accord 
ing to SEQ ID No: 14 as follows: 
Met Thr Ile Val Ser Gly His Ile Gly Lys His Pro Ser Leu Thir Thr 
Val Glin Ala Gly Ser Ser Ala Ser Val Glu Asn Gln Met Pro Asp Pro 
2O 25 3O 
Ala Glin Phe Ser Asp Gly Arg Trp Llys Lys Lieu Pro Thr Glin Leu Ser 
35 40 45 
Ser Ile Thr Lieu Ala Arg Phe Asp Glin Asp Ile Cys Thr Asn. Asn His 
5 O 55 60 
Gly Ile Ser Glin Arg Ala Met Cys Phe Gly Leu Ser Leu Ser Trp Ile 
65 70 75 8O 
Asn Met Ile His Ala Gly Lys Asp His Val Thr Pro Tyr Ala Ser Ala 
85 90 95 
Glu Arg Met Arg Phe Leu Gly Ser Phe Glu Gly Val Val His Ala Arg 
100 105 110 
Thr Val His Asn Phe Tyr Arg Thr Glu His Llys Phe Leu Met Glu Gln 
115 120 125 
Ala Ser Ala Asn Pro Gly Val Ser Ser Gly Ala Met Ala Gly Thr Glu 
130 135 1 4 0 
Ser Lieu Lieu Glin Ala Ala Glu Lieu Lys Gly Lieu Lys Lieu Gln Pro Val 
145 15 O 155 160 
Leu Glu Asp Llys Ser Asn. Ser Gly Lieu Pro Phe Lieu. Ile Ala Cys Lys 
1.65 170 175 
Glin Ser Gly Arg Glin Val Ser Thr Asp Glu Ala Ala Lieu Ser Ser Lieu 
18O 185 19 O 
Cys Asp Ala Ile Val Glu Asn Lys Arg Gly Val Met Val Ile Tyr Ser 
195 200 2O5 
Glin Glu Ile Ala His Ala Leu Gly Phe Ser Val Ser Ser Asp Gly Lys 
210 215 220 
Arg Ala Thr Leu Phe Asp Pro Asn Leu Gly Glu Phe His Thr His Ser 
225 230 235 240 
Lys Ala Lieu Ala Asp Thr Ile Glu Asn. Ile Ser Ser Ala Asp Gly Lieu 
245 250 255 
Pro Leu Ile Gly Val Glin Val Phe Ala Ser Lys Ile His 
260 265 
HopPtoC has been shown to be a secreted protein that is 
expressed by DC3000. 
An eighth nucleic acid molecule is a homolog of avrP- 50 
piB1 of Pseudomonas syringae pv. pisi and has a nucleotide 
sequence according to SEQ ID No: 15 as follows: 
atgcacgcaa atcc tittaag citctttcaac agagctoaac atggcaatct gactaatgta 60 
gaggcc agcc aagttaaatc ggcaggaacc tottccacca citaatataga cagtaaaaac 120 
attgaagaac atgttgcaga cagacitcagt gatttaggca gacct gatgg toggatggttt 180 
titc.gagaagt cacttggcac cittgaaaaat ttaaatcttg agcagttagc cqgaatc.cat 240 
gatgtactaa aattalacaga tiggcgtaaag aac attgtct cittittggagc togggaagga 300 
ggctitcgagt togcaatgca gtttcgtoat gatttataca gatctoaa.ca toc ggatgaa 360 
aacticgcc.gc acgatgcc.gc aactcattat cittgatgcaa totagoctoca atcaaacaaa 420 
26 
tittacaaaac 
gatgtcgggt 
gagtggctgg 
aaag acataa 
acaagtatict 
cc.cgaatcgg 
ttattaactg 
ttgaaaaact 
acaaaaacgg 
gttctgattt 
aatctgcatt 
tdaattittgc 
gattgaataa 
accgtgagtc 
27 
-C 
acaa.catgta 
aattgcgcac 
citgtaaacag 
tgttgatctitt 
agactitccat 
tgtaaaaatc 
atgggaacta 
ontinued 
gatgtattta 
gcaaaaaaaa 
gaatticcagt 
aaagatgtag 
aaatcacgc.g 
gaaaatagog 
aataattitcc. 
US 7,138,569 B2 
aaatgcaaaa 
tgg cattctt 
ggcttagcga 
actitaaaaag 
to atgatggc 
ttgacctgaa 
tagg.cgacta 
The encoded protein, designated AVrPpiB1 has an amino 
acid sequence according to SEQ ID No: 16 as follows: 
Met His Ala 
Lieu. Thir Asn 
Thir Thr Asn 
35 
Leu Ser Asp 
5 O 
Leu Gly. Thr 
65 
Asp Wall Leu 
Ala Arg Glu 
Tyr Arg Ser 
115 
His Tyr Leu 
130 
Glu Lys Lieu 
145 
Asp Val Gly 
Phe Ile Thr 
Glin Trp Lieu 
195 
Ile Phe Lys 
210 
Asn Phe Ala 
225 
Pro Glu Ser 
Asn Phe Lys 
Phe Leu Gly 
275 
Asn. Pro Leu Ser Ser 
Wall Glu Ala Ser Glin 
Ile Asp Ser Lys Asn 
40 
Leu Gly Arg Pro Asp 
55 
Lieu Lys Asn Lieu. Asn 
70 
Lys Lieu. Thr Asp Gly 
85 
Gly Gly Phe Glu Lieu 
100 
Gln His Pro Asp Glu 
120 
Asp Ala Ile Ser Lieu 
135 
Gln His Val Asp Val 
15 O 
Tyr Lys Asn Gly Ile 
1.65 
Pro Glu Trp Leu Gly 
18O 
Ser Glu Thir Lys Asn 
200 
Asp Wall Asp Leu Lys 
215 
Asp Phe His Lys Ser 
230 
Gly Lieu. Asn. Asn Val 
245 
Arg Lieu Lieu. Thr Asp 
260 
Asp 
Phe Asn Arg 
10 
Val Lys Ser 
25 
Ile Glu Glu 
Gly Gly Trp 
Leu Glu Glin 
75 
Wall Lys Asn 
90 
Ala Met Glin 
105 
Asn. Ser Pro 
Glin Ser Asn 
Phe Lys Met 
155 
Ala His Ala 
170 
Ser Asp Phe 
185 
Lys Asp Ile 
Ser Lys Asn 
Arg Val Met 
235 
Lys Ile Glu 
250 
Arg Glu Ser 
265 
Ala Gln His 
Ala Gly Thr 
3O 
His Wall Ala 
45 
Phe Phe Glu 
60 
Leu Ala Gly 
Ile Wal Ser 
Phe Arg His 
110 
His Asp Ala 
125 
Lys Phe Thr 
1 4 0 
Glin Asn Pro 
Lys Lys Met 
Cys Lys Glin 
19 O 
Lys Ser Ala 
2O5 
Met Thir Ser 
220 
Met Ala Ser 
Asn Ser Wall 
Trp Glu Lieu 
27 O 
cc.cgttittgg 
cataacgc.ca 
aaaaaaaac 
caaaaatatg 
aag cacacct 
tittcaagagg 
a. 
Gly Asn 
15 
Ser Ser 
Asp Arg 
Lys Ser 
Ile His 
8O 
Phe Gly 
95 
Asp Lieu 
Ala Thr 
Lys Leiu 
Phe Trp 
160 
Ala Phe 
175 
Glu Phe 
Phe Wall 
Ile Phe 
Thr Pro 
240 
Asp Lieu 
255 
Asn. Asn 
480 
540 
600 
660 
720 
831 
28 
US 7,138,569 B2 
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AvrPpiB1 has been shown to be expressed by DC3000. A borne avirulence gene avrPpiB which matches the R3 resis 
second copy of AVrPpiB1 is present in the genome of tance locus in pea, Mol. Plant Microbe Interact. 8(5): 
DC3000. This second copy is identical and has been desig- 700–708 (1995), which is hereby incorporated by reference 
nated AVrPpiB2. The Pseudomonas syringae pv. pisi in its entirety). 
AvrPpiB effector protein was demonstrated to effect the 5 
expression of a resistance mechanism governed by the R3 
resistance locus of pea (Cournoyer et al., “Molecular char- Xanthomonas Campestris pv. vesicatoria and has a nucle 
acterization of the Pseudomonas Syringae pv. pisi plasmid- otide sequence according to SEQ ID No: 17 as follows: 
A ninth nucleic acid molecule is a homolog of avrXV3 of 
atggggctat gtatttcaaa acactctggt agcagttaca gctacagtga tagc gaccgc 60 
tggcaagtgc citgcatgc.cc to caaacgcc aggtotgitat coagtcatca aacago atct 120 
gcqagtgaca to goatcagg cqatgtggat galacgtcct g caac gtttitc. tcattttcaa 180 
cittgcgcggit gciggtggaga gtacacgctt agcatggttt citgcagoggc titat caag ca 240 
gaaagacggc atc.gcggtaa tittaataaaa gatcgtagt caatccatact cocatggg to 300 
caggtatato attctaaaaa aggtttggat tacagottcc agat.cgacag aactacgact 360 
gttaaagtgg citggattcaa citgctotato cocaataa.ca gagggacitcg go atttatac 420 
agcgctggta cq agt cagac aaa.catgcct gtcatcgcag acaa.catgag cqcatgcatt 480 
gctgtc.gc.gt gtgcggcgga aaacgtggat gctggCacgg gtgaacgtag gCCggggg.cg 540 
aaagttcgcg tatto catct actoccittitt cqacgc gaag accittgttgcc agaagaagtt 600 
ttagottctg to cqc gatta totgcgaacg accaaagaac aggggctaac aatgcgc.gta 660 
gctatocatg gagggaatac agagggtgat ttct cagtca gcactg.cgca gg cattgaaa 720 
ggcctgtttg ctaatgaagg gatc.ccgctt gaatttgacg agacct gtgc aaac cqaacg 780 
totgaaacac tacttggtgc cqttatctta gatgacaact cq acto attt cataaaac at 840 
citggtogcac aataa 855 
35 
The encoded protein, originally designated AvrXV3, and 
now renamed HopPto.J. has an amino acid sequence accord 
ing to SEQ ID No: 18 as follows: 
Met Gly Leu Cys Ile Ser Lys His Ser Gly Ser Ser Tyr Ser Tyr Ser 
Asp Ser Asp Arg Trp Glin Val Pro Ala Cys Pro Pro Asn Ala Arg Ser 
2O 25 30 
Val Ser Ser His Glin Thr Ala Ser Ala Ser Asp Ile Ala Ser Gly Asp 
35 40 45 
Val Asp Glu Arg Pro Ala Thr Phe Ser His Phe Gln Leu Ala Arg Cys 
5 O 55 60 
Gly Gly Glu Tyr Thr Leu Ser Met Val Ser Ala Ala Ala Tyr Glin Ala 
65 70 75 8O 
Glu Arg Arg His Arg Gly Asn Lieu. Ile Lys Asp Arg Ser Glin Ser Ile 
85 90 95 
Leu Pro Trp Val Glin Val Tyr His Ser Lys Lys Gly Lieu. Asp Tyr Ser 
1 OO 105 110 
Phe Glin Ile Asp Arg Thr Thr Thr Val Lys Val Ala Gly Phe Asin Cys 
115 120 125 
Ser Ile Pro Asn Asn Arg Gly Thr Arg His Leu Tyr Ser Ala Gly. Thr 
130 135 1 4 0 
Ser Glin Thr Asn Met Pro Val Ile Ala Asp Asn Met Ser Ala Cys Ile 
145 15 O 155 160 
US 7,138,569 B2 
- continued 
Ala Val Ala Cys Ala Ala Glu Asn. Wall Asp Ala Gly Thr Gly Glu Arg 
1.65 170 175 
Arg Pro Gly Ala Lys Val Arg Val Phe His Lieu Lleu Pro Phe Arg Arg 
18O 185 19 O 
Glu Asp Lieu Val Pro Glu Glu Val Lieu Ala Ser Val Arg Asp Tyr Lieu 
195 200 2O5 
Arg Thr Thr Lys Glu Gln Gly Leu Thr Met Arg Val Ala Met His Gly 
210 215 220 
Gly Asn Thr Glu Gly Asp Phe Ser Val Ser Thr Ala Glin Ala Lieu Lys 
225 230 235 240 
Gly Lieu Phe Ala Asn. Glu Gly Ile Pro Leu Glu Phe Asp Glu Thir Cys 
245 250 255 
Ala Asn Arg Thr Ser Glu Thir Lieu Lieu Gly Ala Val Ile Leu Asp Asp 
260 265 27 O 
Asn Ser Thr His Phe Ile Lys His Leu Val Ala Glin 
275 280 
HopPtol has been shown to be a secreted protein that is effectors in functioning inside plant cells. A uidA fusion 
expressed by DC3000. As reported in Astua-Mongeet al. enabled demonstration that the avrXV3 gene is part of the ("Resistance of tomato and pepper to T3 strains of Xanth- 25 Hrp regulon. A domain in the C terminus of AvrXv3 is 
omonas campestris pv. vesicapia is specified by a plant- possibly responsible for transcriptional activation activity in 
inducible avirulence gene.” Mol. Plant Microbe Interact. yeast. For these reasons, it is also believed that HopPtol 
13:911–921 (2000), which is hereby incorporated by refer- ossesses similar characteristics and properties 
ence in its entirety), it has been demonstrated that the p prop 
Xanthomonas campestris AvrXv3 effector protein elicits a 30 A tenth nucleic acid molecule is a homolog of hrmB of 
hypersensitive response in tomato NIL 216 and certain Pseudomonas Syringae pv. Syringae and has a nucleotide 
pepper genotypes, which suggests that AvrXV3 is like other sequence according to SEQ ID No: 19 as follows: 
atgat catcg acaatacgtt cqc.gctgaca citgtcatgcg attacgc.gcg to agc.gc.citg 60 
citgttgatcg gottgcttga go cqcacaag gacatacctic agcagtgcct tttggctggc 120 
gct citcaatic cqcto citcaa to caggcc.ca ggccttggcc to gatgagaa aag.cggcc to 180 
tat cacgc.gt atcaaag cat coctoga gala aaactcagog tocc gacgct caaacg.cgaa 240 
atggCagg to tactggagtg gatgagggg C toggcgc galag caa.gc.calata g 291 
The encoded protein, believed to be a chaperone for the 
45 protein of SEQ ID No. 22, has an amino acid sequence 
according to SEQ ID No. 20 as follows: 
Met Ile Ile Asp Asn. Thir Phe Ala Lieu. Thir Lieu Ser Cys Asp Tyr Ala 
Arg Glu Arg Lieu Lleu Lleu. Ile Gly Lieu Lieu Glu Pro His Lys Asp Ile 
2O 25 30 
Pro Glin Glin Cys Lieu Lleu Ala Gly Ala Lieu. Asn Pro Leu Lieu. Asn Ala 
35 40 45 
Gly Pro Gly Teu Gly Lieu. Asp Glu Lys Her Gly Lieu. Tyr His Ala Tyr 
5 O 55 60 
Glin Ser Ile Pro Arg Glu Lys Lieu Ser Val Pro Thr Lieu Lys Arg Glu 
65 70 75 8O 
Met Ala Gly Lieu Lieu Glu Trp Met Arg Gly Trp Arg Glu Ala Ser Glin 
85 90 95 
US 7,138,569 B2 
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An eleventh nucleic acid molecule is a homolog of hrma 
(also known as hopPsyA) of Pseudomonas syringae pv. 
syringae and has a nucleotide sequence according to SEQID 
No: 21 as follows: 
atgaac coca ttcagt cacg cittcticcagt gtgcaa.gagc ticagacgatc caacgttgat 60 
attcc.ggcgc. tcaaag.ccaa togccaactg gaggtogacg gcaa.gaggta C gagatticgt 120 
gcagoc gatg acggaacaat titcggtoott cqaccggagc aacaatccaa agc gaaaagt 180 
tttittcaagg gcgctt.ccca gttgataggt ggcagoagcc agcgc.gc.gca gattgcc cag 240 
gc gctdaacg agaaggtogc atcgg cacgc actgtc.ttgc accagagcgc tatgacgggc 300 
ggacgcttgg acacccittga gcgggg.cgaa agcagotcag ccaca acago catcaaacco 360 
actgccaaac aggctg.cgca aagtacttitt alacagotttc atgagtgggc caaac aggca 420 
gaggcgatgc gaalaccc.gto tcgaatggat atctacaaga totataaa.ca agatgcacct 480 
cacticacacc ccatgagciga cqagcago aa gaagagttcc tocacacgct aaagg cattg 540 
aatggcaaaa acggcattga ggtgcgcact caggaccacg acagogtcag aaataaaaaa 600 
gaccgcaa.cc toggacaagta catcgcagag agc.ccggatg caaagaggitt tttctatoga 660 
attatc.ccca alacatgag cq cog agaagat aagaatcaag gg.cgattgac cattggcgtg 720 
caa.ccc caat atgcaa.caca gttgaccc.gc gcc atggcaa ccctdatagg gaaggaaagt 780 
gcaatcacgc atggcaaagt aataggcc cc gcc toccacg gccaaatgac cqattcggca 840 
gttttgtata toaacggtga tigttgcaaag goagaaaagc tigggc gagaa actgaaacag 900 
atgagcggca titccitctgga tigc gttcgtt gag cacacco citttgag cat gcaatcc citg 960 
agtaaagg to tdtccitatgc agaaagcatc ctdgg.cgaca ccagaggcca toggatgtcg 1020 
c gag cq galag tdatcagoga tigc cittgagg atggacggga tigc catttct ggccagattig 1080 
aagctatoac totctgccaa togctatoac ccggaca acc cqgcc ctitcg aaa.cacgaaa 1140 
tga 1143 
The encoded protein, designated HopPsyA, has an amino 0 
acid sequence according to SEQ ID No. 22 as follows: 
Met Asn Pro Ile Glin Ser Arg Phe Ser Ser Val Glin Glu Leu Arg Arg 
Ser Asn. Wall Asp Ile Pro Ala Lieu Lys Ala Asn Gly Glin Leu Glu Val 
2O 25 3O 
Asp Gly Lys Arg Tyr Glu Ile Arg Ala Ala Asp Asp Gly Thir Ile Ser 
35 40 45 
Val Lieu Arg Pro Glu Glin Glin Ser Lys Ala Lys Ser Phe Phe Lys Gly 
5 O 55 60 
Ala Ser Glin Lieu. Ile Gly Gly Ser Ser Glin Arg Ala Glin Ile Ala Glin 
65 70 75 8O 
Ala Lieu. Asn. Glu Lys Wall Ala Ser Ala Arg Thr Val Lieu. His Glin Ser 
85 90 95 
Ala Met Thr Gly Gly Arg Lieu. Asp Thr Lieu Glu Arg Gly Glu Ser Ser 
100 105 110 
Ser Ala Thr Thr Ala Ile Lys Pro Thr Ala Lys Glin Ala Ala Glin Ser 
115 120 125 
Thr Phe Asin Ser Phe His Glu Trp Ala Lys Glin Ala Glu Ala Met Arg 
130 135 1 4 0 
34 
US 7,138,569 B2 
35 
- continued 
Asn. Pro Ser Met Ile Tyr Lys Ile Glin 
145 
Asp 
15 O 
Tyr 
155 
Met 
1.65 
Glu Glin Glin 
170 
His Ser His Pro Ser Asp Glu Glu Phe 
Ala Lieu. Asn Asn Ile Glu Wall 
18O 
Teu Gly Lys Gly 
185 
Arg 
Ser Wall Asn Asn. Teu 
195 
His Asp Arg Lys 
200 
Asp Arg Asp 
2O5 
Ala Glu 
210 
Ser Pro Asp Ala Lys Phe Phe Ile 
215 
Arg Arg 
220 
His Glu Glu Asn Glin Leu. Thr 
225 
Arg Asp 
230 
Gly Arg 
235 
Glin Glin Ala 
245 
Pro Tyr Thr Glin Leu Thr Arg Ala Met Ala 
250 
Gly Glu Ser Ala Ile Thr His Wall Ile 
260 
Lys Gly 
265 
Lys Gly 
Glin 
275 
Met Thr Ala 
280 
Wall Ile Asn 
285 
His Gly Asp Ser Telu 
Ala Ala Glu Glu Glin Lys Teu Telu Met 
29 O 
Lys Gly 
295 
Thr Leu Ser Met 
315 
Ala Phe Wall His Pro 
310 
Pro Leu Glu 
305 
Asp 
Ala Glu Ile 
330 
Ser Ser Teu 
325 
Ser Gly Lieu Gly Asp 
Met Ala Glu Wall Ile 
345 
Ser Ser Ala Lieu 
340 
His Gly Arg Asp 
Gly Met Phe Ala Ser 
365 
Telu Teu Ser Leu 
360 
Pro Teu 
355 
Arg 
Ala 
375 
Asp Pro Asn. Pro Telu Asn Thr 
370 
Asp Arg Lys 
HopPsyA has been shown to be a secreted protein that is 
expressed by DC3000. It has been shown that HopPsy A is 
characterized by cytotoxicity when expressed recombinantly 
in eukaryotes (i.e., in plants and yeast), and further that 
HopPsy A is capable of altering metabolic (e.g., Mad2) 
pathways in targeted cells (see PCT Application Publication 
No. WO 01/75066 to Collmer et al., published Oct. 11, 2001, 
which is hereby incorporated by reference in its entirety). 
Moreover, it has been shown that HopPsyA (HrmA) can be 
used to effect enhanced resistance to bacterial, fungal, and 
gtgcc.gc.gta 
gtogagctgt 
attgtcg atc 
Caggggcaat 
agc catgcc.c 
tacgaaatgc 
gaccc gaccg 
agttttgttgg 
totcc.gc.cgc 
Asp 
Telu 
Thr 
19 O 
Ile 
Ile 
Thr 
Pro 
27 O 
Gly 
Ser 
Glin 
Thr 
Arg 
35 O 
Ala 
40 
45 
togtogcc.gg 
cc.ggtagaac 
cagaaaacco 
gg cagottgt 
acctg.ccc.ga 
cggcc.gc.cat 
ggattgg cat 
cgc.gcaggga 
caaag.ccgca 
36 
Ala Pro 
160 
His Thr 
175 
Glin Asp 
Ile 
Pro Lys 
Wall 
240 
Gly 
Lieu. Ile 
255 
Ala Cys 
Asp Wall 
Gly Ile 
Telu 
320 
Ser 
Arg 
335 
Gly 
Met Asp 
Asn Gly 
viral pathogens upon recombinant expression thereof in 
plants (U.S. Pat. No. 6,342,654 to Li et al., which is hereby 
incorporated by reference in its entirety). Based on its shared 
amino acid identity of about 52% when compared to 
HopPsyA, it is believed that HopPsyA possesses these 
same characteristics. 
A twelfth nucleic acid molecule is hopPtoB2, a homolog 
of hopB of Pseudomonas syringae pv. Syringae DC3000, 
and has a nucleotide sequence according to SEQID No: 23 
as follows: 
cc atgcagaa tggtoaacgg ccgg cact at 60 
citttcaagttc cattacgaca cacatctg.cg 120 cggctggCag 
gttc.gc.cttt tttggccag c ccitagatgaa 180 
cgc.ccg.tc.ga cqtctg.cgtg goggtogcgt aggtgacitcc 240 
agaalacacc g g g citccago a caggctcqat to cq agcgac 300 
gcaggcaggc cittgatgtcg togttgagcaa caagcc ctac 360 
ggagtc.ttac tittgagagct attitcgtgga totg.cgtoag 420 
aaagctittat gaggatgccc ggacatttitt cqc.cggttitt 480 
attgcct cog citgg.cgc.cac citgttgc.cat cqac accotg 540 

US 7,138,569 B2 
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The encoded HopPtoB2 protein has an amino acid sequence 
according to SEQ ID No. 24 as follows: 
Val Pro Arg Ile Val Ala Gly. His Ala Glu Gly Val Cys Val Val Asn 
Gly Arg His Tyr Val Glu Leu Ser Gly Arg Thr Phe Glin Val His Tyr 
2O 25 3O 
Asp Thr His Leu Arg Gly Trp Glin Ile Val Asp Pro Glu Asn Pro Phe 
35 40 45 
Ala Phe Phe Gly Glin Glin Pro Val Arg Lieu. Asp Glu Glin Gly Glin Trp 
5 O 55 60 
Glin Leu Val Ala Arg Arg Arg Lieu Arg Gly Gly Gly Val Gly Asp Ser 
65 70 75 8O 
Ser His Ala His Leu Pro Glu Glu Thr Pro Gly Ser Ser Thr Gly Ser 
85 90 95 
Ile Pro Ser Asp Tyr Glu Met Pro Ala Ala Met Glin Ala Gly Lieu. Asp 
100 105 110 
Val Val Leu Ser Asn Lys Pro Tyr Asp Pro Thr Gly Ile Gly Met Glu 
115 120 125 
Ser Tyr Phe Glu Ser Tyr Phe Val Asp Leu Arg Glin Ser Phe Val Ala 
130 135 1 4 0 
Arg Arg Glu Lys Lieu. Tyr Glu Asp Ala Arg Thr Phe Phe Ala Gly Phe 
145 15 O 155 160 
Ser Pro Pro Pro Lys Pro Gln Leu Pro Pro Leu Ala Pro Pro Val Ala 
1.65 170 175 
Ile Asp Thr Leu Ile Glu His Val Phe Ala Glin Gly Asn Gly Leu Val 
18O 185 19 O 
Leu Ser Glu Ala Pro Lys Ser Val Ala Ser Lys Arg Lieu Lleu Lleu Lieu 
195 200 2O5 
Asn Met Pro Leu Lleu Ala Glu Glin Arg Val Lys Ile Leu Tyr Ile Glu 
210 215 220 
His Lieu Lieu. Thir Asp Lys His Leu Ser Lys Lieu Ala Arg Tyr Arg Glin 
225 230 235 240 
Leu Gly Lys Lys Ser Arg Ser Gly Ser His Glu Lieu Lys His Tyr Lieu 
245 250 255 
His Asp Lieu. Asn Arg Gly. Thir Lieu. Asn. Asn. Ser Ser Thr Asp Tyr Asp 
260 265 27 O 
Tyr Tyr His Lieu. Ile Lys Ala Ala His Arg Tyr Gly Ile Glu Val Arg 
275 280 285 
Pro Phe Ser Ser Ser Ile Ser Tyr Pro Phe Leu Asp His Pro Val Leu 
29 O 295 3OO 
Ser Ala Ala Asn Asp Thir Thr Ala Val Glin Lys Met Ser Asin Phe Phe 
305 310 315 320 
Gly His Thr Leu Ile Ser Ser Asp Val Ala Ser Ala Pro Thr Lys Arp 
325 330 335 
Trp Val Ala Lieu Lleu. Asp Gln Lys Lieu Ala Thr Thr His Asp Gly Val 
340 345 35 O 
Leu Gly Ile Ala Glu Met Gln Gly Val Val Ser Val His Val Arg Asp 
355 360 365 
Ile Pro Ala Gly Arg Pro Thr Arg Ile Thr Lys Gly Thr Gly Glu Leu 
370 375 38O 
Pro Arp Glu Gly Thr Glin Ala Arg Cys Asp Phe Thr Ile Ala Phe Ser 
385 390 395 400 
40 
Asp 
Teu 
Gly 
Gly 
Met 
465 
Teu 
Gly 
Arg 
Teu 
Asn 
545 
Thr 
Thr 
Asp 
Teu 
625 
Thr 
Arg 
Asp 
Thr 
Teu 
705 
Ile 
Pro 
Ala 
Glu 
Wall 
785 
Glu 
Trp 
Pro 
Asp 
Gly 
Ala 
450 
Thr 
Asp 
Telu 
Asn 
Ile 
530 
Pro 
Asp 
Met 
Telu 
Arg 
610 
Phe 
Ala 
Gly 
Telu 
69 O. 
Wall 
Ala 
Gly 
Asp 
Ile 
770 
Thr 
Ser 
Ile 
Thr 
Asp 
Glu 
435 
Trp 
Ala 
Thr 
Asp 
Wall 
515 
Ser 
Arg 
Gly 
Ile 
Tyr 
595 
Phe 
Wall 
Glu 
Ile 
Ser 
675 
Arg 
Gly 
Glu 
Glin 
Ile 
755 
Glu 
Telu 
Glu 
His 
Telu 
Met 
420 
Arg 
Arg 
Ile 
Arg 
Met 
5 OO 
Phe 
Ala 
Thr 
Ile 
Ile 
Met 
Phe 
Telu 
Glin 
Asp 
660 
Ile 
Arg 
Asn 
Telu 
Ser 
740 
Ser 
Ile 
Glu 
Gly 
Arg 
820 
Ile 
405 
Teu 
Trp 
Trp 
Glin 
Thr 
485 
Glu 
Ala 
Wall 
Thr 
Wall 
565 
Asp 
Glu 
Glu 
Asp 
Teu 
645 
Cys 
Thr 
His 
Ser 
Glu 
725 
Lys 
Pro 
Glin 
Asn 
805 
Thr 
Wall 
Teu 
Ala 
Ile 
Glin 
470 
Thr 
Teu 
Glin 
Thr 
550 
Ile 
Asn 
His 
Thr 
Arg 
630 
Wall 
Ala 
Arg 
Glin 
His 
710 
Gly 
Gly 
Thr 
Arg 
Arg 
790 
Teu 
Pro 
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Pro Glin Ala Pro 
Arg Glu 
Gly Glin 
4 40 
Ala Pro 
455 
Ser Lieu 
Lieu. His 
Phe Phe 
His Arg 
52O 
Leu Pro 
535 
Ala Glin 
Gly Glu 
Leu Pro 
Teu Telu 
600 
Gly Glin 
615 
Gly His 
Ile Lys 
Ala Ser 
Glin Glin 
680 
Asp Wall 
695 
Ser Asn 
Gly Ile 
Wal Met 
Lys Wall 
760 
Ala Lys 
775 
Leu Ala 
Leu. Thr 
Wall Leu 
Telu 
425 
Glu 
Thr 
Thr 
Glu 
505 
Pro 
Telu 
Ser 
Telu 
585 
Thr 
Met 
Arg 
Ala 
Tyr 
665 
Met 
Met 
Wall 
Gly 
His 
745 
His 
Asp 
Arg 
Ile 
Wall 
825 
410 
Arg 
Gly 
Asp 
Asp 
Telu 
490 
Glu 
Arg 
Phe 
His 
570 
Telu 
Asp 
Ser 
Thr 
Glin 
650 
His 
Met 
Gly 
Telu 
730 
Asp 
Ile 
Ala 
Pro 
Wall 
810 
Asn 
His 
Gly 
Phe 
Trp 
Pro 
475 
Ala 
Ser 
Teu 
Pro 
Glu 
555 
Phe 
Ser 
Teu 
Asp 
635 
Glin 
Teu 
Asn 
Ser 
Glin 
715 
Arg 
Teu 
Ile 
Gly 
795 
His 
Ala 
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Pro 
Glin 
Ile 
Pro 
460 
Wall 
Asn 
Glin 
Glin 
Thr 
540 
Thr 
Ser 
Glin 
His 
Thr 
Pro 
His 
Ser 
His 
7 OO 
Gly 
Wall 
Gly 
Gly 
Arg 
Teu 
Arg 
Glu 
His 
Ser 
Arg 
4 45 
Ala 
Glin 
525 
Met 
Teu 
Wall 
Glin 
Glin 
605 
Teu 
Asp 
Gly 
Gly 
Phe 
685 
Wall 
Ile 
Glu 
Asp 
765 
Pro 
Phe 
Ala 
Gly 
Gly 
Ala 
43 O 
Asp 
Asp 
Glu 
Glu 
Glu 
Asp 
Pro 
Ala 
Asn 
59 O 
Ala 
Telu 
Met 
Telu 
67 O 
Ala 
Trp 
Wall 
Asp 
Telu 
750 
Pro 
Telu 
Arg 
Lys 
83O 
Thr 
415 
Gly 
Glu 
Ser 
Met 
Arg 
495 
Thr 
Ala 
Ala 
Glin 
Ser 
575 
Wall 
Asp 
His 
Wall 
Glu 
655 
Asp 
Ser 
Ile 
Pro 
Wall 
735 
Wall 
Arg 
Glin 
Wall 
Asp 
815 
Telu 
Ala 
Asp 
Pro 
Pro 
480 
Arg 
Wall 
Ala 
Wall 
His 
560 
Arg 
Telu 
Asp 
Tyr 
640 
Wall 
Asn 
Arg 
Ala 
Gly 
720 
Ala 
Ser 
Wall 
Pro 
Glu 
Thr 
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Leu Glu Arg Val Arg Trp Pro Arg Ile His Lieu Lys Pro Phe Asp Asp 
835 840 845 
Met Asp Ala Lieu Val Ala Ala Leu Glu Glu Met Asn Lieu. Thir Arg Val 
85 O 855 860 
Gly 
865 
HopPtoB2 has been shown to be a secreted protein that is 
expressed by DC3000. 
Fragments of the above-identified proteins or polypep 
tides as well as fragments of full length proteins can also be 
used according to the present invention. 
Suitable fragments can be produced by several means. 
Subclones of the gene encoding a known protein can be 
produced using conventional molecular genetic manipula 
tion for Subcloning gene fragments, such as described by 
Sambrook et al., Molecular Cloning. A Laboratory Manual. 
Cold Springs Laboratory, Cold Springs Harbor, N.Y. (1989), 
and Ausubel et al. (ed.), Current Protocols in Molecular 
Biology, John Wiley & Sons (New York, N.Y.) (1999 and 
preceding editions), each of which is hereby incorporated by 
reference in its entirety. The subclones then are expressed in 
vitro or in vivo in bacterial cells to yield a smaller protein or 
polypeptide that can be tested for activity, e.g., as a product 
required for pathogen virulence. 
In another approach, based on knowledge of the primary 
structure of the protein, fragments of the protein-coding 
gene may be synthesized using the PCR technique together 
with specific sets of primers chosen to represent particular 
portions of the protein. Erlich, H. A., et al., “Recent 
Advances in the Polymerase Chain Reaction.” Science 252: 
1643–51 (1991), which is hereby incorporated by reference. 
These can then be cloned into an appropriate vector for 
expression of a truncated protein or polypeptide from bac 
terial cells as described above. 
As an alternative, fragments of a protein can be produced 
by digestion of a full-length protein with proteolytic 
enzymes like chymotrypsin or Staphylococcus proteinase A, 
or trypsin. Different proteolytic enzymes are likely to cleave 
different proteins at different sites based on the amino acid 
sequence of the particular protein. Some of the fragments 
that result from proteolysis may be active virulence proteins 
or polypeptides. 
Chemical synthesis can also be used to make Suitable 
fragments. Such a synthesis is carried out using known 
amino acid sequences for the polyppetide being produced. 
Alternatively, Subjecting a full length protein to high tem 
peratures and pressures will produce fragments. These frag 
ments can then be separated by conventional procedures 
(e.g., chromatography, SDS-PAGE). 
Variants may also (or alternatively) be modified by, for 
example, the deletion or addition of amino acids that have 
minimal influence on the properties, secondary structure and 
hydropathic nature of the polypeptide. For example, a 
polypeptide may be conjugated to a signal (or leader) 
sequence at the N-terminal end of the protein which co 
translationally or post-translationally directs transfer of the 
protein. The polypeptide may also be conjugated to a linker 
or other sequence for ease of synthesis, purification, or 
identification of the polypeptide. 
The proteins or polypeptides used in accordance with the 
present invention are preferably produced in purified form 
(preferably at least about 80%, more preferably 90%, pure) 
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by conventional techniques. Typically, the protein or 
polypeptide of the present invention is secreted into the 
growth medium of recombinant host cells (discussed infra). 
Alternatively, the protein or polypeptide of the present 
invention is produced but not secreted into growth medium. 
In Such cases, to isolate the protein, the host cell (e.g., E. 
coli) carrying a recombinant plasmid is propagated, lysed by 
Sonication, heat, or chemical treatment, and the homogenate 
is centrifuged to remove bacterial debris. The supernatant is 
then Subjected to sequential ammonium Sulfate precipita 
tion. The fraction containing the protein or polypeptide of 
interest is subjected to gel filtration in an appropriately sized 
dextran or polyacrylamide column to separate the proteins. 
If necessary, the protein fraction may be further purified by 
HPLC. 
Other DNA molecules encoding other effector proteins or 
polypeptides can also be identified by determining whether 
such DNA molecules hybridize under stringent conditions to 
a nucleic acid molecule as identified above. An example of 
Suitable stringency conditions is when hybridization is car 
ried out at a temperature of about 37° C. using a hybridiza 
tion medium that includes 0.9x sodium citrate (“SSC) 
buffer, followed by washing with 0.2xSSC buffer at 37° C. 
Higher Stringency can readily be attained by increasing the 
temperature for either hybridization or washing conditions 
or increasing the Sodium concentration of the hybridization 
or wash medium. Nonspecific binding may also be con 
trolled using any one of a number of known techniques such 
as, for example, blocking the membrane with protein-con 
taining solutions, addition of heterologous RNA, DNA, and 
SDS to the hybridization buffer, and treatment with RNase. 
Wash conditions are typically performed at or below strin 
gency. Exemplary high Stringency conditions include carry 
ing out hybridization at a temperature of about 42°C. up to 
and including about 65° C. for up to about 20 hours in a 
hybridization medium containing 1M NaCl, 50 mM Tris 
HCl, pH 7.4, 10 mM EDTA, 0.1% sodium dodecyl sulfate 
(SDS), 0.2% ficoll, 0.2% polyvinylpyrrolidone, 0.2% bovine 
serum albumin, and 50 lug/ml E. coli DNA, followed by 
washing carried out at between about 42°C. to about 65° C. 
in a 0.2XSSC buffer. 
The delivery of effector proteins or polypeptides can be 
achieved in several ways: (1) as a stable transgene; (2) 
transiently expressed via Agrobacterium or viral vectors, (3) 
delivered by the type III secretion systems of disarmed 
pathogens or recombinant nonpathogenic bacteria which 
express a functional, heterologous type III Secretion system; 
or (4) delivered via topical application followed by TAT 
protein transduction domain-mediated spontaneous uptake 
into cells. Each of these is discussed infra. 
The DNA molecule encoding the protein or polypeptide 
can be incorporated in cells using conventional recombinant 
DNA technology. Generally, this involves inserting the DNA 
molecule into an expression system to which the DNA 
molecule is heterologous (i.e. not normally present). The 
heterologous DNA molecule is inserted into the expression 
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system or vector in proper sense orientation and correct 
reading frame. The vector contains the necessary elements 
for the transcription and translation of the inserted protein 
coding sequences. 
U.S. Pat. No. 4,237,224 to Cohen and Boyer, which is 
hereby incorporated by reference in its entirety, describes the 
production of expression systems in the form of recombinant 
plasmids using restriction enzyme cleavage and ligation 
with DNA ligase. These recombinant plasmids are then 
introduced by means of transformation and replicated in 
unicellular cultures including prokaryotic organisms and 
eukaryotic cells grown in tissue culture. 
Recombinant genes may also be introduced into viruses, 
Such as vaccina virus. Recombinant viruses can be generated 
by transfection of plasmids into cells infected with virus. 
Suitable vectors include, but are not limited to, the 
following viral vectors such as lambda vector system gt11, 
gt WES...thB, Charon 4, and plasmid vectors such as pBR322, 
pBR325, p.ACYC177, p.ACYC1084, puC8, puC9, puC18, 
pUC19, pI G339, pR290, pKC37, pKC101, SV 40, pBlue 
script II SK +/- or KS +/- (see "Stratagene Cloning Sys 
tems’ Catalog (1993) from Stratagene, La Jolla, Calif., 
which is hereby incorporated by reference), pOE, pIH821, 
pGEX, pET series (see F. W. Studier et. al., “Use of T7 RNA 
Polymerase to Direct Expression of Cloned Genes. Gene 
Expression Technology vol. 185 (1990), which is hereby 
incorporated by reference in its entirety), and any derivatives 
thereof Recombinant molecules can be introduced into cells 
via transformation, particularly transduction, conjugation, 
mobilization, or electroporation. The DNA sequences are 
cloned into the vector using standard cloning procedures in 
the art, as described by Sambrook et al., Molecular Cloning: 
A Laboratory Manual, Cold Springs Laboratory, Cold 
Springs Harbor, N.Y. (1989), which is hereby incorporated 
by reference in its entirety. 
A variety of host-vector systems may be utilized to 
express the protein-encoding sequence(s). Primarily, the 
vector system must be compatible with the host cell used. 
Host-vector systems include but are not limited to the 
following: bacteria transformed with bacteriophage DNA, 
plasmid DNA, or cosmid DNA; microorganisms such as 
yeast containing yeast vectors; mammalian cell systems 
infected with virus (e.g., vaccinia virus, adenovirus, etc.); 
insect cell systems infected with virus (e.g., baculovirus); 
and plant cells infected by bacteria. The expression elements 
of these vectors vary in their strength and specificities. 
Depending upon the host-vector System utilized, any one of 
a number of Suitable transcription and translation elements 
can be used. 
Different genetic signals and processing events control 
many levels of gene expression (e.g., DNA transcription and 
messenger RNA (mRNA) translation). 
Transcription of DNA is dependent upon the presence of 
a promoter which is a DNA sequence that directs the binding 
of RNA polymerase and thereby promotes mRNA synthesis. 
The DNA sequences of eukaryotic promoters differ from 
those of prokaryotic promoters. Furthermore, eukaryotic 
promoters and accompanying genetic signals may not be 
recognized in or may not function in a prokaryotic system, 
and, further, prokaryotic promoters are not recognized and 
do not function in eukaryotic cells. 
Similarly, translation of mRNA in prokaryotes depends 
upon the presence of the proper prokaryotic signals which 
differ from those of eukaryotes. Efficient translation of 
mRNA in prokaryotes requires a ribosome binding site 
called the Shine-Dalgarno (“SD) sequence on the mRNA. 
This sequence is a short nucleotide sequence of mRNA that 
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is located before the start codon, usually AUG, which 
encodes the amino-terminal methionine of the protein. The 
SD sequences are complementary to the 3'-end of the 16S 
rRNA (ribosomal RNA) and probably promote binding of 
mRNA to ribosomes by duplexing with the rRNA to allow 
correct positioning of the ribosome. For a review on maxi 
mizing gene expression, see Roberts and Lauer, Methods in 
Enzymology, 68:473 (1979), which is hereby incorporated 
by reference in its entirety. 
Promoters vary in their “strength” (i.e. their ability to 
promote transcription). For the purposes of expressing a 
cloned gene, it is desirable to use strong promoters in order 
to obtain a high level of transcription and, hence, expression 
of the gene. Depending upon the host cell system utilized, 
any one of a number of suitable promoters may be used. For 
instance, when cloning in E. coli, its bacteriophages, or 
plasmids, promoters such as the T7 phage promoter, lac 
promoter, trp promoter, recA promoter, ribosomal RNA 
promoter, the P and P. promoters of coliphage lambda and 
others, including but not limited, to lacUV5, ompl, bla, lpp, 
and the like, may be used to direct high levels of transcrip 
tion of adjacent DNA segments. Additionally, a hybrid 
trp-lacUV5 (tac) promoter or other E. coli promoters pro 
duced by recombinant DNA or other synthetic DNA tech 
niques may be used to provide for transcription of the 
inserted gene. 
Bacterial host cell strains and expression vectors may be 
chosen which inhibit the action of the promoter unless 
specifically induced. In certain operations, the addition of 
specific inducers is necessary for efficient transcription of 
the inserted DNA. For example, the lac operon is induced by 
the addition of lactose or IPTG (isopropylthio-beta-D-ga 
lactoside). A variety of other operons, such as trp, pro, etc., 
are under different controls. 
Specific initiation signals are also required for efficient 
gene transcription and translation in prokaryotic cells. These 
transcription and translation initiation signals may vary in 
'strength' as measured by the quantity of gene specific 
messenger RNA and protein synthesized, respectively. The 
DNA expression vector, which contains a promoter, may 
also contain any combination of various "strong transcrip 
tion and/or translation initiation signals. For instance, effi 
cient translation in E. coli requires an SD sequence about 
7–9 bases 5' to the initiation codon (ATG') to provide a 
ribosome binding site. Thus, any SD-ATG combination that 
can be utilized by host cell ribosomes may be employed. 
Such combinations include but are not limited to the SD 
ATG combination from the cro gene or the N gene of 
coliphage lambda, or from the E. coli tryptophan E, D, C, B 
or A genes. Additionally, any SD-ATG combination pro 
duced by recombinant DNA or other techniques involving 
incorporation of synthetic nucleotides may be used. 
Once the isolated DNA molecule encoding the polypep 
tide or protein has been cloned into an expression system, it 
is ready to be incorporated into a host cell. Such incorpo 
ration can be carried out by the various forms of transfor 
mation noted above, depending upon the vector/host cell 
system. Suitable host cells include, but are not limited to, 
bacteria, virus, yeast, mammalian cells, insect, plant, and the 
like. 
Because it is desirable for recombinant host cells to 
secrete the encoded protein or polypeptide, it is preferable 
that the host cell also possess a functional type III secretion 
system. The type III Secretion system can be heterologous to 
host cell (Ham et al., “A Cloned Erwinia chrysanthemi Hrp 
(Type III Protein Secretion) System Functions in Escheri 
chia coli to Deliver Pseudomonas syringae AVr Signals to 
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Plant Cells and Secrete Avr Proteins in Culture, Microbiol. 
95:10206-10211 (1998), which is hereby incorporated by 
reference in its entirety) or the host cell can naturally possess 
a type III secretion system. Host cells which naturally 
contain a type III secretion system include many pathogenic 
Gram-negative bacterium, Such as numerous Erwinia spe 
cies, Pseudomonas species, Xanthomonas species, etc. 
Other type III secretion systems are known and still others 
are continually being identified. Pathogenic bacteria that can 
be utilized to deliver effector proteins or polypeptides are 
preferably disarmed according to known techniques, i.e., as 
described above. Alternatively, isolation of the effector 
protein or polypeptide from the host cell or growth medium 
can be carried out as described above. 
Another aspect of the present invention relates to a 
transgenic plant which express a protein or polypeptide of 
the present invention and methods of making the same. 
In order to express the DNA molecule in isolated plant 
cells or tissue or whole plants, a plant expressible promoter 
is needed. Any plant-expressible promoter can be utilized 
regardless of its origin, i.e., viral, bacterial, plant, etc. 
Without limitation, two suitable promoters include the nopa 
line synthase promoter (Fraley et al., Proc. Natl. Acad. Sci. 
USA 80:4803–4807 (1983), which is hereby incorporated by 
reference in its entirety) and the cauliflower mosaic virus 
35S promoter (O'Dell et al., “Identification of DNA 
Sequences Required for Activity of the Cauliflower Mosaic 
Virus 35S Promoter,” Nature, 313(6005):810-812 (1985), 
which is hereby incorporated by reference in its entirety). 
Both of these promoters yield constitutive expression of 
coding sequences under their regulatory control. 
While constitutive expression is generally suitable for 
expression of the DNA molecule, it should be apparent to 
those of skill in the art that temporally or tissue regulated 
expression may also be desirable, in which case any regu 
lated promoter can be selected to achieve the desired expres 
Sion. Typically, the temporally or tissue regulated promoters 
will be used in connection with the DNA molecule that are 
expressed at only certain stages of development or only in 
certain tissues. 
In some plants, it may also be desirable to use promoters 
which are responsive to pathogen infiltration or stress. For 
example, it may be desirable to limit expression of the 
protein or polypeptide in response to infection by a particu 
lar pathogen of the plant. One example of a pathogen 
inducible promoter is the gstl promoter from potato, which 
is described in U.S. Pat. Nos. 5,750,874 and 5,723,760 to 
Strittmayer et al., each of which is hereby incorporated by 
reference in its entirety. 
Expression of the DNA molecule in isolated plant cells or 
tissue or whole plants also requires appropriate transcription 
termination and polyadenylation of mRNA. Any 3' regula 
tory region Suitable for use in plant cells or tissue can be 
operably linked to the first and second DNA molecules. A 
number of 3' regulatory regions are known to be operable in 
plants. Exemplary 3' regulatory regions include, without 
limitation, the nopaline synthase 3' regulatory region (Fra 
ley, et al., “Expression of Bacterial Genes in Plant Cells.” 
Proc. Natl. Acad. Sci. USA, 80:4803–4807 (1983), which is 
hereby incorporated by reference in its entirety) and the 
cauliflower mosaic virus 3' regulatory region (Odell, et al., 
“Identification of DNA Sequences Required for Activity of 
the Cauliflower Mosaic Virus 35S Promoter,” Nature, 313 
(6005):810-812 (1985), which is hereby incorporated by 
reference in its entirety). 
The promoter and a 3' regulatory region can readily be 
ligated to the DNA molecule using well known molecular 
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cloning techniques described in Sambrook et al., Molecular 
Cloning: A Laboratory Manual, Second Edition, Cold 
Spring Harbor Press, NY (1989), which is hereby incorpo 
rated by reference in its entirety. 
One approach to transforming plant cells with a DNA 
molecule of the present invention is particle bombardment 
(also known as biolistic transformation) of the host cell. This 
can be accomplished in one of several ways. The first 
involves propelling inert or biologically active particles at 
cells. This technique is disclosed in U.S. Pat. Nos. 4,945, 
050, 5,036,006, and 5,100,792, all to Sanford, et al., each of 
which is hereby incorporated by reference in its entirety. 
Generally, this procedure involves propelling inert or bio 
logically active particles at the cells under conditions effec 
tive to penetrate the outer surface of the cell and to be 
incorporated within the interior thereof When inert particles 
are utilized, the vector can be introduced into the cell by 
coating the particles with the vector containing the heter 
ologous DNA. Alternatively, the target cell can be sur 
rounded by the vector so that the vector is carried into the 
cell by the wake of the particle. Biologically active particles 
(e.g., dried bacterial cells containing the vector and heter 
ologous DNA) can also be propelled into plant cells. Other 
variations of particle bombardment, now known or hereafter 
developed, can also be used. 
Another method of introducing the DNA molecule into 
plant cells is fusion of protoplasts with other entities, either 
minicells, cells, lysosomes, or other fusible lipid-surfaced 
bodies that contain the DNA molecule. Fraley, et al., Proc. 
Natl. Acad. Sci. USA, 79:1859–63 (1982), which is hereby 
incorporated by reference in its entirety. 
The DNA molecule may also be introduced into the plant 
cells by electroporation. Fromm, et al., Proc. Natl. Acad. Sci. 
USA, 82:5824 (1985), which is hereby incorporated by 
reference in its entirety. In this technique, plant protoplasts 
are electroporated in the presence of plasmids containing the 
DNA molecule. Electrical impulses of high field strength 
reversibly permeabilize biomembranes allowing the intro 
duction of the plasmids. Electroporated plant protoplasts 
reform the cell wall, divide, and regenerate. 
Another method of introducing the DNA molecule into 
plant cells is to infect a plant cell with Agrobacterium 
tumefaciens or Agrobacterium rhizogenes previously trans 
formed with the DNA molecule. Under appropriate condi 
tions known in the art, the transformed plant cells are grown 
to form shoots or roots, and develop further into plants. 
Generally, this procedure involves inoculating the plant 
tissue with a Suspension of bacteria and incubating the tissue 
for 48 to 72 hours on regeneration medium without antibi 
otics at 25–28° C. 
Agrobacterium is a representative genus of the Gram 
negative family Rhizobiaceae. Its species are responsible for 
crown gall (A. tumefaciens) and hairy root disease (A. 
rhizogenes). The plant cells in crown gall tumors and hairy 
roots are induced to produce amino acid derivatives known 
as opines, which are catabolized only by the bacteria. The 
bacterial genes responsible for expression of opines are a 
convenient source of control elements for chimeric expres 
sion cassettes. In addition, assaying for the presence of 
opines can be used to identify transformed tissue. 
Heterologous genetic sequences such as a DNA molecule 
of the present invention can be introduced into appropriate 
plant cells by means of the Tiplasmid of A. tumefaciens or 
the Ri plasmid of A. rhizogenes. The Ti or Ri plasmid is 
transmitted to plant cells on infection by Agrobacterium and 
US 7,138,569 B2 
49 
is stably integrated into the plant genome. Schell, J., Science, 
237:1176–83 (1987), which is hereby incorporated by ref 
erence in its entirety. 
Plant tissue suitable for transformation include leaf tissue, 
root tissue, meristems, Zygotic and somatic embryos, and 
anthers. 
After transformation, the transformed plant cells can be 
selected and regenerated. 
Preferably, transformed cells are first identified using, 
e.g., a selection marker simultaneously introduced into the 
host cells along with the DNA molecule of the present 
invention. Suitable selection markers include, without limi 
tation, markers coding for antibiotic resistance, Such as 
kanamycin resistance (Fraley, et al., Proc. Natl. Acad. Sci. 
USA, 80:4803–4807 (1983), which is hereby incorporated 
by reference in its entirety). A number of antibiotic-resis 
tance markers are known in the art and other are continually 
being identified. Any known antibiotic-resistance marker 
can be used to transform and select transformed host cells in 
accordance with the present invention. Cells or tissues are 
grown on a selection media containing an antibiotic, 
whereby generally only those transformants expressing the 
antibiotic resistance marker continue to grow. 
Once a recombinant plant cell or tissue has been obtained, 
it is possible to regenerate a full-grown plant therefrom. 
Thus, another aspect of the present invention relates to a 
transgenic plant that includes a DNA molecule of the present 
invention, wherein the promoter induces transcription of the 
first DNA molecule in response to infection of the plant by 
an oomycete. Preferably, the DNA molecule is stably 
inserted into the genome of the transgenic plant of the 
present invention. 
Plant regeneration from cultured protoplasts is described 
in Evans, et al., Handbook of Plant Cell Cultures Vol. 1: 
(MacMillan Publishing Co., New York, 1983); and Vasil I. 
R. (ed.), Cell Culture and Somatic Cell Genetics of Plants, 
Acad. Press, Orlando, Vol. I, 1984, and Vol. III (1986), each 
of which is hereby incorporated by reference in their 
entirety. 
It is known that practically all plants can be regenerated 
from cultured cells or tissues, including but not limited to, all 
major species of rice, wheat, barley, rye, cotton, Sunflower, 
peanut, corn, potato, Sweet potato, bean, pea, chicory, let 
tuce, endive, cabbage, cauliflower, broccoli, turnip, radish, 
spinach, onion, garlic, eggplant, pepper, celery, carrot, 
Squash, pumpkin, Zucchini, cucumber, apple, pear, melon, 
Strawberry, grape, raspberry, pineapple, soybean, tobacco, 
tomato, Sorghum, and Sugarcane. 
Means for regeneration vary from species to species of 
plants, but generally a suspension of transformed protoplasts 
or a petri plate containing transformed explants is first 
provided. Callus tissue is formed and shoots may be induced 
from callus and Subsequently rooted. Alternatively, embryo 
formation can be induced in the callus tissue. These embryos 
germinate as natural embryos to form plants. The culture 
media will generally contain various amino acids and hor 
mones, such as auxin and cytokinins. It is also advantageous 
to add glutamic acid and proline to the medium, especially 
for Such species as corn and alfalfa. Efficient regeneration 
will depend on the medium, on the genotype, and on the 
history of the culture. If these three variables are controlled, 
then regeneration is usually reproducible and repeatable. 
After the DNA molecule is stably incorporated in trans 
genic plants, it can be transferred to other plants by sexual 
crossing or by preparing cultivars. With respect to sexual 
crossing, any of a number of standard breeding techniques 
can be used depending upon the species to be crossed. 
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Cultivars can be propagated in accord with common agri 
cultural procedures known to those in the field. 
Diseases caused by the vast majority of bacterial patho 
gens result in limited lesions. That is, even when everything 
is working in the pathogen's favor (e.g., no triggering of the 
hypersensitive response because of R-gene detection of one 
of the effectors), the parasitic process still triggers defenses 
after a couple of days, which then stops the infection from 
spreading. Thus, the very same effectors that enable para 
sitism to proceed must also eventually trigger defenses. 
Therefore, premature expression of these effectors is 
believed to “turn on plant defenses earlier (i.e., prior to 
infection) and make the plant resistant to either the specific 
bacteria from which the effector protein was obtained or 
many pathogens. An advantage of this approach is that it 
involves natural products and plants seem highly sensitive to 
pathogen effector proteins. 
According to one embodiment, a transgenic plant is 
provided that contains a heterologous DNA molecule of the 
present invention. When the heterologous DNA molecule is 
expressed in the transgenic plant, plant defenses are acti 
vated, imparting disease resistance to the transgenic plant. 
The transgenic plant can also contain an R-gene whose 
product is activated by the protein or polypeptide product of 
the heterologous DNA molecule. The R gene can be natu 
rally occurring in the plant or heterologously inserted 
therein. By disease resistance, it is believed that the effector 
proteins of the present invention can impart to plants resis 
tance against bacterial, viral, and/or fungal diseases. 
In addition to imparting disease resistance, it is believed 
that stimulation of plant defenses in transgenic plants of the 
present invention will also result in a simultaneous enhance 
ment in growth and resistance to insects. 
Alternative to transgenic expression is topical application 
of the effector proteins to plants. The embodiments of the 
present invention where the effector polypeptide or protein 
is applied to the plant can be carried out in a number of ways, 
including: 1) application of an isolated protein (or compo 
sition containing the same) or 2) application of bacteria 
which do not cause disease and are transformed with a gene 
encoding the effector protein of the present invention. In the 
latter embodiment, the effector protein can be applied to 
plants by applying bacteria containing the DNA molecule 
encoding the effector protein. Such bacteria are preferably 
capable of secreting or exporting the protein so that the 
protein can contact plant cells. In these embodiments, the 
protein is produced by the bacteria in planta. 
Such topical application can be carried out using an 
effector-TAT protein, which will afford transduction 
domain-mediated spontaneous uptake of the effector protein 
into cells. Basically, this is carried out by fusing an 11-amino 
acid peptide (YGRKKRRQRRR, SEQ ID No. 25) by stan 
dard rDNA techniques to the N-terminus of the effector 
protein, and the resulting tagged protein is taken up into 
animal cells by a poorly understood process. This peptide is 
the protein transduction domain (PTD) of the human immu 
nodeficiency virus (HIV) TAT protein (Schwarze et al., 
“Protein transduction: unrestricted delivery into all cells? 
Trends Cell Biol. 10:290–295 (2000), which is hereby incor 
porated by reference in its entirety). Other PTDs are known 
and can be used for this purpose (Prochiantz, "Messenger 
proteins: homeoproteins, TAT and others. Curr. Opin. Cell 
Biol. 12:400–406 (2000), which is hereby incorporated by 
reference in its entirety). See PCT Application Publication 
No. WO 01/19393 to Collmer et al., which is hereby 
incorporated by reference in its entirety. 
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When the effector protein is topically applied to plants, it 
can be applied as a composition, which includes a carrier in 
the form, e.g., of water, aqueous solutions, slurries, or dry 
powders. In this embodiment, the composition contains 
greater than about 5 nM of the protein of the present 
invention. 
Although not required, this composition may contain 
additional additives including fertilizer, insecticide, fungi 
cide, nematicide, and mixtures thereof Suitable fertilizers 
include (NH)NO. An example of a suitable insecticide is 
Malathion. Useful fungicides include Captan. 
Other suitable additives include buffering agents, wetting 
agents, coating agents, and, in Some instances, abrading 
agents. These materials can be used to facilitate the process 
of the present invention. 
According to one embodiment, a transgenic plant includ 
ing a heterologous DNA molecule of the present invention 
expresses one or more effector proteins, wherein the trans 
genic plant is capable of Supporting growth of compatible 
nonpathogenic bacteria. The compatible nonpathogenic bac 
teria can be naturally occurring or it can be recombinant. 
Preferably, the nonpathogenic bacteria is recombinant and 
expresses one or more useful products. Thus, the transgenic 
plant becomes a green factory for producing desirable 
products. Desirable products include, without limitation, 
products that can enhance the nutritional quality of the plant 
or products that are desirable in isolated form If desired in 
isolated form, the product can be isolated from plant tissues. 
To prevent competition between the non-pathogenic bacteria 
which express the desired product and those that do not, it 
is possible to tailor the needs of recombinant, non-patho 
genic bacteria so that only they are capable if living in plant 
tissues expressing a particular effector protein or polypep 
tide of the present invention. 
The effector proteins or polypeptides of the present inven 
tion are believed to alter the plant physiology by shifting 
metabolic pathways to benefit the parasite and by activating 
or Suppressing cell death pathways. Thus, they may also 
provide useful tools for efficiently altering the nutrient 
content of plants and delaying or triggering Senescence. 
There are agricultural applications for all of these possible 
effects. 
Thus, a further aspect of the present invention relates 
more generally to a method of modifying a metabolic 
pathway in a cell by introducing into the cell an effector 
protein or polypeptide of the present invention which inter 
acts with a native cellular protein involved in a metabolic 
pathway of the cell. As a result of introducing the protein or 
polypeptide into the cell, the protein or polypeptide modifies 
the metabolic pathway through its interaction with the native 
cellular protein. By way of example, the HopPsyA protein 
(SEQ ID No. 22) is believed to interact with Mad2. 
Yet another aspect of the present invention relates to a 
method of causing eukaryotic cell death which is carried out 
by introducing into a eukaryotic cell a Pseudomonas protein 
which is cytotoxic and causes cell death. One preferred 
protein of the present invention is HopPsy A (SEQID No: 
22), homolog of HopPsyA. The eukaryotic cell which is 
treated can be either in vitro or in vivo. When treating 
eukaryotic cells in vivo, a number of different protein- or 
DNA-delivery systems can be employed to introduce the 
effector protein into the target eukaryotic cell. 
The protein- or DNA-delivery systems can be provided in 
the form of pharmaceutical compositions which include the 
delivery system in a pharmaceutically acceptable carrier, 
which may include suitable excipients or stabilizers. The 
dosage can be in Solid or liquid form, Such as powders, 
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Solutions, Suspensions, or emulsions. Typically, the compo 
sition will contain from about 0.01 to 99 percent, preferably 
from about 20 to 75 percent of active compound(s), together 
with the carrier, excipient, stabilizer, etc. 
The compositions of the present invention are preferably 
administered in injectable or topically-applied dosages by 
Solution or Suspension of these materials in a physiologically 
acceptable diluent with a pharmaceutical carrier. Such car 
riers include sterile liquids, such as water and oils, with or 
without the addition of a surfactant and other pharmaceuti 
cally and physiologically acceptable carrier, including adju 
vants, excipients or stabilizers. Illustrative oils are those of 
petroleum, animal, vegetable, or synthetic origin, for 
example, peanut oil, soybean oil, or mineral oil. In general, 
water, saline, aqueous dextrose and related Sugar Solution, 
and glycols, such as propylene glycol or polyethylene gly 
col, are preferred liquid carriers, particularly for injectable 
Solutions. 
Alternatively, the effector proteins can also be delivered 
via Solution or Suspension packaged in a pressurized aerosol 
container together with Suitable propellants, for example, 
hydrocarbon propellants like propane, butane, or isobutane 
with conventional adjuvants. The materials of the present 
invention also may be administered in a non-pressurized 
form such as in a nebulizer or atomizer. 
Depending upon the treatment being effected, the com 
pounds of the present invention can be administered orally, 
topically, transdermally, parenterally, Subcutaneously, intra 
venously, intramuscularly, intraperitoneally, by intranasal 
instillation, by intracavitary or intravesical instillation, 
intraocularly, intraarterially, intralesionally, or by applica 
tion to mucous membranes, such as, that of the nose, throat, 
and bronchial tubes. 
Compositions within the scope of this invention include 
all compositions wherein the compound of the present 
invention is contained in an amount effective to achieve its 
intended purpose. While individual needs vary, determina 
tion of optimal ranges of effective amounts of each compo 
nent is within the skill of the art. 
One approach for delivering an effector protein into cells 
involves the use of liposomes. Basically, this involves 
providing a liposome which includes that effector protein to 
be delivered, and then contacting the target cell with the 
liposome under conditions effective for delivery of the 
effector protein into the cell. 
Liposomes are vesicles comprised of one or more con 
centrically ordered lipid bilayers which encapsulate an aque 
ous phase. They are normally not leaky, but can become 
leaky if a hole or pore occurs in the membrane, if the 
membrane is dissolved or degrades, or if the membrane 
temperature is increased to the phase transition temperature. 
Current methods of drug delivery via liposomes require that 
the liposome carrier ultimately become permeable and 
release the encapsulated drug at the target site. This can be 
accomplished, for example, in a passive manner wherein the 
liposome bilayer degrades over time through the action of 
various agents in the body. Every liposome composition will 
have a characteristic half-life in the circulation or at other 
sites in the body and, thus, by controlling the half-life of the 
liposome composition, the rate at which the bilayer degrades 
call be somewhat regulated. 
In contrast to passive drug release, active drug release 
involves using an agent to induce a permeability change in 
the liposome vesicle. Liposome membranes can be con 
structed so that they become destabilized when the environ 
ment becomes acidic near the liposome membrane (see, e.g., 
Proc. Natl. Acad. Sci. USA 84:7851 (1987); Biochemistry 
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28:908 (1989), each of which is hereby incorporated by 
reference in their entirety). When liposomes are endocy 
tosed by a target cell, for example, they can be routed to 
acidic endosomes which will destabilize the liposome and 
result in drug release. 
Alternatively, the liposome membrane can be chemically 
modified Such that an enzyme is placed as a coating on the 
membrane which slowly destabilizes the liposome. Since 
control of drug release depends on the concentration of 
enzyme initially placed in the membrane, there is no real 
effective way to modulate or alter drug release to achieve 
“on demand drug delivery. The same problem exists for 
pH-sensitive liposomes in that as soon as the liposome 
vesicle comes into contact with a target cell, it will be 
engulfed and a drop in pH will lead to drug release. 
This liposome delivery system can also be made to 
accumulate at a target organ, tissue, or cell via active 
targeting (e.g., by incorporating an antibody or hormone on 
the surface of the liposomal vehicle). This can be achieved 
according to known methods. 
Different types of liposomes can be prepared according to 
Bangham et al., J. Mol. Biol. 13:238–252 (1965); U.S. Pat. 
No. 5,653,996 to Hsu et al.; U.S. Pat. No. 5,643,599 to Lee 
et al., U.S. Pat. No. 5,885,613 to Holland et al.; U.S. Pat. No. 
5,631,237 to Dzau et al.; and U.S. Pat. No. 5,059,421 to 
Loughrey et al., each of which is hereby incorporated by 
reference in their entirety. 
An alternative approach for delivery of effector proteins 
involves the conjugation of the desired effector protein to a 
polymer that is stabilized to avoid enzymatic degradation of 
the conjugated effector protein. Conjugated proteins or 
polypeptides of this type are described in U.S. Pat. No. 
5,681,811 to Ekwuribe, which is hereby incorporated by 
reference in its entirety. 
Yet another approach for delivery of proteins or polypep 
tides involves preparation of chimeric proteins according to 
U.S. Pat. No. 5,817,789 to Heartlein et al., which is hereby 
incorporated by reference in its entirety. The chimeric pro 
tein can include a ligand domain and, e.g., an effector protein 
of the present invention. The ligand domain is specific for 
receptors located on a target cell. Thus, when the chimeric 
protein is delivered intravenously or otherwise introduced 
into blood or lymph, the chimeric protein will adsorb to the 
targeted cell, and the targeted cell will internalize the chi 
meric protein, which allows the effector protein to de 
stabilize the cell checkpoint control mechanism, affording 
its cytotoxic effects. 
When it is desirable to achieve heterologous expression of 
an effector protein of the present invention in a target cell, 
DNA molecules encoding the desired effector protein can be 
delivered into the cell. Basically, this includes providing a 
nucleic acid molecule encoding the effector protein and then 
introducing the nucleic acid molecule into the cell under 
conditions effective to express the effector protein in the cell. 
Preferably, this is achieved by inserting the nucleic acid 
molecule into an expression vector before it is introduced 
into the cell. 
When transforming mammalian cells for heterologous 
expression of an effector protein, an adenovirus vector can 
be employed. Adenovirus gene delivery vehicles can be 
readily prepared and utilized given the disclosure provided 
in Berkner, Biotechniques 6:616–627 (1988) and Rosenfeld 
et al., Science 252:431–434 (1991), WO 93/07283, WO 
93/06223, and WO 93/07282, each of which is hereby 
incorporated by reference in their entirety. Adeno-associated 
viral gene delivery vehicles can be constructed and used to 
deliver a gene to cells. The use of adeno-associated viral 
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gene delivery vehicles in vitro is described in Chatterjee et 
al., Science 258: 1485–1488 (1992); Walsh et al., Proc. Natl. 
Acad. Sci. 89:7257 7261 (1992); Walsh et al., J. Clin Invest. 
94: 1440–1448 (1994); Flotte et al., J. Biol. Chem. 268: 
3781–3790 (1993); Ponnazhagan et al., J. Exp. Med 179: 
733–738 (1994); Miller et al., Proc. Nat'l Acad. Sci. 
91:10183–10187 (1994); Einerhand et al., Gene Ther. 
2:336–343 (1995); Luo et al., Exp. Hematol. 23:1261–1267 
(1995); and Zhou et al., Gene Ther. 3:223–229 (1996), each 
of which is hereby incorporated by reference in their 
entirety. In vivo use of these vehicles is described in Flotte 
et al., Proc. Nat'l Acad. Sci. 90:10613-10617 (1993); and 
Kaplitt et al., Nature Genet. 8:148-153 (1994), each of 
which is hereby incorporated by reference in their entirety. 
Additional types of adenovirus vectors are described in U.S. 
Pat. No. 6,057,155 to Wickham et al.; U.S. Pat. No. 6,033, 
908 to Bout et al.; U.S. Pat. No. 6,001,557 to Wilson et al.: 
U.S. Pat. No. 5,994,132 to Chamberlain et al.; U.S. Pat. No. 
5,981,225 to Kochanek et al.; and U.S. Pat. No. 5,885,808 
to Spooner et al.; and U.S. Pat. No. 5,871,727 to Curiel, each 
of which is hereby incorporated by reference in their 
entirety). 
Retroviral vectors which have been modified to form 
infective transformation systems can also be used to deliver 
nucleic acid encoding a desired effector protein into a target 
cell. One such type of retroviral vector is disclosed in U.S. 
Pat. No. 5,849,586 to Kriegler et al., which is hereby 
incorporated by reference in its entirety. 
Regardless of the type of infective transformation system 
employed, it should be targeted for delivery of the nucleic 
acid to a specific cell type. For example, for delivery of the 
nucleic acid into tumor cells, a high titer of the infective 
transformation system can be injected directly within the 
tumor site so as to enhance the likelihood of tumor cell 
infection. The infected cells will then express the desired 
effector protein, thereby causing cytotoxic effects. 
Particularly preferred is use of the effector proteins of the 
present invention to treat a cancerous condition (i.e., the 
eukaryotic cell which is affected is a cancer cell). This can 
be carried out by introducing or administering to a patient, 
a cytotoxic Pseudomonas protein under conditions effective 
to inhibit cancer cell division, thereby treating the cancer 
condition. 
By introducing, it is intended that the effector protein is 
administered to the patient, preferably in the form of a 
composition which will target delivery to the cancer cells. 
Alternatively, when using DNA-based therapies, it is 
intended that the introducing be carried out by administering 
a targeted DNA delivery system to the patient such that the 
cancer cells are targeted and the effector protein is expressed 
therein. A number of known targeted delivery systems are 
known in the art and can be employed herewith. 
EXAMPLES 
The following Examples are intended to be illustrative 
and in no way are intended to limit the scope of the present 
invention. 
Example 1 
Detection of Protein Expression by Pseudomonas 
syringae pv. tomato DC3000 
ORF-specific DNA fragments were amplified by PCR 
from DC3000 genomic DNA and printed onto amine-coated 
slides from Cell Associates (Houston). Each DNA sample 
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was printed three times on each slide with a BioRobotics (Boston) Microgrid II Arrayer by using MicroSpot2500 split 
pins. Slides were blocked according to the recommended 
protocol from Cell Associates. Of total RNA, 50–100 ug was 
used to synthesize cDNA probes for microarray analysis. 
RNA was mixed with 3 lug of random hexamers (Invitrogen) 
in a total volume of 15ul and incubated at 65° C. for 10 min. 
Reactions were then placed on ice for 2 min, to which were 
added 3 ul of 1 mM FluoroLink Cy3- or Cy5-dUTP (Amer 
sham Biosciences, Piscataway, N.J.), 3 ul of 0.1 M DTT, 6 
ul of 5x first-strand buffer, 0.6 ul of 50xdNTPs mix (25 mM 
dATP, dCTP, dGTP/10 mM dTTP), and 2 ul of Superscript 
II (GIBCO/BRL). Reactions were incubated at room tem 
perature for 10 min, followed by 42° C. for 110 min. RNA 
was hydrolyzed by adding 1.5ul of 1 M NaOH at 65° C. for 
10 min followed by neutralizing with 1.5 ul of 1 M HCl. 
cDNA probes were purified by using a PCR purification kit 
(Qiagen, Valencia, Calif.) and were resuspended in 20 Jul of 
hybridization buffer (5xSSC, 0.1% SDS, and 25% forma 
mide, where 1 xSSC=0.15 M sodium chloride/0.015 M 
sodium citrate, pH 7). Denatured probes (99° C., 2 min) 
were hybridized to slides at 60° C. overnight in hybridiza 
tion cassettes (Coming), after which slides were washed 
twice with 2xSSC, 0.1% SDS (60° C., 5 min), once with 
2xSSC (room temperature, 5 min), and once with 0.2xSSC 
(room temperature, 5 min). 
Microarray images were visualized by using a Scan Array 
5000 (Packard), using laser and PMT settings of 100 and 90, 
respectively. Images were overlaid and quantified by using 
IMAGENE 4.1 software (BioDiscovery: Marina Del Rey, 
Calif.). Ratio data were extracted by using GENESIGHT 2.1 
software (BioDiscovery). For these analyses, local back 
ground for each spot was corrected, and signals lower than 
50 were flagged and eliminated. After flooring low signals to 
the value of 100, ratios of the overlaid images were calcu 
lated for individual spots. 16S rRNA was used and, to 
normalize the data, the 16S rRNA was expressed to similar 
levels in both tested strains based on RNA blots. Finally, all 
of the replicated data were combined, and mean ratio data 
and SDs were calculated for each ORF. 
To corroborate the microarray results, RNA blotting was 
performed on 10 ORFs from similarly grown cultures. RNA 
blot analyses were performed as described (Sambrook et al., 
Molecular Cloning. A Laboratory Manual, Cold Spring 
Harbor Lab. Press, Plainview, N.Y. (1989), which is hereby 
incorporated by reference). Of each RNA sample, 25 ug was 
resolved on 1.2% formaldehyde-agarose gels and transferred 
to Nylon membranes (Hybond-N+) by capillary blotting 
using 20xSSC. transferred to Nylon membranes (Hybond 
N+) by capillary blotting using 20xSSC. RNA was bound to 
the membrane by UV cross-linking. Probes were generated 
by PCR amplification from genomic DNA, using ORF 
specific primers, and labeled with P-dATP by random 
priming with a DECAprime II kit (Ambion). Hybridization 
was performed in 5xSSC, 50% formamide, 0.1% sodium 
lauroylsarcosine,0.02% SDS, and 2% blocking reagent 
(Roche Molecular Biochemicals) at 42°C. overnight. Mem 
branes were then washed twice with 2XSSC/0.1% SDS for 
15 min, twice with 1xSSC/0.1% SDS for 15 min, and once 
with 0.1xSSC/0.1% SDS for 15 min before exposure on a 
phosphor Screen. Signals were detected and evaluated by 
using a Storm system (Molecular Dynamics) (FIG. 1). 
The microarray experiments were in qualitative agree 
ment with the RNA blot. These data indicate that Hrp 
promoter candidates with E Values Smaller (more signifi 
cant) than 1e-4 are expressed at levels detected by the 
microarray and RNA blotting. However, within this group 
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there was no apparent relationship between the magnitude of 
the E value and the level of expression. Furthermore, one of 
16 examined ORFs (see Fouts et al. (Proc. Natl. Acad. Sci 
USA99:2275–2280 (2002), which is hereby incorporated by 
reference in its entirety) with an E value substantially lower 
than this threshold, AvrXV3 (4e–6), was expressed at a level 
that was detected only by RNA blot analysis (Table 1 
below), indicating that significant E values do not always 
predict strong expression. 
TABLE 1. 
Results of Microarray Analysis 
GenBank Amino 
Des- accession acid BLASTP HMM Microarray 
ignation number' % identity p value E-value signal ratio? 
HopPsyAP, L14926 52 9e-93 1.0e-5 11 - 9 
AvrPphEp, U16817 67 1e-117 2.5e-4 5 - 2 
AvrPphFP, AF231452 51 3e-36 1.7e-6 3 - 2 
AvrPphD1 AJ277494 89 O 1.9e-6 30 - 17 
AvrXv3P, AF190120 27 7e-12 3.4e-6 ND 
AvrPpiB1, X84843 100 1e-152 7.8e-6 11 - 9 
AvrPpiB2p X84843 100 1e-1SO 7.8e-6 10 - 6 
AvrPphD2, AJ277494 53 2e-44 3.0e-5 27 11 
HopPtoB2 AF232004 2.6e-3 ND 
AvrRps4p L43559 72 2e-44 2.5e-2 ND 
Reference genes 
16S rRNA 1 
23S rRNA** 1 
GenBank accession number AF232004 is for DC3000 sequences, all oth 
ers are for homologs originally found in other bacteria. 
“Microarray signal is the mean ratio and standard deviation from 3 repli 
cates of 2 independent experiments, calculated as described in the Materi 
als and Methods. AvrPpiB1 and AvrPpiB2B are 100% identical, so their 
signals cannot be distinguished. AVrPph)1P and AVrPphi)2P, are 62% 
identical. ND = not detected. 
HopPtoB1 is secreted in a Hrp-dependent manner; HopPtoB2 has dupli 
cated regions of homology with HopPtoB1. 
By using an iterative process involving computational and 
gene expression data, an initial inventory of P. S. tomato 
DC3000 candidate type III secretion effector proteins was 
obtained. These are the presumed prime agents of host 
metabolic subversion. These analyses have revealed that the 
Hrp regulon, the primary regulon known to be expressed 
during infection, seems to control at least 48 genes and a 
Subsidiary regulon directing phytotoxin production. The 
iterative process focused on Hrp promoters in DC3000 and 
featured microarray experiments that tested the activity of 
novel Hrp promoters and demonstrated the validity of this 
approach for genomewide transcriptional profiling in 
DC3000. These findings suggest that the P. syringae Hrp 
regulon is more complex than expected and encompasses 
more than type III secretion system genes and effector genes. 
The global search for DC3000 ORFs that are similar to 
known Avr/Hop proteins yielded AvrXV3, AvrPtoB, and 
the AvrPphl) families as the only candidate effectors shared 
with Xanthomonas spp. (Noel et al., Mol. Microbiol. 
41:1271–1281 (2001), which is hereby incorporated by 
reference in its entirety). Notably missing were members of 
the AvrBs2 and AvrBs3 families, which are widespread in 
Xanthomonas spp., or any members of the AvrRXV/Yop.J 
family, which are found in genera as diverse as Salmonella, 
Yersinia, Xanthomonas, Erwinia, and Rhizobium, and have 
also been reported in another strain of P. Syringae (i.e., P. S. 
syringae B728a) (Galán & Collmer, Science 284:1322–1328 
(1999); Alfano et al., Proc. Natl. Acad. Sci. USA 
97:4856–4861 (2000), each of which is hereby incorporated 
by reference in its entirety). However, it is important to note 
that further searches after closure and annotation of the 
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DC3000 genome may yield additional homologs of known 
effectors. In addition, genomic projects with other pathogens 
will enlarge the set of candidate effector genes available for 
comparison. 
The majority of P. syringae avr genes that have been 
cloned on the basis of AVr phenotype have come from three 
pathovars that parasitize legumes glycinea, phaseolicola, 
and pisi. P. S. tomato has a different host range and diverges 
from these other pathovars in rRNA comparisons (Manceau 
& Horvais, Appl. Environ. Microbiol. 63:498–505 (1997), 
which is hereby incorporated by reference in its entirety). 
Nevertheless, of the 15 avr gene families found in these 
legume-attacking pathovars, 6 are also found in DC3000. 
This finding Suggests the existence of a core set of P 
syringae effectors in addition to those in the Hrp pathoge 
nicity island CEL. 
The analyses described above and reported in Fouts et al. 
(Proc. Natl. Acad. Sci USA99: 2275–2280 (2002), which is 
hereby incorporated by reference in its entirety) revealed a 
striking apparent redundancy among the candidate effector 
protein genes hopPtoA, hopPtoB, avrPphl), and 
avrPpiB1, as well as in three Hrp-related factors that may 
play a role in type III protein translocation across bacterial 
and plant cell walls. 
All of the analyzed candidate effector genes seem to be 
expressed in a HrpL-dependent manner except for 
avrRps4, hopPtoA2, and hopPtoB2 (avrXV3 was 
HrpL-activated, but relatively poorly). avrRps4 was 
cloned originally from Pseudomonas Syringae pisi and ren 
ders recombinant DC3000 avirulent on most Arabidopsis 
accessions (Hinsch & Staskawicz, Mol. Plant-Microbe 
Interact. 9:55–61 (1996), which is hereby incorporated by 
reference in its entirety), and avrXV3 is from an Xanthomo 
nas campestris pv. vesicatoria race that is avirulent on 
tomato carrying the XV3 R gene (Astua-Monge et al., Mol. 
Plant-Microbe Interact. 13:911–921 (2000), which is hereby 
incorporated by reference in its entirety). There exists a 
possibility that poor expression of these two avr genes in 
DC3000 is a factor in the virulence of DC3000 on Arabi 
dopsis and tomato carrying the cognate R genes. 
Example 2 
In vitro Secretion of Effector Proteins 
Secretion assays were performed using P. S. tomato 
DC3000 strains carrying a pML 123 derivative containing a 
PCR-cloned ORF (encoding a candidate Hrp-secreted pro 
tein) fused to nucleotide sequences that encoded either the 
HA or FLAG epitopes along with their native ribosome 
binding sites and an engineered stop codon (Labes et al., 
Gene 89:37–46 (1990), which is hereby incorporated by 
reference in its entirety). 
Four effector proteins were tested for their secretion from 
the above-identified strains. Primers and the constructs used 
to prepare the transform the host strains are identified as 
follows: 
For HopPtoC expression, the hopPtoC gene was cloned 
using forward primer (agteggatccgaataggg.cgct 
gaaaatatgacaatcgtgtc., SEQID No. 26) containing a BamHI 
site and reverse primer (agtCcticgagtcacttgtcatcgtcgtc 
cttgtagtcgtgtatttittgaag.cgaa, SEQ ID No. 27) containing an 
XhoI site and FLAG epitope codons. The hopPtoC gene was 
cloned into plasmid vector plN50. 
For HopPtol D1 expression, the hopPtold 1 gene was cloned 
using forward primer (ccacacattggatccgattactitcatc 
cgggacagctgatagcgc, SEQ ID No. 28) containing a BamHI 
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site and reverse primer (attcticgagtcatttatcatcat 
catctittataatcgggtgcgggctg.ccg.cgac, SEQID No. 29) contain 
ing an XhoI site and FLAG epitope codons. The hopPtold 1 
gene was cloned into plasmid vector plN167. 
For HopPtol)2 expression, the hopPtol D2 gene was cloned 
using forward primer (atgcaagcttatccaatgcctttcgtca, SEQID 
No. 30) containing a HindIII site and reverse primer (atgc 
cticgagtcaagcgtaatctggaacatcgtatggg tattotaacgctatttittgc, SEQ 
ID No. 31) containing an XhoI site and HA epitope codons. 
The hopPtol)2 gene was cloned into plasmid vector 
pLN130. 
For HopPtol expression, the hopPtol gene was cloned 
using forward primer (agtaaagcttgagctgcacgcatgcgag, SEQ 
ID No. 32) containing a HindIII site and reverse primer (agtatctagatcacttgtcatcgtegtecttgtagtettgtgcgaccagatgttt, 
SEQID No. 33) containing an Xbal site and FLAG epitope 
codons. The hopPtol gene was cloned into plasmid vector 
pLN164. 
Constructs carrying different epitope-tagged ORFs were 
electroporated into DC3000 and a DC3000 hrcC mutant and 
grown in Hrp-inducing conditions (Yuan & He, J. Bacteriol. 
178:6399–6402 (1996), which is hereby incorporated by 
reference in its entirety). Additionally, all of the DC3000 
strains also carried pCPP2318, a construct that contains 
blaM lacking signal peptide sequences (Charkowski et al., J. 
Bacteriol. 179:3866–3874 (1997), which is hereby incorpo 
rated by reference in its entirety). DC3000 cultures were 
separated into cell-bound and Supernatant fractions as 
described (van Dijk et al., J. Bacteriol. 181:4790 4797 
(1999), which is hereby incorporated by reference in its 
entirety). Proteins were separated with SDS-PAGE by stan 
dard procedures (Sambrook et al., Molecular Cloning Sec 
ond Ed. (Cold Spring Harbor Laboratory Press, Cold Spring 
Harbor, N.Y.) (1989), which is hereby incorporated by 
reference in its entirety), transferred to polyvinylidene dif 
luoride membranes, and immunoblotted using anti-FLAG 
(Sigma Chemical Co., St. Louis, Mo.), -HA (Roche Molecu 
lar Biochemicals, Indianapolis, Ind.), or -3-lactamase (5 
Prime->3 Prime Inc., Boulder, Colo.) as primary antibodies. 
Primary antibodies were recognized by goat anti-rabbit 
immunoglobulin G-alkaline phosphatase conjugate (Sigma 
Chemical Co.), which were visualized by chemilumines 
cence using a Western-Light chemilumincescence detection 
system (Tropix. Bedford, Mass.) and X-Omat X-ray film. 
Each of these DC3000 proteins were found to be secreted 
(FIG. 2A). Because the secretability of these proteins was 
demonstrated (and the avirulence activity of these DC3000 
homologs is unknown), the proteins were renamed as HopP 
toC (AvrPpiC2 homolog), HopPtoD1 and HopPtolD2 (Avr 
PphD homologs), and HopPtol (AvrXV3 homolog). 
Example 3 
In vitro Translocation of Effectors 
Arabidopsis thaliana accession Columbia (Col-0) and 
rps2–201 mutant plants were grown in a growth chamber 
with 12 hr of light at 24° C. (22° C. at night) and 70% 
relative humidity. For HopPtoK expression, the hopPtoK 
gene was cloned using forward primer (gcgaattcatcggtttaat 
cacgcaaggc, SEQ ID No. 34) containing a EcoRI site and 
reverse primer (ttggtacctcagcagtagagcgtgt, SEQID No. 35) 
containing an Kipnl site. The hopPtoK gene was cloned into 
plasmid vector phopPtoK. In addition, a hopPtoK-'avrRpt2 
fusion was prepared using SEQ ID No. 34 (above) as 
forward primer and reverse primer (aaggatcc.gcagagcgt 
gtcgcgacc, SEQ ID No. 36) containing an BamHI site to 
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clone the hopPtoK gene. The partial avrRpt2 gene with the 
N terminal 40 codons deleted was amplified using standard 
PCR procedures and cloned into pMOD (Madison, Wis.). 
After confirmation by sequence analysis, it was cloned into 
the KpnI and SalI sites of the broad-host-plasmid plK, 
resulting in paavrRpt2. DNA fragments spanning 200 bp 
upstream of the Hrp boxes and the complete ORFs for 
hopPtoK was cloned into paavrRpt2 to produce phopPtoK 
AavrRpt2. Additionally, the full-length hopPtoK was cloned 
using PCR into pIK to generate phopPtoK. Each construct 
was introduced in P. S. phaseolicola 3121 by electroporation. 
Bacterial strains in 10 mM MgCl, at a cell density of 10 
cfu/ml were infiltrated into A. thaliana Col-O plants with a 
needleless Syringe. Plant responses were documented 18 
hours postinoculation. 
The AVrRpt2 translocation assay was used to test whether 
the DC3000 ORF that is similar to AvrRps4 (Hinsch & 
Staskawicz, Mol. Plant-Microbe Interact. 9:55–61 (1996), 
which is hereby incorporated by reference in its entirety) 
was translocated into Arabidopsis plant cells (Mudgett et al., 
Proc. Natl. Acad. Sci. USA 97:13324-13329 (2000):Gutt 
man & Greenberg, Mol. Plant-Microbe Interact. 
14:145-155) (2001), each of which is hereby incorporated 
by reference in its entirety). P. S. phaseolicola carrying a 
broad-host-range plasmid expressing the AVrRps4 homolog 
fused to the Avr domain of AvrRpt2 (but lacking the secre 
tion signals of AvrRpt2) elicited an RPS2-dependent HR on 
A. thaliana Col-0 (FIG. 2B), indicating that the amino 
terminus of the AvrRps4 homolog supplied sufficient infor 
mation to direct translocation of the fusion protein into plant 
cells. Consequently, the AVrRps4 homolog was renamed 
HopPtoK. P. S. phaseolicola expressing HopPtoK did not 
elicit an HR, indicating that although translocated into host 
cells, HopPtoK is probably not recognized by the RPS4 
protein present in A. thaliana Col-0, in contrast to its P. S. 
pisi 151 homolog (Hinsch & Staskawicz, Mol. Plant-Mi 
crobe Interact. 9:55–61 (1996), which is hereby incorpo 
rated by reference in its entirety). 
Example 4 
Determining Cytotoxicity of Effector in Yeast 
Effector proteins of the present invention will be cloned 
into pFLAG-CTC (Kodak) to generate an in-frame fusion 
with the FLAG epitope, which will permit monitoring of 
protein production with anti-FLAG monoclonal antibodies. 
The FLAG-tagged genes will then be cloned under the 
control of the GAL1 promoter in the yeast shuttle vector 
p415GAL1 (Mumberg et al., 1994). These regulatable pro 
moters of Saccharomyces cerevisiae will allow comparison 
of transcriptional activity and heterologous expression. The 
recombinant plasmids will be transformed into uracil aux 
otrophic yeast strains FY833/4, then selected for growth on 
SC-Ura (synthetic complete medium lacking uracil) based 
on the presence of the URA3 gene on the plasmid. The 
transformants will then be streaked onto SC-Ura medium 
plates containing either 2% galactose (which will induce 
expression of the effector proteins) or 2% glucose. The 
presence or absence of growth on the plates Supplemented 
with 2% galactose will be observed. If no growth is observed 
on 2% galactose (but growth is observed in the 2% glucose 
control), this result will suggest that the effector protein is 
having a cytotoxic effect on the transformed yeast. Empty 
vector controls will also be used. FLAG-tagged nontoxic 
Avr proteins will be used to confirm that the recombinant 
effector genes were differentially expressed, as expected, on 
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plates containing galactose. To further confirm the results, 
albeit at lower expression levels, the recombinant effector 
gene will be recloned into p416GALS, which expresses 
foreign genes at a substantially lower level than p415GAL1. 
Example 5 
Determining Cytotoxicity of Effector in Plants 
To determine whether effector proteins induce cell death 
on tobacco leaves, a transformation system that delivers the 
effector gene on T-DNA of Agrobacterium tumefaciens will 
be used (Rossi et al., Plant Mol. Biol. Reporter 11:220–229 
(1993); van den Ackerveken et al., Cell 87: 1307–1316 
(1996), each of which is hereby incorporated by reference in 
its entirety). This delivery system works better than biolis 
tics for transiently transforming whole plant leaves. For 
these experiments, vector pTA7002, kindly provided by 
Nam-Hai Chua and his colleagues at Rockefeller University, 
will be used. The unique property of this vector is that it 
contains an inducible expression system that uses the regu 
latory mechanism of the glucocorticoid receptor (Picard et 
al., Cell 54:1073–1080 (1988); Aoyama and Chua, Plant J. 
11(3):605–612 (1997); McNellis et al., Plant J. 14(2): 
247-257 (1998), each of which is hereby incorporated by 
reference in its entirety). pTA7002 encodes a chimeric 
transcription factor consisting of the DNA-binding domain 
of GAL4, the transactivating domain of the herpes viral 
protein VP16, and the receptor domain of the rat glucocor 
ticoid receptor. Also contained on this vector is a promoter 
containing GAL4 upstream activating sequences (UAS) 
upstream of a multiple cloning site. Thus, any gene cloned 
downstream of the promoter containing the GAL4-UAS can 
be induced by glucocorticoids, of which a synthetic gluco 
corticoid, dexamethasone (DEX), is available commercially. 
Effector proteins of the present invention will be PCR 
cloned downstream of the GAL4-UAS. Thereafter, plant 
leaves from several different test plants will be infiltrated 
with Argrobacterium carrying recombinant pTA7002 carry 
ing the effector ORF and after 48 hours these plants will be 
sprayed with DEX to induce expression of the effectors. 
Tobacco (Nicotiana tabacum) and tomato (Lycopersicon 
esculentum) will be grown undergreenhouse conditions and 
then maintained at 25° C. with daylight and supplemental 
halide illumination for HR and virulence assays. Bacteria 
will be grown overnight on King's medium Bagar Supple 
mented with appropriate antibiotics, suspended in 5 mM 
MES pH 5.6, and then infiltrated with a needleless syringe 
into the leaves of test plants at 10 cfu/ml for HR assays and 
10 cfu/ml for pathogenicity assays (Charkowski et al., J. 
Bacteriol. 180:5211–5217 (1998), which is hereby incorpo 
rated by reference in its entirety). All assays will be repeated 
at least four times on leaves from different plants. Bacterial 
growth in tomato leaves will be assayed by excising disks 
from infiltrated areas with a cork borer, comminuting the 
tissue in 0.5 ml of 5 mM MES, pH 5.6, with an appropriate 
pestle, and then dilution plating the homogenate on King's 
medium B agar with 50 ug/ml rifampicin and 2 g/ml 
cycloheximide to determine bacterial populations. The mean 
and SD from three leaf samples will be determined for each 
time point. 
Plant leaves will be examined to determine the response 
of plant tissue to the expression of the effector proteins. In 
particular, plant tissues will be examined for tissue necrosis 
indicative of a hyperSensitive response. 
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Although the invention has been described in detail for by those skilled in the art without departing from the spirit 
the purposes of illustration, it is understood that such detail and scope of the invention which is defined by the following 
is solely for that purpose, and variations can be made therein claims. 
SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS: 36 
<210> SEQ ID NO 1 
&2 11s LENGTH 1155 
&212> TYPE DNA 
<213> ORGANISM: Pseudomonas syringae 
<400 SEQUENCE: 1 
atgaaaatac ataacgctgg cctaaccoca cotttgc.cgg gCattitcgaa to gaaacgtt 60 
ggaaaggcgg cqcaatcatc aataacticaa cogcagagcc agcaaggctic titatggcttg 120 
ccaccagaaa gotctgagac to gocctgat aggg.cgc.gtg cqaactatoc at attcatca 18O 
gtacaaacac ggttgcc.gcc cgttgcgtot gotgggaaac cqct gcctoga tacaccatct 240 
totttgc.ccg gCtact tact gttgc galagg citggaccatc gcc.ctgtgga to agga aggt 3OO 
accaaaagttctgatc.ccggc agacaaggct gtggctgaag cqc.gc.cgtgc attgcc ctitt 360 
ggaag aggca at attgatgt ggatgc.gcaa ctitt.ccaatc toggaaagtgg agc.ccgcacc 420 
cittgcagdala ggtgcttgag aaaagatgcc gaggcc.gc.cg gtcatgagcc tatgcctg.cg 480 
aatgagc.cga togaactggca tottcttgtt go gatgtcag go caggtgtt cqgcgcgggc 540 
aactgtggcg aa catgctog tatago gagc titc.gccitat g gagctttggc cc aggaaaac 600 
ggacgatctgaatatgaaaa catct acttig gotgcatcga citgaggaaga to atgtgtgg 660 
gctgaaaccg acgaatc.cca gttctggcacc to aacgattig to atggatcc gtggtoaaat 720 
ggttcago.ca tatttgcgga ggacagtagg tittgcgaaaa atcgaaatgc totagagcgt. 78O 
acggatacgt ttaatctttcaa.ccgcago C gaag.cgggca aaattacgcg to agacagoc 840 
gagaaggctt to acgcaggt cacaa.ccc.ga ttgcagaaac goctogcgga toag caggag 9 OO 
caagttct cqc coatcaaaag togtogctat cqaccagaala aatcgg tact to at gatgca 96.O 
tttgtcc.gca gagtgag cqa caagttgacc tocc ctdatt to cqgcgtgc actacaggta 1020 
gatattgaag cqgtoggagt cqcaatgtcg citcggcacca aggg.cgtoaa ggacgctact 1080 
cgacaagcc c gacctittggit to agcttgca gtgaaggtog cotcitccitca aggcttgg.cg 1140 
agacgagatg totga 1155 
<210> SEQ ID NO 2 
&2 11s LENGTH 384 
&212> TYPE PRT 
<213> ORGANISM: Pseudomonas syringae 
<400 SEQUENCE: 2 
Met Lys Ile His Asn Ala Gly Leu Thr Pro Pro Leu Pro Gly Ile Ser 
1 5 10 15 
Asn Gly Asn Val Gly Lys Ala Ala Glin Ser Ser Ile Thr Glin Pro Glin 
20 25 30 
Ser Glin Gln Gly Ser Tyr Gly Leu Pro Pro Glu Ser Ser Glu Thr Arg 
35 40 45 
Pro Asp Arg Ala Arg Ala Asn Tyr Pro Tyr Ser Ser Val Glin Thr Arg 
50 55 60 
Leu Pro Pro Val Ala Ser Ala Gly Lys Pro Leu Pro Asp Thr Pro Ser 
65 70 75 8O 
Ser Lieu Pro 
Asp Glin Glu 
Glu Ala Arg 
115 
Ala Glin Leu 
130 
Cys Lieu Arg 
145 
Asn Glu Pro 
Phe Gly Ala 
Tyr Lieu Ala 
210 
Glu Ser Glin 
225 
Gly Ser Ala 
Ala Wall Glu 
Gly Lys Ile 
Thr Arg Lieu 
29 O 
Ile Lys Ser 
305 
Phe Val Arg 
Ala Leu Glin 
Thr Lys Gly 
355 
Leu Ala Wall 
370 
63 
Gly Tyr Lieu Lleu Lieu 
85 
Gly Thr Lys Ser Lieu 
100 
Arg Ala Lieu Pro Phe 
120 
Ser Asn Lieu Glu Ser 
135 
Lys Asp Ala Glu Ala 
15 O 
Met Asn Trp His Val 
1.65 
Gly Asn. Cys Gly Glu 
18O 
Leu Ala Glin Glu Asn 
200 
Ala Ser Thr Glu Glu 
215 
Ser Gly Thr Ser Thr 
230 
Ile Phe Ala Glu Asp 
245 
Arg Thr Asp Thr Phe 
260 
Thr Arg Glu Thr Ala 
280 
Gln Lys Arg Lieu Ala 
295 
Gly Arg Tyr Arg Pro 
310 
Arg Val Ser Asp Lys 
325 
Val Asp Ile Glu Ala 
340 
Wall Lys Asp Ala Thr 
360 
Lys Val Ala Ser Pro 
<210> SEQ ID NO 3 
&2 11s LENGTH 1017 
&212> TYPE 
<213> ORGANISM: Pseudomonas 
DNA 
<400 SEQUENCE: 3 
atgaatc.gca 
gaag.cgcaaa 
totatogccc 
cagogactgc 
gctaaagctt 
ccacacttga 
citagaaatcc 
tittcaaccag 
accgctitcgc 
aag.cgt.cgga 
gccaattgat 
ttgatgctca 
acgctdtcaa 
cagttacatc 
375 
citcagtaaat 
citcago.gc.cc 
agggctacaa 
ggggagc.ccg. 
acgcc-taaac 
cacgctocaa 
caacticcitta 
Arg Arg Lieu 
90 
Ile Pro Ala 
105 
Gly Arg Gly 
Gly Ala Arg 
Ala Gly His 
155 
Leu Wall Ala 
170 
His Ala Arg 
185 
Gly Arg Ser 
Asp His Val 
Ile Wal Met 
235 
Ser Arg Phe 
250 
Asn Lieu. Ser 
265 
Glu Lys Ala 
Asp Glin Glin 
Glu Lys Ser 
315 
Leu. Thir Ser 
330 
Val Gly Val 
345 
Arg Glin Ala 
Glin Gly Lieu 
syringae 
tdcagottca 
gacaatticcc 
aggc.cggggg 
totgagcagt 
attalacactic 
caacgacact 
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Asp His Arg 
Asp Lys Ala 
110 
Asn. Ile Asp 
125 
Thir Leu Ala 
1 4 0 
Glu Pro Met 
Met Ser Gly 
Ile Ala Ser 
19 O 
Glu Tyr Glu 
2O5 
Trp Ala Glu 
220 
Asp Pro Trp 
Ala Lys Asn 
Thir Ala Ala 
27 O 
Leu. Thr Glin 
285 
Glu Glin Wall 
3OO 
Val Lieu. Asp 
Pro Asp Lieu 
Ala Met Ser 
35 O 
Arg Pro Leu 
365 
Ala Arg Arg 
38O 
attacacggc 
citctagttgt 
caacgctaag 
gcc.ggaggga 
aag caggctic 
tdaaacctg.c 
gCagg Caagt 
ued 
Pro Wall 
95 
Wall Ala 
Val Asp 
Ala Arg 
Pro Ala 
160 
Glin Wall 
175 
Phe Ala 
Asn. Ile 
Thr Asp 
Ser Asn 
240 
Arg Asn 
255 
Glu Ala 
Wall Thr 
Ser Pro 
Asp Ala 
320 
Arg Arg 
335 
Leu Gly 
Wall Glu 
Asp Wall 
cccitacggag 
CaCCaCaa.ca 
catgcaggcc 
cacaatgtta 
titccaacago 
ggctggtggg 
citatcaaatt 
60 
120 
18O 
240 
360 
420 
64 
ggct catcgt. 
aggg.cgcttg 
agaggcagca 
atcaacticta 
gtgttgtgcaa 
ggitatcggct 
gctttgcaaa 
ggcago tatg 
gc gcgcttgc 
aatgttctg.c 
cacgc.gagct 
agcggctgca 
acgtgttggc 
alaga.cggctg 
gaggcatgga 
Caccagagga 
toaaatactic 
acgacgagca 
atgitat coga 
tgatgcctga 
<210> SEQ ID NO 4 
&2 11s LENGTH 338 
&212> TYPE PRT 
65 
aagccaccga 
cgc.cgagttg 
citcaaacgtg 
cca aggcatt 
tagaga aggg 
taccatggct 
cctgg taggc 
aagctttittg 
aggcgaagag 
cc.ggtocaatg 
tittagaggtg 
agg gatgtcg 
ggcaccactg 
citt.ccggtoc 
acticttgatc 
ggcatcatca 
gcattgaaag 
gacgtgcata 
tacggtogcg 
<213> ORGANISM: Pseudomonas syringae 
<400 SEQUENCE: 4 
Met Asn Arg 
1 
Ala Pro Thr 
Ser Pro Leu 
35 
Leu Glin Arg 
5 O 
Gln Leu Met 
65 
Ala Lys Ala 
Ser Ser Asn 
His Phe Lys 
115 
Ser Lieu. Lieu 
130 
Arg Glu Lieu 
145 
Arg Ala Lieu 
Glu Phe Wall 
Val Asp Met 
195 
Gly Ile Gly 
210 
Gly Met Asp 
225 
Gly Ile Gly 
Arg Asp Lys 
Ile Ser Thr Ser Ser 
5 
Glu Glu Ala Glin Asn 
Wall Wall. Thir Thir Thr 
40 
Pro Gly Ala Thr Leu 
Gly Ser P 
55 
ro Ser Glu 
70 
Phe Asp Ala Glin Arg 
85 
Ser Pro H 
100 
is Lieu. Asn 
Pro Ala Ala Gly Gly 
Gly Gly G 
120 
ly Arg Glin 
135 
Ser His Arg Pro Val 
1 
Glu Arg L. 
1.65 
Pro Arg G 
18O 
50 
eu. His Ala 
ly Ser Asn 
Asp Glu Phe Asp Wall 
Th Thr G 
Arg Glu G 
2 
Ser Pro G 
245 
Gly Ala L 
260 
200 
ly Lieu Gly 
215 
ly Lieu Pro 
30 
lu Asp Thr 
eu Glin Ile 
Wall Asn. Ser 
10 
Arg Phe Ala 
25 
Ser Ile Ala 
Ser Met Glin 
Glin Cys Arg 
75 
Lieu. Asn. Ile 
90 
Ala Lieu. Asn 
105 
Leu Glu Ile 
Val Tyr Glin 
Asn Asp Glin 
155 
Glu Leu Phe 
170 
Wall Leu Ala 
185 
Ile Asn. Ser 
Pro Cys Ile 
Val Lieu Gly 
235 
Met Ala Thr 
250 
Lys Tyr Ser 
265 
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atcaggaccg 
ggc.cgattga 
acatggacga 
gcc toggacC 
tgggtgtcta 
aag.cgatgcg 
tgcctaaaga 
gcagttatto 
CCggC gagga 
acacgctcta 
Ser Phe Asn 
Ser Ala Pro 
3O 
Glin Ala Ser 
45 
Ala Glin Arg 
60 
Arg Asp Thr 
Asn Thr Glin 
Thir Leu Glin 
110 
Pro Wall Thr 
125 
Ile Gly Ser 
1 4 0 
Asp Arg Ala 
Arg Gly Gly 
Ser Asn. Wall 
19 O 
2O5 
Ala Val Cys 
220 
Val Tyr His 
Leu Asp Glin 
Leu Val Gly 
27 O 
ued 
cgc.gc.cctitc 
gtttgttgcct 
gttcgatgtc 
citgcattgca 
tdaccacagt 
cgataaaggt 
ggalagaggct 
aatcgaaggg 
caa.ca.gtgtc 
citgctga 
Tyr Thr 
15 
Asp Asn 
Glu Gly 
Leu Arg 
Met Leu 
8O 
Ala Gly 
95 
Glin Arg 
Ser Asn 
Ser Ser 
Pro Phe 
160 
Pro Ile 
175 
Arg Asp 
Cys Glin 
Ala Arg 
His Ser 
240 
Ala Met 
255 
Gly Met 
480 
540 
600 
660 
720 
840 
9 OO 
96.O 
101.7 
66 
Ile Met Pro Lys Glu G 
275 
Phe Leu Ala Lieu Lys G 
29 O 
Val Ser Glu Gly Glu G 
305 
Asn Wall 
3 
325 
Tyr Cys 
<400 
SEQ ID NO 5 
LENGTH 396 
TYPE DNA 
67 
lu Glu Ala 
280 
ly Ser Tyr 
295 
lu Asp Wal 
10 
Lieu Lleu Met Pro Asp Arg 
Gly Ser Tyr 
Ser Ile Glu 
His Thr Gly 
315 
Val Leu Tyr 
330 
ORGANISM: Pseudomonas syringae 
SEQUENCE: 5 
atgaaaaacg catttgacct 
ttgcctgaca agaaac at at 
gtaaaagtat accalagacga 
caagatagoa gtattgacac 
aaacctittcc td acctitcgg 
cc cittgattg aggtag acaa 
gCaggtgaaa totagaaaaac 
<400 
SEQ ID NO 6 
LENGTH 131 
TYPE PRT 
gcttgtggaa 
cgatgaagtc 
attitcgctgg 
attaalactac 
aatgacgaag 
cgtgcaaatg 
actaaaactic 
gggctggcta 
tattgctittg 
gtatatttca 
gc gcticcago 
gagaaaaatg 
cgcaggatat 
aaatag 
ORGANISM: Pseudomonas syringae 
SEQUENCE: 6 
Met Lys Asn Ala Phe Asp Leu Lieu 
1 5 
Asn Met Pro Pro Leul P 
Phe Glu Phe Glin Ser G 
35 
ro Asp Lys 
ly Met Asn 
40 
Arg Trp Val Tyr Phe Thr Ala Asp 
5 O 55 
Ile Asp Thr Lieu. Asn Tyr Ala Lieu 
65 70 
Lys Pro Phe Leu Thr Phe Gly Met 
85 
His Thr Arg Thr Pro L 
100 
Ile Phe Glu Glu Lieu. I 
115 
Lys Lieu Lys 
130 
<400 
SEQ ID NO 7 
LENGTH 579 
TYPE DNA 
eu. Ile Glu 
le Gly Val 
120 
Val Glu Gly 
10 
Lys His Ile 
25 
Val Lys Val 
Val Gly Thr 
Gln Leu Asn 
75 
Thr Lys Glu 
90 
Val Asp Asn 
105 
Ala Gly Glu 
ORGANISM: Pseudomonas syringae 
SEQUENCE: 7 
US 7,138, 
-contin 
Asp Asp Glu 
285 
Gly Ala Arg 
3OO 
Glu Asp Asn 
Gly Arg Asp 
aggactacaa 
agtttcaaag 
cc.gctgacgt. 
tgaacaactt 
gtgtattgca 
ttgaggagct 
Leu Ala Lys 
Asp Glu Wall 
3O 
45 
Phe Glin Asp 
60 
Asn Phe Ser 
Lys Asn Gly 
Wall Glin Met 
110 
Ile Arg Lys 
125 
569 B2 
ued 
Glin Ser 
Lieu. His 
Ser Wall 
320 
Thir Leu 
335 
catgcc.gc.cc 
tgg tatgaac 
tggga cattt 
tag cottaga 
tacacgcacc 
tatagg.cgtg 
Asp Tyr 
15 
Glu Phe 
Ser Ser 
Leu Arg 
8O 
Wall Leu 
95 
Arg Arg 
Thir Leu 
60 
120 
18O 
240 
360 
396 
68 
gtgtatagoc 
ggtggagata 
aacatgcatg 
acggatag to 
atccittatgc 
cacgaa.gcaa 
citgaacgtaa 
gataatcagg 
tatgcc.gacg 
ttgcc.caaag 
catcc catac 
cactgacatc 
atccaatgag 
gctatataaa 
atgaagaact 
ggg.cgitacgt. 
tgactogcto 
totctgtcaa 
cittcgtotgt 
gacagaaagt 
<210 SEQ ID NO 8 
&2 11s LENGTH 192 
&212> TYPE PRT 
69 
acaac gaata 
cattcatcag 
agtaatggga 
aaacgataaa 
gc gcc.ccaat 
to C gaaaaga 
gctagogC ga. 
aatgc gacitg 
agctgacgat 
gcc.ggtogaa 
actitcagotc 
cittitc.gcata 
cittgaccatg 
Ctcgcgggca 
cgttittgcca 
ataaaag.cca 
gacggaatta 
ggagattittc 
ggggaalacat 
agggtotga 
<213> ORGANISM: Pseudomonas syringae 
<400 SEQUENCE: 8 
Val Tyr Ser 
1 
Ser Thr His 
His Ser Glin 
35 
Met Gly Leu 
5 O 
Tyr Ile Lys 
65 
Ile Leu Met 
Gly Ala Glin 
Ala Thr Asp 
115 
Ala Arg Asp 
130 
Ser Val Lys 
145 
Tyr Ala Asp 
Leu. Ile Wall 
Pro Ser H 
5 
Val Gly G 
2O 
Arg Glu G 
is Thr Glin 
ly Asp Thr 
lin Phe Leu 
40 
Asp His Asp Thr Glu 
55 
Asn Asp Lys Lieu Ala 
His Glu G 
85 
Pro His G 
100 
Leu Gly V 
70 
lu Lieu Arg 
lu Ala Arg 
al Pro Ser 
120 
Gly Ile Arg Ala Tyr 
Met Arg L. 
1 
Ala Ser S 
1.65 
Thir Leu P 
18O 
<210 SEQ ID NO 9 
<211& LENGTH 2118 
&212> TYPE DNA 
135 
eu Gly Asp 
50 
er Wall Ala 
ro Lys Gly 
Arg Ile Thr 
10 
Leu. Thir Ser 
25 
Asn Met His 
Leu Phe Arg 
Gly Asn Pro 
75 
Pro Asn Arg 
90 
Ala Tyr Val 
105 
Lieu. Asn. Wall 
Asp His Met 
Phe Leu Glu 
155 
Asp Asp Gly 
170 
Gln Lys Wall 
185 
<213> ORGANISM: Pseudomonas syringae 
<400 SEQUENCE: 9 
US 7,138,569 B2 
-contin 
ccitctacatc 
gtoaga.gaga 
ataccgagct 
atccacaatc 
gccatacagg 
cc gatctagg 
gag cittatoga 
togaaagggg 
cacaagctdt 
Ser Ala Pro 
Ile His Glin 
3O 
Asp Pro Met 
45 
Thir Thr Asp 
60 
Glin Ser Met 
Phe Ala Ser 
Pro Lys Arg 
110 
Met Thr Gly 
125 
Ser Asp Asn 
1 4 0 
Arg Gly Gly 
Glu Thir Ser 
Pro Wall Glu 
19 O 
ued 
cactcatgtt 
gcagtttctg 
titt cagaacg. 
catgg.cgagt 
tgcc.calacca 
agttccatca 
to acatgagt 
tggcaaggto 
gattgtcaca 
Ser Thr 
15 
Teu Ser 
Arg Val 
Ser Arg 
Ala Ser 
8O 
His Thr 
95 
Ile Lys 
Ser Lieu 
Glin Wall 
Lys Wall 
160 
Glin Ala 
175 
Arg Val 
atgaatcc to tacgatct at tdaacacaac attgcaacto coccaatcag togcggtoag 
cc attagacg cqgtggg.ccc to aggcc.cag caatcc catc ctaaaaggat titcaccittct 
caattgagcc aaag.cgctica coaggctota gaacgcc titt cagotaatgc cqaacaccala 
60 
120 
18O 
240 
360 
420 
480 
540 
579 
60 
120 
18O 
70 

His 
Ala 
Teu 
65 
Asn 
Thr 
Glin 
Teu 
Pro 
145 
Gly 
Glu 
Pro 
Wall 
Asp 
225 
Glu 
Gly 
Ser 
Teu 
Ser 
305 
Teu 
Teu 
Ser 
Ser 
385 
Glin 
Ile 
Pro 
Telu 
5 O 
Wall 
His 
Asp 
Ala 
His 
130 
Ala 
Met 
Thr 
Ser 
210 
Glin 
Met 
Ala 
Glu 
Telu 
29 O 
Ile 
Ile 
His 
Ile 
370 
Glu 
Glu 
Gly 
Lys 
35 
Glu 
Arg 
Thr 
Thr 
Arg 
115 
Gly 
His 
Ser 
Pro 
Pro 
195 
Asp 
Ala 
Arg 
Phe 
Arg 
275 
Gly 
Thr 
Gly 
Wall 
355 
Gly 
Telu 
Ala 
Ser 
Glu 
435 
Arg 
Arg 
Asn 
Glin 
Wall 
100 
Telu 
Ser 
Gly 
Arg 
Telu 
18O 
Wall 
Asn 
Phe 
Pro 
Thr 
260 
Wall 
Ala 
Glin 
Ser 
Asp 
340 
Ala 
Wall 
Telu 
Telu 
Met 
420 
Glu 
Ile 
Teu 
Ala 
Wall 
85 
Arg 
Asn 
Ser 
Ser 
Wall 
1.65 
Teu 
His 
Pro 
Pro 
Arg 
245 
Wall 
Asp 
Ile 
Asn 
Asn 
325 
Asp 
Thr 
Ser 
Lys 
Glin 
405 
Asp 
Trp 
Ser 
Ser 
Teu 
70 
Thr 
Thr 
Asp 
Ala 
15 O 
Teu 
Ser 
Ile 
Wall 
Pro 
230 
Arg 
Wall 
Glu 
Glu 
Ser 
310 
Asp 
Asp 
Ser 
Asn 
390 
Teu 
Thr 
Ser 
73 
Pro 
Ala 
55 
Glin 
Asp 
Glin 
Ala 
135 
Ser 
Ser 
Ser 
Gly 
Wall 
215 
Glin 
Asp 
Asp 
Arg 
295 
Ala 
Asp 
Teu 
Ile 
375 
Ala 
Ala 
Met 
Met 
Ser 
40 
Asn 
Lys 
His 
Ser 
120 
Ile 
Ser 
Glin 
Pro 
Ser 
200 
Glin 
Ala 
Ile 
Ala 
Wall 
280 
Gly 
Lys 
Wall 
Glin 
Glu 
360 
Telu 
Ile 
Gly 
Cys 
Ser 
4 40 
Glin 
Ala 
Gly 
Ala 
Telu 
105 
Glu 
Ser 
Wall 
Asp 
Asp 
185 
Wall 
Ala 
Ala 
Glu 
Glin 
265 
Asn 
Ala 
Ala 
Telu 
Wall 
345 
Phe 
Gly 
Phe 
Ile 
Wall 
425 
Asp 
Telu 
Glu 
Thr 
Ser 
90 
Ile 
Tyr 
Phe 
Telu 
Ala 
170 
His 
Arg 
Telu 
Ser 
Lys 
250 
Telu 
Ala 
Ala 
Phe 
Ser 
330 
Arg 
Glin 
Ser 
Gly 
Asp 
410 
Telu 
Telu 
Ser 
His 
Phe 
75 
Ile 
Asn 
Asp 
Asp 
Ser 
155 
Wall 
Ser 
Arg 
Teu 
Ile 
235 
Ala 
Met 
Asp 
Ala 
Teu 
315 
Glu 
Teu 
Teu 
Ala 
Lys 
395 
Ser 
Ala 
Teu 
US 7,138,569 B2 
-continued 
Glin 
Glin 
60 
Glin 
Asn 
Ile 
Wall 
1 4 0 
Glu 
Asp 
Arg 
Asp 
Ser 
220 
Ala 
Teu 
Ser 
Ile 
Phe 
Ala 
Phe 
Gly 
Gly 
Trp 
Asn 
Wall 
Ile 
Pro 
Ser 
45 
Arg 
Phe 
Teu 
Glu 
Wall 
125 
Pro 
Arg 
Ser 
Pro 
Ser 
Phe 
Gly 
Glu 
Gly 
His 
285 
Gly 
Ser 
Ile 
Ala 
Gly 
365 
Glu 
Phe 
Pro 
Ile 
Lys 
4 45 
Ala 
Telu 
Glin 
Pro 
Telu 
110 
Ser 
Ser 
Thr 
Ser 
Pro 
19 O 
Gly 
Ala 
Wall 
Glu 
Ala 
27 O 
Ile 
Pro 
Asn 
Glin 
35 O 
Telu 
Telu 
Ser 
Pro 
Lys 
43 O 
Ala 
His 
Ala 
Ser 
Ala 
95 
Thr 
Ala 
Pro 
His 
Ser 
175 
Ser 
Ser 
Glin 
Glin 
Phe 
255 
Asn 
Pro 
Asn 
Ala 
Glin 
335 
Glu 
Ala 
Gly 
Pro 
Telu 
415 
Gly 
Telu 
Glin 
Ser 
Ser 
Asp 
Wall 
His 
Pro 
Telu 
160 
Telu 
Glin 
Telu 
Ala 
Telu 
240 
Ser 
Telu 
Ala 
Pro 
320 
Telu 
Gly 
Ala 
Ser 
400 
Ile 
Met 
74 
Ala Gly Ala 
450 
Tyr Ala Gly 
465 
Thir Thr Glu 
Wall Lys Glu 
Thir Ile Glu 
530 
Ser Thr Ala 
545 
Pro Lieu. Ie 
Leu Arg Ile 
Teu Asn Ala 
Asp Ser Asp 
610 
Arg Ala Ser 
625 
Glu Lieu. His 
Gly Ser Ala 
Ala Leu Wall 
675 
Ile Pro Tyr 
69 O. 
Pro 
705 
75 
Ile Ser Ser Wal Wall 
455 
Phe Lys Ser Arg Val 
470 
Ala Ala Ile Phe Gly 
485 
Ser Glu Glu Lieu Met 
5 OO 
Wal Met Ala His Ser 
Arg Met Thr Arg His 
535 
Val Lys Ser Met Gly 
550 
Ala Ser Asn Lys Ala 
565 
Phe Arg Ser Ala Val 
Leu Ala Lieu Gly Gly 
600 
Asn Ala Lys His Ala 
Gln His Met Glu Ala 
630 
Gln Met Leu Ala Pro 
645 
Ile Val Asn Gly Met 
660 
Arg Lys Lieu Gly Tyr 
680 
Glin Asp Leu Ala Val 
<210> SEQ ID NO 11 
&2 11s LENGTH 14. Of 
&212> TYPE DNA 
Ser Phe Pro 
Gly Asp Lieu 
475 
Ala Ala Ser 
490 
Arg Ala Gly 
505 
Gly Glu Gly 
Ala Lieu. Asp 
Leu Ala Ser 
555 
Thr Gly Leu 
570 
Phe Asin Pro 
585 
Arg Val Asn 
Arg Val Val 
Gly Asp Arg 
635 
Arg Ser Glu 
650 
Asn Ala Ser 
665 
Gly Glu Ala 
Pro Asp Thr 
<213> ORGANISM: Pseudomonas syringae 
<400 SEQUENCE: 11 
atgaatcc cc 
caattagagg 
ctitt.cccaat 
accgatcacc 
cittcaatc.ca 
gcc.gacacca 
aatgat caac 
to catc gatg 
cgitacgcatc 
galagaccaat 
tgcaaccitat 
CggagggctC 
tgagccaaag 
aacgc.gttgc 
gtaacgacac 
tggggg.ccgc 
ttgagtacga 
catccagtcc 
tagg tatgaa 
gtgttatggit 
totago acago 
to aggcc.cac 
cgctcaccita 
atc actogta 
gcaagtaacc 
ccact taatt 
catcgtoagc 
toccitcggcc 
togtgtc.citc 
gatcgacaaa 
attacalaatt 
aatticcitatt 
gctictagatc 
cgcaacgctg 
tataaaactt 
aataacgagc 
gctcatttgt 
aac gatctag 
ttacgctacg 
atgcc.ccccc 
US 7,138,569 B2 
-contin 
Asn Asn. Wall 
460 
Ala Ala Asn 
Gly Ile Pro 
Leu Phe Glin 
51O. 
Val Asp Thr 
525 
Ile Ala Pro 
540 
Ile Val Gly 
Leu Ser Glu 
Ile Glu Ala 
59 O 
Val Pro Gly 
605 
Glin Thir Ile 
62O 
Asp Ile Ser 
Phe Leu Arg 
Phe Glu Ala 
67 O 
Pro Leu Ala 
685 
Ser Arg Glin 
7 OO 
cc caaatgag 
cccatcctga 
acctittcaac 
tgcaggacgg 
cagtctgtcc 
tgacggttca 
atgg.ccctitc 
cgtc.citctgg 
cggtgcc.ccc 
ccaaacacgg 
ued 
Leu Glin 
Ser Wall 
480 
Pro Glu 
495 
Ser Met 
Gly Glu 
Met Ile 
560 
Glin Wall 
575 
Ile Ala 
Leu Phe 
Leu Ala 
Ala Glu 
640 
His Wall 
655 
Ile Pro 
Glu Arg 
Pro Ala 
tggtggtcag 
caggattitcg 
tdag cctaat 
taagttccala 
gcc agctaac 
ggc.ccgatta 
ggaagccata 
cittgagc gala 
togggaalacc 
caaaatgtct 
60 
120 
18O 
240 
360 
420 
480 
540 
600 
76 
ttctitcc.gta 
to cq acct ga 
cgc.gcagogC 
attgttcaacg 
toccaggttg 
totttaacgt 
gaactgaaaa 
tatcgcc.gc.g 
gtag acatca 
ggtogggg CC 
cattcc.gcag 
gatctaggca 
caggccttitc 
tggcgc.gcaa. 
ccactaatga 
aattggctgg 
ttggaggcgg 
gtttgccitat 
acggagcggC 
tgg to gatgc 
atttgaatgt 
tggcc attac 
tgcgcc actd 
gtactaccac 
aaa.cccitcait 
gcatttctg.c 
acgacitat gc 
aaatagogtt 
<210> SEQ ID NO 12 
&2 11s LENGTH 468 
&212> TYPE PRT 
77 
cittgagcaaa 
ttgttgaacgt. 
gcc.gcto acc 
caccittacgt 
acgtgaaagt 
caattatgta 
CCggagcgag 
c gaccataac 
cctgcaggca 
ggctatoata 
cacgc.gtatg 
acticaag.cgg 
cc.gcaacaac 
agaatga 
citgcc tittgg 
atttctitcc.g 
gtact agatc 
ggCCC gatgg 
gcc atgatta 
aaaggtaaaa 
C gagaagtcg 
aggcc tag to 
aatgagtc.gc 
atggtogaca 
gccaa.gctaa 
ccattcc tag 
ccaag.cggat 
<213> ORGANISM: Pseudomonas syringae 
<400 SEQUENCE: 12 
Met Asn. Pro 
1 
Ser Gly Gly 
Tyr Ser His 
35 
His Leu Ala 
5 O 
Arg Val Ala 
65 
Leu Glin Ser 
Pro Pro Ala 
Glu Lieu. Thr 
115 
Wal Ser Ala 
130 
Ser Ser Pro 
145 
Arg Thr His 
Pro Arg Glu 
Pro Pro Lys 
195 
Ser Lys Lieu 
210 
Leu Ala Gly 
Leu Glin P 
5 
Glin Glin L. 
2O 
ro Ile Glin 
eu Glu Ala 
Pro Asp Arg Ile Ser 
Lieu. Asp H 
Ser Leu W 
40 
is Lieu Ser 
55 
al Arg Asn 
70 
Ser Asn Asp Thr Glin 
85 
Asn Ala Asp Thr Met 
100 
Val Glin Ala Arg Lieu 
120 
His Leu Tyr Gly Pro 
135 
Pro Ser Ala Asn Asp 
1 
Leu Gly M 
1.65 
50 
et Asn Arg 
Thr Glu Asp Glin Cys 
18O 
His Gly Lys Met Ser 
Pro Leu G 
200 
ly Met Glu 
215 
Cys Glu Arg Ile Ser 
His Ser Ile 
10 
Glu Gly Ser 
25 
Leu Ser Glin 
Thr Glin Pro 
Ala Wall Glin 
75 
Val Thr Tyr 
90 
Gly Ala Ala 
105 
Asn Asp Glin 
Ser Glu Ala 
Leu Ala Ser 
155 
Wall Leu Lieu 
170 
Wal Met Wall 
185 
Phe Phe Arg 
Thr Gly Gly 
Ser Wall Glu 
US 7,138,569 B2 
-contin 
gaatggagac 
to gag caggt 
tgcgc galaga 
attgggccala 
cagaactgaa 
aaagtaatcc 
ttacagaggc 
Cggaag.cgac 
tagttgttgca 
tgcttaagaa 
gctatoacta 
aggacagact 
tat citcttaa. 
Thir Asn. Ser 
Glin Ala His 
3O 
Leu Ser Glin 
45 
Asn Thr Asp 
60 
Asp Gly Lys 
Lys Thr Ser 
His Lieu. Ile 
110 
Leu Glu Tyr 
125 
Ile Ser Ile 
1 4 0 
Ser Gly Lieu 
Arg Tyr Ala 
Ile Asp Lys 
19 O 
Thir Thr Asn 
2O5 
Leu Ser Asp 
220 
Glin Wall Lys 
ued 
ggg.cgggttg 
gaagagtatic 
atcto atgcg 
cgc.cggccta 
gc gcactaag 
toaaacgaca 
Cgg.cgcgacC 
cgacgagcta 
citgtaacggc 
cgctogtaac 
caa.catgacg 
aaaatttctg 
ttggacacag 
Gln Met 
15 
Asn. Ser 
Ser Ala 
His Glin 
Phe Glin 
8O 
Val Cys 
95 
Asn. Asn 
Asp Ile 
Asp Ala 
Ser Glu 
160 
Wall Pro 
175 
Met Pro 
Asp Lieu 
Lieu Lys 
Ser Ile 
660 
720 
840 
9 OO 
96.O 
1020 
1080 
1140 
1200 
1260 
1320 
1380 
1407 
78 
225 
Arg Ala Ala 
Glu Ser His 
Met Asp Trp 
275 
Glu Ser Ala 
29 O 
Val Asp Ala 
305 
Glu Lieu Lys 
Ala Gly Ala 
Ser Pro Glu 
355 
Glin Ala Asn 
370 
Th Thir Thr 
385 
His Ser Ala 
Tyr Asn Met 
Leu Glu Asp 
435 
Asn. Asn. Pro 
450 
Ile Ala Leu 
465 
79 
230 
Leu Gly Gly Gly Pro 
245 
Ala Ile Val Asn Gly 
260 
Ala Asn Ala Gly Lieu 
280 
Met Ile Thr Glu Lieu 
295 
Asn Tyr Val Lys Gly 
310 
Asn Lieu. Asn Val Arg 
325 
Thr Tyr Arg Arg Val 
340 
Ala Thr Asp Glu Lieu 
360 
Glu Ser Leu Wal Wall 
375 
Ala Met Ile Met Wall 
390 
Glu Thir Lieu. Ile Thr 
405 
Thr Asp Leu Gly Ser 
420 
Arg Lieu Lys Phe Lieu 
4 40 
Ser Gly Lieu Ser Lieu 
Glu 
<210> SEQ ID NO 13 
&2 11s LENGTH 810 
&212> TYPE DNA 
455 
235 
Leu. Thr Wall 
250 
Leu Pro Ile 
265 
Ser Glin Wall 
Lys Arg Thr 
Lys Lys Ser 
315 
Ser Glu Arg 
330 
Ala Ile Thr 
345 
Val Asp Ile 
His Cys Asn 
Asp Met Lieu 
395 
Arg Met Ala 
410 
Ile Ser Ala 
425 
Glin Ala Phe 
Asn Trp Thr 
<213> ORGANISM: Pseudomonas syringae 
<400 SEQUENCE: 13 
atgacaatcg 
tottcggctt 
aaaaagct to 
acgaataatc 
aacatgatto 
tittctgggitt 
gag cacaaat 
gctggCacag 
citagaggaca 
Caggtgagca 
agaggggtaa 
toagatggca 
aaag.cgttgg 
tgtctggaca 
Cggtogagaa 
cg accoaatt 
atggcatcag 
atgc.cgggaa 
cctittgaagg 
ttctgatgga 
aaagtttatt 
agtcgaactc 
cagatgaagc 
tggtgatata 
aaagagcgac 
citgatactat 
catcggaaaa 
tdaaatgcct 
gtogtoaatt 
tdagogtgca 
agatcatgtt 
ggtggtgcat 
gcaa.gctt.cc 
gcaa.gctgct 
aggccitaccc 
tgcgctaagc 
cagocaagaa 
cittatttgat 
cgaaaacata 
cacccaa.gc.c 
gatcc tocac 
acattgg.cga 
atgtgctittg 
acgcc ctato 
gctcqtactg 
gcaaaccocg 
gagttgaagg 
titcctaattg 
toctitatgttg 
attgcc.cacg 
cccaatctog 
to atcgg cag 
US 7,138,569 B2 
-contin 
Leu Asp Lieu 
Thr Lieu Arg 
27 O 
Asp Gly Ala 
285 
Lys Ser Lieu 
3OO 
Asn Pro Glin 
Glu Wal Wall 
Asp His Asn 
35 O 
Met Arg His 
365 
Gly Gly Arg 
38O 
Lys Asn Ala 
Lys Lieu Ser 
Leu Lys Arg 
43 O 
His Asp Tyr 
4 45 
Glin Trp Arg 
460 
taaccactgt 
agttcagtga 
gattc gatca 
gcctittcatt 
catcggcaga 
titcatalactit 
gagtatcaag 
ggittaaagct 
cgtgtaagca 
atgcaattgt 
citttgggctt 
gag agtttca 
atgggct gcc 
ued 
240 
Arg Glu 
255 
Gly Pro 
Ala Arg 
Thir Leu 
Th Thr 
320 
Thr Glu 
335 
Arg Pro 
Cys Lieu 
Gly Arg 
Arg Asn 
400 
Tyr Asp 
415 
Pro Phe 
Ala Arg 
Ala Lys 
toaa.gctggg 
tggacggtgg 
ggatatttgc 
gagctggatt 
aagaatgagg 
citatcgg act 
tgg.cgcgatg 
tdaacctgtt 
gtoaggg.cgg 
agaaaataag 
ttctgitatca 
tacacactcg 
tittaatcggc 
60 
120 
18O 
240 
360 
420 
480 
540 
600 
660 
720 
80 
81 
gttcaagtat togcttcaaa aatacactga 
<210> SEQ ID NO 14 
&2 11s LENGTH 269 
&212> TYPE PRT 
<213> ORGANISM: Pseudomonas syringae 
<400 SEQUENCE: 14 
Met Thir Ile 
1 
Wall Glin Ala 
Ala Glin Phe 
35 
Ser Ile Thr 
5 O 
Gly Ile Ser 
65 
Asn Met Ile 
Glu Arg Met 
Thr Wal His 
115 
Ala Ser Ala 
130 
Ser Lieu. Lieu 
145 
Leu Glu Asp 
Gln Ser Gly 
195 
Glin Glu Ile 
210 
Arg Ala Thr 
225 
Lys Ala Lieu 
Pro Leu. Ile 
Wal Ser G 
5 
Gly Ser S 
2O 
Ser Asp G 
ly His Ile 
er Ala Ser 
ly Arg Trp 
40 
Leu Ala Arg Phe Asp 
55 
Glin Arg Ala Met Cys 
His Ala G 
85 
Arg Phe L 
100 
70 
ly Lys Asp 
eu Gly Ser 
Asin Phe Tyr Arg Thr 
Asn. Pro G 
120 
ly Val Ser 
135 
Glin Ala Ala Glu Lieu 
1 50 
Lys Ser Asn. Ser Gly 
1.65 
Arg Glin V 
18O 
Ile Wall G 
al Ser Thr 
lu Asn Lys 
200 
Ala His Ala Leu Gly 
215 
Leu Phe Asp Pro Asn 
2 30 
Ala Asp Thir Ile Glu 
245 
Gly Val G 
260 
<210 SEQ ID NO 15 
&2 11s LENGTH 831 
&212> TYPE DNA 
lin Wall Phe 
Gly Lys His 
10 
Wall Glu Asn 
25 
Lys Lys Lieu 
Glin Asp Ile 
Phe Gly Leu 
75 
His Wall Thr 
90 
Phe Glu Gly 
105 
Glu His Lys 
Ser Gly Ala 
Lys Gly Lieu 
155 
Leu Pro Phe 
170 
Asp Glu Ala 
185 
Arg Gly Val 
Phe Ser Wall 
Leu Gly Glu 
235 
Asn. Ile Ser 
250 
Ala Ser Lys 
265 
<213> ORGANISM: Pseudomonas syringae 
<400 SEQUENCE: 15 
atgcacgcaa 
gaggc.ca.gc.c 
attgaagaac 
titc.gagaagt 
gatgtactaa 
atcctittaag 
aagttaaatc 
atgttgcaga 
cacttggcac 
aattalacaga 
citctittcaac 
ggCaggaacC 
cagacitcagt 
cittgaaaaat 
tgg.cgtaaag 
agagctdaac 
tottccacca 
gatttaggca 
ttaaatcttg 
aacattgttct 
US 7,138,569 B2 
-contin 
Pro Ser Lieu 
Gln Met Pro 
3O 
Pro Thr Glin 
45 
Cys Thr Asn 
60 
Ser Leu Ser 
Pro Tyr Ala 
Wal Wal His 
110 
Phe Leu Met 
125 
Met Ala Gly 
1 4 0 
Lys Lieu Glin 
Lieu. Ile Ala 
Ala Leu Ser 
19 O 
Met Wall Ile 
2O5 
Ser Ser Asp 
220 
Phe His Thr 
Ser Ala Asp 
Ile His 
atggcaatct 
citaatataga 
gacct gatgg 
agcagttagc 
cittittggagc 
ued 
Th Thr 
15 
Asp Pro 
Teu Ser 
Asn His 
Trp Ile 
8O 
Ser Ala 
95 
Ala Arg 
Glu Glin 
Thr Glu 
Pro Wall 
160 
Cys Lys 
175 
Ser Lieu 
Tyr Ser 
Gly Lys 
His Ser 
240 
Gly Lieu 
255 
gactaatgta 
cagtaaaaac 
tggatggttt 
cggaatc cat 
togggaagga 
810 
60 
120 
18O 
240 
82 
US 7,138,569 B2 
83 
-continued 
ggctitcgagt togcaatgca gtttcgtoat gatttataca gatctoaa.ca toc ggatgaa 360 
aacticgcc.gc acgatgcc.gc aactcattat cittgatgcaa totagoctoca atcaaacaaa 420 
tttacaaaac ttgaaaaact acaa.catgta gatgtattta aaatgcaaaa ccc.gttittgg 480 
gatgtcgggit acaaaaacgg aattgcgcac goaaaaaaaa togcattctt cataacgc.ca 540 
gagtggctgg gttctgattt citgtaaacag gaatticcagt ggcttagcga aacaaaaaac 600 
aaag acataa aatctgcatt totgatctitt aaagatgtag acttaaaaag caaaaatatg 660 
acaagtatct tcaattittgc agactitcc at aaatcacgc.g. tcatcatggc aag cacacct 720 
cc.cgaatcgg gattgaataa totaaaaatc gaaaatagog ttgacctgaa tttcaag agg 78O 
ttatta actd accgtgagtc atgggaacta aataattitcc tagg.cgacta a 831 
<210> SEQ ID NO 16 
&2 11s LENGTH 276 
&212> TYPE PRT 
<213> ORGANISM: Pseudomonas syringae 
<400 SEQUENCE: 16 
Met His Ala Asn Pro Leu Ser Ser Phe Asin Arg Ala Gln His Gly Asn 
1 5 10 15 
Leu Thr Asn Val Glu Ala Ser Glin Val Lys Ser Ala Gly Thr Ser Ser 
2O 25 3O 
Thir Thr Asn. Ile Asp Ser Lys Asn. Ile Glu Glu His Val Ala Asp Arg 
35 40 45 
Leu Ser Asp Leu Gly Arg Pro Asp Gly Gly Trp Phe Phe Glu Lys Ser 
5 O 55 60 
Leu Gly. Thir Lieu Lys Asn Lieu. Asn Lieu Glu Glin Leu Ala Gly Ile His 
65 70 75 8O 
Asp Wall Leu Lys Lieu. Thir Asp Gly Wall Lys Asn. Ile Val Ser Phe Gly 
85 90 95 
Ala Arg Glu Gly Gly Phe Glu Lieu Ala Met Glin Phe Arg His Asp Lieu 
100 105 110 
Tyr Arg Ser Glin His Pro Asp Glu Asn. Ser Pro His Asp Ala Ala Thr 
115 120 125 
His Tyr Lieu. Asp Ala Ile Ser Lieu Glin Ser Asn Lys Phe Thr Lys Lieu 
130 135 1 4 0 
Glu Lys Leu Gln His Val Asp Val Phe Lys Met Gln Asn Pro Phe Trp 
145 15 O 155 160 
Asp Val Gly Tyr Lys Asn Gly Ile Ala His Ala Lys Lys Met Ala Phe 
1.65 170 175 
Phe Ile Thr Pro Glu Trp Leu Gly Ser Asp Phe Cys Lys Glin Glu Phe 
18O 185 19 O 
Glin Trp Lieu Ser Glu Thir Lys Asn Lys Asp Ile Lys Ser Ala Phe Val 
195 200 2O5 
Ile Phe Lys Asp Wall Asp Leu Lys Ser Lys Asn Met Thr Ser Ile Phe 
210 215 220 
Asn Phe Ala Asp Phe His Lys Ser Arg Val Met Met Ala Ser Thr Pro 
225 230 235 240 
Pro Glu Ser Gly Lieu. Asn. Asn. Wall Lys Ile Glu Asn. Ser Val Asp Lieu 
245 250 255 
Asn Phe Lys Arg Lieu Lieu. Thr Asp Arg Glu Ser Trp Glu Lieu. Asn. Asn 
260 265 27 O 
Phe Leu Gly Asp 
275 
<210 SEQ ID NO 17 
&2 11s LENGTH 855 
&212> TYPE DNA 
85 
<213> ORGANISM: Pseudomonas syringae 
<400 SEQUENCE: 17 
atggggctat 
tggcaagtgc 
gCgagtgaca 
cittgcgcggit 
gaaagacggC 
caggtatato 
gttaaagtgg 
agcgctggta 
gctgtc.gc.gt 
aaagttc.gc.g 
ttagcttctg 
gctato catg 
ggcctgtttg 
totgaaacac 
citggtogcac 
gtatttcaaa 
citgcatgccc 
togcatcagg 
gCggtggaga 
atc.gcggtaa 
attctaaaaa. 
citggattcaa 
cgagtcagac 
gtgcgg.cgga 
tattocatct 
tgcgc.gatta 
gagggaatac 
citaatgaagg 
tgcttggtgc 
aataa 
<210> SEQ ID NO 18 
<211& LENGTH 2.84 
&212> TYPE PRT 
acactctggit 
to caaacgcc 
cgatgtggat 
gtacacgctt 
tittaataaaa. 
aggtttggat 
citgctctato 
aaacatgcct 
aaacgtggat 
acticcottitt 
totgc gaacg 
agagggtgat 
gatccc.gctt 
cgittatctta 
agcagttaca 
aggtotgitat 
gaacgtocto 
agcatcgttt 
gatcgtag to 
tacagottcc 
cocaataa.ca 
gtoatcgcag 
gctgg Cacgg 
Cgacgcgaag 
accaaagaac 
ttctdag toa 
gaatttgacg 
gatgacaact 
<213> ORGANISM: Pseudomonas syringae 
<400 SEQUENCE: 18 
Met Gly Leu 
1 
Asp Ser Asp 
Wal Ser Ser 
35 
Val Asp Glu 
5 O 
Gly Gly Glu 
65 
Glu Arg Arg 
Leu Pro Trp 
Phe Glin Ile 
115 
Ser Ile Pro 
130 
Ser Glin Thr 
145 
Ala Wall Ala 
Cys Ile S 
5 
Arg Trp G 
2O 
er Lys His 
lin Wall Pro 
His Glin Thr Ala Ser 
40 
Arg Pro Ala Thr Phe 
Tyr Thr L 
His Arg G 
85 
Wall Glin W 
100 
55 
eu Ser Met 
70 
ly Asn Lieu 
all Tyr His 
Asp Arg Thr Thr Thr 
120 
Asn Asn Arg Gly Thr 
Asn Met P 
1 
135 
ro Wall Ile 
50 
Cys Ala Ala Glu Asn 
Ser Gly Ser 
10 
Ala Cys Pro 
25 
Ala Ser Asp 
Ser His Phe 
Wal Ser Ala 
75 
Ile Lys Asp 
90 
Ser Lys Lys 
105 
Val Lys Val 
Arg His Lieu 
Ala Asp Asn 
155 
Val Asp Ala 
US 7,138,569 B2 
-continued 
gctacagtga 
ccagtcatca 
caacgtttitc 
Ctgcagogg C 
aatccatact 
agatcgacag 
gagggacitcg 
acaa.cat gag 
gtgaacgtag 
accittgttgcc 
aggggctaac 
gcactg.cgca 
agacctgtgc 
cg acticattt 
Ser Tyr Ser 
Pro Asn Ala 
3O 
Ile Ala Ser 
45 
Glin Leu Ala 
60 
Ala Ala Tyr 
Arg Ser Glin 
Gly Lieu. Asp 
110 
Ala Gly Phe 
125 
Tyr Ser Ala 
1 4 0 
Met Ser Ala 
tag cqaccgc 
aac agcatct 
toattittcaa. 
ttatcaa.gca 
cc catgggto 
aactacgact 
gcatttatac 
cgcatcCatt 
gcc.ggggg.cg 
agaagaagtt 
aatgcgc.gta 
ggcattgaaa 
aalacc galacg 
cataaaa.cat 
Tyr Ser 
15 
Arg Ser 
Gly Asp 
Arg Cys 
Glin Ala 
Ser Ile 
95 
Tyr Ser 
Asn. Cys 
Gly Thr 
160 
Gly Thr Gly Glu Arg 
60 
120 
18O 
240 
360 
420 
480 
540 
600 
660 
720 
840 
855 
86 
87 
1.65 170 
Arg Pro Gly Ala Lys Val Arg Val Phe His Lieu 
18O 185 
Glu Asp Lieu Val Pro Glu Glu Val Lieu Ala Ser 
195 200 
Arg Thr Thr Lys Glu Gln Gly Leu Thr Met Arg 
210 215 
Gly Asn Thr Glu Gly Asp Phe Ser Val Ser Thr 
225 230 235 
Gly Lieu Phe Ala Asn. Glu Gly Ile Pro Leu Glu 
245 250 
Ala Asn Arg Thr Ser Glu Thir Lieu Lieu Gly Ala 
260 265 
Asn Ser Thr His Phe Ile Lys His Leu Val Ala 
<400 
275 280 
SEQ ID NO 19 
LENGTH 291 
TYPE DNA 
ORGANISM: Pseudomonas syringae 
SEQUENCE: 19 
atgatcatcg acaatacgtt cqc.gctgaca citgtcatgcg 
citgttgatcg gcttgcttga gcc.gcacaag gacataccto 
gctotcaatc cqctoctoaa togcagg.ccca ggCCttggCC 
tatcacgc.gt atcaaag.cat cocto gagaa aaacticagog 
atgg Cagg to tdCtggagtg gatgaggggc tiggcgcgaag 
<400 
SEQ ID NO 20 
LENGTH 96 
TYPE PRT 
ORGANISM: Pseudomonas syringae 
SEQUENCE: 20 
Met Ile Ile Asp Asn Thr Phe Ala Leu Thr Leu 
1 5 10 
Arg Glu Arg Lieu Lleu Lieu. Ile Gly Lieu Lieu Glu 
2O 25 
Pro Glin Glin Cys Lieu Lieu Ala Gly Ala Lieu. Asn 
35 40 
Gly Pro Gly Lieu Gly Lieu. Asp Glu Lys Ser Gly 
5 O 55 
Gln Ser Ile Pro Arg Glu Lys Leu Ser Val Pro 
65 70 75 
Met Ala Gly Lieu Lleu Glu Trp Met Arg Gly Trp 
<400 
85 90 
SEQ ID NO 21 
LENGTH 1143 
TYPE DNA 
ORGANISM: Pseudomonas syringae 
SEQUENCE: 21 
US 7,138,569 B2 
-continued 
Teu 
Wall 
Wall 
220 
Ala 
Phe 
Wall 
Glin 
Pro 
Arg 
Ala 
Glin 
Asp 
Ile 
Phe 
19 O 
Asp 
Met 
Ala 
Glu 
Telu 
27 O 
attacgc.gc.g 
agcagtgcct 
tggatgagaa 
tgc.cgacgct 
caa.gc.calata 
Ser 
Pro 
Pro 
Teu 
60 
Thr 
Arg 
His 
Teu 
45 
Teu 
Glu 
Asp 
Lys 
3O 
Telu 
His 
Ala 
175 
Arg Arg 
Tyr Leu 
His Gly 
Lieu Lys 
240 
Thr Cys 
255 
Asp Asp 
tgagc.gc.ctg 
tittggctggc 
aag.cggcctg 
caaacgc gala 
Tyr Ala 
15 
Asp Ile 
Asn Ala 
Ala Tyr 
Arg Glu 
Ser Glin 
95 
atgaac coca ttcagt cacg cittcticcagt gtgcaa.gagc ticagacgatc caacgttgat 
attcc.ggcgc. tcaaag.ccaa togccaactg gaggtogacg gcaa.gaggta C gagatticgt. 
60 
120 
18O 
240 
291 
60 
120 
88 
gCagcc gatg 
tttittcaagg 
gc gctdaacg 
ggacgcttgg 
actgccaaac 
gaggcgatgc 
cacticacacic 
aatggcaaaa 
gaccgcaacc 
attatc.ccca 
caa.ccc.caat 
gcaatcacgc 
gttttgtata 
atgagcggca 
agtaaaggto 
C gag.cggaag 
aagctatolac 
tga 
acggaacaat 
gc gctt.ccca 
agalaggtogC 
acaccottga 
aggctg.cgca 
gaalaccc.gto 
ccatgagc ga 
acggcattga 
tggacaagta 
aac atgagcg 
atgcaa.caca 
atggcaaagt 
tdaacggtga 
titcctotgga 
tgtc.ctatoc 
tgatcagoga 
tgtctgccala 
<210> SEQ ID NO 22 
&2 11s LENGTH 380 
&212> TYPE PRT 
89 
titcggtoctit 
gttgataggit 
atcgg cacgc 
gCgggg.cgaa 
aagtacttitt 
to gaatggat 
Cgagcagdaa 
ggtgcgcact 
catc.gcagag 
cc.gagaagat 
gttgaccc.gc 
aataggcc cc 
tgttgcaaag 
tg.cgttctgtt 
agaaagcatc 
tgc cittgagg 
tggctatoac 
C gaccggagc 
ggCagcagoC 
actgtcttgc 
agcagotcag 
aacag ctittc 
atctaca aga 
gaagagttcc 
caggaccacg 
agcc.cggatg 
aagaatcaag 
gcc atggcaa 
gcc toccacg 
gCagaaaag.c 
gag cacaccc 
Ctggg.cgaca 
atggacggga 
cc.ggaca acc 
<213> ORGANISM: Pseudomonas syringae 
<400 SEQUENCE: 22 
Met Asn. Pro 
1 
Ser Asn. Wall 
Asp Gly Lys 
35 
Val Lieu Arg 
5 O 
Ala Ser Glin 
65 
Ala Lieu. Asn 
Ala Met Thr 
Ser Ala Thr 
115 
Thr Phe Asn 
130 
Asn. Pro Ser 
145 
His Ser His 
Leu Lys Ala 
Ile Glin S 
5 
Asp Ile P 
2O 
Arg Tyr G 
Pro Glu G 
Lieu. Ile G 
Glu Lys V 
85 
er Arg Phe 
ro Ala Leu 
lu Ile Arg 
40 
ln Glin Ser 
55 
ly Gly Ser 
70 
all Ala Ser 
Gly Gly Arg Lieu. Asp 
100 
Thr Ala I 
Ser Phe H 
le Lys Pro 
120 
is Glu Trip 
135 
Arg Met Asp Ile Tyr 
1 
Pro Met S 
1.65 
Lieu. Asn. G 
18O 
50 
er Asp Glu 
ly Lys Asn 
Ser Ser Wall 
10 
Lys Ala Asn 
25 
Ala Ala Asp 
Lys Ala Lys 
Ser Glin Arg 
75 
Ala Arg Thr 
90 
Thir Leu Glu 
105 
Thir Ala Lys 
Ala Lys Glin 
Lys Ile Tyr 
155 
Glin Glin Glu 
170 
Gly Ile Glu 
185 
US 7,138,569 B2 
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aacaatccala 
agcgc.gc.gca 
accagag cq c 
ccaca acago 
atgagtgggc 
totataaa.ca 
tgcacacgct 
acagogt cag 
caaagaggitt 
ggc gattgac 
ccctdatagg 
gccaaatgac 
tgggC gagaa 
citttgag cat 
ccagaggcca 
tgccatttct 
cggcc ctitcg 
Glin Glu Lieu 
Gly Glin Lieu 
3O 
Asp Gly Thr 
45 
Ser Phe Phe 
60 
Ala Glin Ile 
Wall Leu. His 
Arg Gly Glu 
110 
Glin Ala Ala 
125 
Ala Glu Ala 
1 4 0 
Lys Glin Asp 
Glu Phe Leu 
Val Arg Thr 
19 O 
ued 
agc gaaaagt 
gattgcc cag 
tatgacgggc 
catcaaacco 
caaac aggca 
agatgcacct 
aaagg cattg 
aaataaaaaa. 
tittctatoga 
cattggcgtg 
gaaggaaagt 
cgatt.cggca 
actgaaa.ca.g 
gcaatcc citg 
tgggatgtcg 
ggc.ca.gattg 
aaacacgaaa 
Arg Arg 
15 
Glu Wall 
Ile Ser 
Lys Gly 
Ala Glin 
8O 
Glin Ser 
95 
Ser Ser 
Glin Ser 
Met Arg 
Ala Pro 
160 
His Thr 
175 
Glin Asp 
18O 
240 
360 
420 
480 
540 
600 
660 
720 
840 
9 OO 
96.O 
1020 
1080 
1140 
1143 
90 


Ile 
Wall 
Ser 
Arg 
145 
Ser 
Ile 
Teu 
Asn 
His 
225 
Teu 
His 
Pro 
Ser 
305 
Gly 
Trp 
Teu 
Ile 
Pro 
385 
Asp 
Teu 
Gly 
Gly 
Met 
465 
Teu 
Gly 
Pro 
Wall 
Tyr 
130 
Arg 
Pro 
Asp 
Ser 
Met 
210 
Telu 
Gly 
Asp 
Phe 
29 O 
Ala 
His 
Wall 
Gly 
Pro 
370 
Arg 
Pro 
Asp 
Gly 
Ala 
450 
Thr 
Asp 
Telu 
Ser 
Telu 
115 
Phe 
Glu 
Pro 
Thr 
Glu 
195 
Pro 
Telu 
Telu 
His 
275 
Ser 
Ala 
Thr 
Ala 
Ile 
355 
Ala 
Glu 
Thr 
Asp 
Glu 
435 
Trp 
Ala 
Thr 
Asp 
Asp 
100 
Ser 
Glu 
Pro 
Telu 
18O 
Ala 
Telu 
Thr 
Asn 
260 
Telu 
Ser 
Asn 
Telu 
Telu 
340 
Ala 
Gly 
Gly 
Telu 
Met 
420 
Arg 
Arg 
Ile 
Arg 
Met 
5 OO 
Tyr 
Asn 
Ser 
Teu 
Lys 
1.65 
Ile 
Pro 
Teu 
Ser 
245 
Arg 
Ile 
Ser 
Asp 
Ile 
325 
Teu 
Glu 
Thr 
Ile 
405 
Teu 
Trp 
Trp 
Glin 
Thr 
485 
Glu 
Glu 
Tyr 
15 O 
Pro 
Glu 
Ala 
Lys 
230 
Arg 
Gly 
Ile 
Thr 
310 
Ser 
Asp 
Met 
Pro 
Glin 
390 
Wall 
Teu 
Ala 
Ile 
Glin 
470 
Thr 
95 
Met 
Pro 
Phe 
135 
Glu 
Glin 
His 
Ser 
Glu 
215 
His 
Ser 
Thr 
Ala 
Ser 
295 
Thr 
Ser 
Glin 
Glin 
Thr 
375 
Ala 
Pro 
Gly 
Ala 
455 
Ser 
Teu 
Phe 
Pro 
Tyr 
120 
Wall 
Telu 
Wall 
Wall 
200 
Glin 
Telu 
Gly 
Telu 
Ala 
280 
Tyr 
Ala 
Asp 
Lys 
Gly 
360 
Glin 
Glu 
Glin 
4 40 
Pro 
Telu 
His 
Phe 
Ala 
105 
Asp 
Asp 
Ala 
Pro 
Phe 
185 
Ala 
Arg 
Ser 
Ser 
Asn 
265 
His 
Pro 
Wall 
Wall 
Telu 
345 
Wall 
Ile 
Cys 
Ala 
Telu 
425 
Tyr 
Glu 
Thr 
Thr 
Glu 
505 
Ala 
Pro 
Telu 
Arg 
Pro 
170 
Ala 
Ser 
Wall 
His 
250 
Asn 
Arg 
Phe 
Glin 
Ala 
330 
Ala 
Wall 
Thr 
Asp 
Pro 
410 
Arg 
Gly 
Asp 
Asp 
Telu 
490 
Glu 
Met 
Thr 
Arg 
Thr 
155 
Teu 
Glin 
Teu 
235 
Glu 
Ser 
Teu 
Lys 
315 
Ser 
Thr 
Ser 
Phe 
395 
His 
Gly 
Phe 
Trp 
Pro 
475 
Ala 
Ser 
US 7,138,569 B2 
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Glin 
Gly 
Glin 
1 4 0 
Phe 
Ala 
Gly 
Arg 
Ile 
220 
Ala 
Teu 
Ser 
Gly 
Asp 
Met 
Ala 
Thr 
Wall 
Gly 
Thr 
Pro 
Glin 
Ile 
Pro 
460 
Wall 
Asn 
Glin 
Ala 
Ile 
125 
Ser 
Phe 
Pro 
Asn 
Teu 
Teu 
Arg 
Thr 
Ile 
285 
His 
Ser 
Pro 
His 
His 
365 
Thr 
Ile 
His 
Ser 
Arg 
4 45 
Ala 
Gly 
110 
Gly 
Phe 
Ala 
Pro 
Gly 
19 O 
Telu 
His 
Asp 
27 O 
Glu 
Pro 
Asn 
Thr 
Asp 
35 O 
Wall 
Gly 
Ala 
Gly 
Ala 
43 O 
Asp 
Asp 
Glu 
Glu 
Glu 
51O. 
Telu 
Met 
Wall 
Gly 
Wall 
175 
Telu 
Telu 
Ile 
Arg 
Tyr 
255 
Wall 
Wall 
Phe 
Lys 
335 
Gly 
Arg 
Glu 
Phe 
Thr 
415 
Gly 
Glu 
Ser 
Met 
Arg 
495 
Thr 
Asp 
Glu 
Ala 
Phe 
160 
Ala 
Wall 
Telu 
Glu 
Glin 
240 
Telu 
Asp 
Arg 
Telu 
Phe 
320 
Arg 
Wall 
Asp 
Telu 
Ser 
400 
Ala 
Asp 
Pro 
Pro 
480 
Arg 
Wall 
96 
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-continued 
Arg Asn Val Phe Ala Lieu. His Arg Lys Lys Lieu Glin Glin Asp Ala Ala 
515 52O 525 
Leu Ile Ser Ala Val Glin Leu Pro Pro Arg Pro Thr Met Pro Ala Val 
530 535 540 
Asn Pro Arg Thr Thr Thr Ala Gln Leu Phe Glu Thir Leu Tyr Glin His 
545 550 555 560 
Thr Asp Gly Ile Val Ile Gly Glu Ser His Phe Ser Val Ala Ser Lys 
565 570 575 
Lys Met Ile Ile Asp Asn Lieu Pro Leu Lleu Ser Glin Glin Asn Val Arg 
58O 585 59 O 
Thr Lieu. Tyr Met Glu His Leu Lieu. Thir Asp Lieu. His Glin Ala Asp Lieu 
595 600 605 
Asp Arg Phe Phe Glu Thr Gly Glin Met Ser Lys Thr Lieu Lieu. His Asp 
610 615 62O 
Leu Lys Val Lieu. Asp Arg Gly His Arg Thr Asp Pro Asp Llys Val Tyr 
625 630 635 640 
Thr Phe Glu Gln Leu Val Ile Lys Ala Glin Gln His Gly Met Glu Val 
645 650 655 
Arg Ala Ile Asp Cys Ala Ala Ser Tyr His Leu Ser Gly Lieu. Asp Asn 
660 665 67 O 
Asp Gly Ser Ile Thr Arg Glin Gln Met Met Asn Tyr Phe Ala Ser Arg 
675 680 685 
Thr Lieu Arg Arg His Glin Asp Wal Met Gly Ser His Lys Trp Ile Ala 
69 O. 695 7 OO 
Leu Val Gly Asn Ser His Ser Asn Val Tyr Glin Gly Val Val Pro Gly 
705 710 715 720 
Ile Ala Glu Lieu Glu Gly Gly Ile Gly Lieu Arg Val Ile Asp Val Ala 
725 730 735 
Pro Gly Glin Ser Lys Gly Wal Met His Asp Leu Gly Glu Lieu Val Ser 
740 745 750 
Ala Asp Ile Ser Arg Thr Lys Wal His Ile Lys Gly Asp Tyr Arg Val 
755 760 765 
Glu Ile Glu Ile Pro Arg Ala Lys Asp Ala Ile Arg Pro Pro Glin Pro 
770 775 78O 
Val Thr Lieu Glu Glin Arg Lieu Ala Arg Pro Gly Lieu Phe Lieu Val Glu 
785 790 795 8OO 
Glu Ser Glu Gly Asn Lieu Lleu Thir Ile Val His Arg Ala Arg Asp Thr 
805 810 815 
Trp Ile His Arg Thr Pro Wall Leu Val Asn Ala Glu Gly Lys Lieu. Tyr 
820 825 83O 
Leu Glu Arg Val Arg Trp Pro Arg Ile His Lieu Lys Pro Phe Asp Asp 
835 840 845 
Met Asp Ala Lieu Val Ala Ala Leu Glu Glu Met Asn Lieu. Thir Arg Val 
85 O 855 860 
Gly 
865 
<210> SEQ ID NO 25 
<211& LENGTH: 11 
&212> TYPE PRT 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE 
<223> OTHER INFORMATION: Description of Artificial Sequence: human 
immunodeficiency virus, TAT protein transduction 
domain 
US 7,138,569 B2 
99 
-continued 
<400 SEQUENCE: 25 
Tyr Gly Arg Lys Lys Arg Arg Glin Arg Arg Arg 
1 5 10 
<210> SEQ ID NO 26 
<211& LENGTH 42 
&212> TYPE DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE 
<223> OTHER INFORMATION: Description of Artificial Sequence: hopPtoC 
primer 
<400 SEQUENCE: 26 
agtcggat.cc gaataggg.cg citgaaaatat gacaatcgtg to 42 
<210 SEQ ID NO 27 
&2 11s LENGTH 55 
&212> TYPE DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE 
<223> OTHER INFORMATION: Description of Artificial Sequence: hopPtoC 
primer 
<400 SEQUENCE: 27 
agtc.citcgag to acttgtca togtogtoct totag togtog tatttittgaa gogaa 55 
<210> SEQ ID NO 28 
&2 11s LENGTH 45 
&212> TYPE DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE 
<223> OTHER INFORMATION: Description of Artificial Sequence: hopPtoD1 
primer 
<400 SEQUENCE: 28 
ccacacattg gatcc.gatta citt catcc.gg gacagotgat agcgc 45 
EQ ID NO 29 
ENGTH 55 
YPE DNA 
RGANISM: Artificial Sequence 
EATURE 
THER INFORMATION: Description of Artificial Sequence: hopPtoD1 
Lille 
EQUENCE: 29 
attcto gagt catttatcat catcatctitt ataatcgggit gcgggct gcc gcgac 55 
EQ ID NO 30 
ENGTH 2.8 
YPE DNA 
RGANISM: Artificial Sequence 
EATURE 
THER INFORMATION: Description of Artificial Sequence: hopPtoD2 
Lille 
<400 SEQUENCE: 30 
atgcaagctt atccaatgcc tittcgtoa 28 
<210> SEQ ID NO 31 
&2 11s LENGTH 58 
&212> TYPE DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE 
<223> OTHER INFORMATION: Description of Artificial Sequence: hopPtoD2 
primer 
100 
US 7,138,569 B2 
101 
-continued 
<400 SEQUENCE: 31 
atgc citcgag toaa.gc.gtaa totggaac at cqtatgggta ttctaacgct atttittgc 58 
<210> SEQ ID NO 32 
&2 11s LENGTH 2.8 
&212> TYPE DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE 
<223> OTHER INFORMATION: Description of Artificial Sequence: hopPtolJ 
primer 
<400 SEQUENCE: 32 
agtaaagctt gagctgcacg catgc gag 28 
<210 SEQ ID NO 33 
&2 11s LENGTH 55 
&212> TYPE DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE 
<223> OTHER INFORMATION: Description of Artificial Sequence: hopPtolJ 
primer 
<400 SEQUENCE: 33 
agitatctaga toacttgtca togtogtoct totagtottg togc gaccaga tigttt 55 
<210> SEQ ID NO 34 
&2 11s LENGTH 29 
&212> TYPE DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE 
<223> OTHER INFORMATION: Description of Artificial Sequence: hopPtoK 
primer 
<400 SEQUENCE: 34 
gc gaattcat cqgtttaatc acgcaaggc 29 
<210 SEQ ID NO 35 
&2 11s LENGTH 25 
&212> TYPE DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE 
<223> OTHER INFORMATION: Description of Artificial Sequence: hopPtoK 
primer 
<400 SEQUENCE: 35 
ttggtaccto agcagtagag cqtgt 25 
<210 SEQ ID NO 36 
&2 11s LENGTH 26 
&212> TYPE DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE 
<223> OTHER INFORMATION: Description of Artificial Sequence: hopPtoK 
primer 
<400 SEQUENCE: 36 
aaggat.ccgc agagcgtgtc. gog acc 26 
102 
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What is claimed: 
1. An isolated nucleic acid molecule comprising a nucle 
otide sequence which 
encodes a protein or polypeptide comprising SEQID No: 
12. 
2. The nucleic acid molecule according to claim 1, 
wherein the nucleic acid molecule comprises the nucleotide 
sequence according to SEQ ID No: 11. 
3. The nucleic acid molecule according to claim 1, 
wherein the nucleic acid molecule is DNA. 
4. An expression system comprising a vector into which 
is inserted the nucleic acid molecule according to claim 3. 
5. The expression system according to claim 4, wherein 
10 
104 
10. A method of making a transgenic plant cell compris 
1ng: 
providing nucleic acid molecule according to claim3, and 
transforming a plant cell with the nucleic acid molecule, 
whereby the nucleic acid molecule is expressed by the 
transformed plant cell. 
11. A method of making a transgenic plant comprising: 
transforming a plant cell with the nucleic acid molecule 
according to claim 3, whereby the nucleic acid mol 
ecule is expressed by the transformed plant cell, and 
regenerating a transgenic plant from the transformed plant 
cell. 
12. A method of making a plant hypersusceptible to 
colonization by nonpathogenic bacteria, said method com 
the nucleic acid molecule is inserted in sense orientation 15 pr1Sing: 
relative to a promoter. 
6. A host cell comprising the nucleic acid molecule 
according to claim 3. 
7. The host cell according to claim 6, wherein the host cell 
is a bacterial cell or a plant cell. 
8. The host cell according to claim 7, wherein the bacterial 
cell is Agrobacterium. 
9. A transgenic plant comprising the nucleic acid mol 
ecule according to claim 3. 
transforming a plant cell with the nucleic acid molecule of 
claim 3, and 
regenerating a transgenic plant from the transformed plant 
cell, 
20 wherein a transgenic plant expresses a protein or polopep 
tide encoded by a nucleic acid molecule, thereby rendering 
the transgenic plant hypersusceptible to colonization by 
nonpathogenic bacteria. 
k k k k k 
